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Abstract 
Obesity is the most significant risk factor for developing type II diabetes mellitus 
(T2DM). Obesity induces adipocyte endoplasmic reticulum (ER) stress, prior to 
onset of insulin resistance. A pathological inability of white adipose tissue (WAT) 
to expand to accommodate excess energy is predominantly due to impaired 
adipogenesis. The research hypothesis was that ER stress in human WAT is 
important in inducing WAT dysfunction and subsequent insulin resistance and 
T2DM. The aims of this study were to elucidate interactions of ER stress in 
human WAT and to characterise the role of ER stress in human adipogenesis. 
Abdominal SAT biopsies and anthropometry were collected from T2DM subjects 
before and after bariatric surgery and non-diabetic subjects. Preadipocytes were 
extracted from human WAT and differentiated into adipocytes. Lipogenesis, 
lipolysis, glucose uptake, insulin sensitivity, and ER stress and adipogenesis gene 
and protein expression were assessed in control cells and with ER stress inducers, 
inhibitors or siRNA. The results of this study found both restrictive and 
malabsorptive bariatric interventions are effective weight loss interventions for 
obese T2DM patients and result in significantly improved glucose and insulin 
levels six months after surgery. WAT health is better following restrictive 
procedures as shown by lower and better regulation of ER stress markers. 
Adipogenesis in primary human preadipocytes is influenced by adiposity and 
WAT depot and the IRE1-XBP1s UPR is essential in human adipogenesis. 
XBP1s plays a vital role upstream of CEBP and PPAR in human adipogenesis 
and it is necessary for mediating the action of insulin. Wnt10b plays an inhibitory 
role in human adipogenesis and acts independently of XBP1s. Collectively these 
findings suggest that WAT function is key for metabolic health and can be 
impaired by ER stress; however regulated adipogenesis may serve to improve 
WAT function and therefore improve metabolic health.  
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Introduction 
People with type II diabetes mellitus (T2DM) experience reduced quality and 
length of life. The disease presents a huge burden on global society through 
medical, social and financial implications. Current clinical interventions are 
failing to ensure patient glycaemic control. The initiation of insulin resistance in 
T2DM requires further elucidation. If the underlying cellular mechanisms that 
drive the initiation of insulin resistance can be characterised then a novel 
therapeutic window will be presented allowing early intervention and potentially 
reducing the encumbrance of the metabolic disease. This chapter reviews current 
literature about the importance of white adipose tissue (WAT) in metabolic health 
and reviews endoplasmic reticulum (ER) stress in adipocytes as a key factor in the 
initiation of insulin resistance. The review is human-focused, holistic, and 
organised in a reductionist way. It opens with the impact of T2DM on people and 
the global population. Then WAT multifunctional integrated physiology is 
considered because of its role in metabolism and because obesity, characterised by 
WAT expansion, is the most significant risk factor for developing T2DM. The 
importance of adipogenesis in WAT regulation is highlighted. ER stress as an 
initiator of T2DM through inhibiting insulin action and inducing WAT 
inflammation is reviewed. The chapter closes with a translation of findings to a 
clinical context before summerasing and ending with hypotheses, aims and 
objectives. 
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1.1 Type II diabetes mellitus  
1.1.1 Definition of diabetes mellitus 
Diabetes mellitus is defined in the Oxford Concise Medical Dictionary as ‘a 
disorder of carbohydrate metabolism in which sugars in the body are not oxidized 
to produce energy’ (Oxford, 2015). Type I diabetes mellitus is characterised by 
patients having little or no ability to produce insulin from birth or an early age. 
Type II diabetes mellitus (T2DM) is acquired and is characterised by patients 
where the pancreas retains some ability to produce insulin but this is inadequate 
for the needs of the body; or, the body becomes resistant to the effects of insulin 
(Oxford, 2015). The World Health Organisation (WHO) published its current 
diagnostic criteria for diabetes mellitus in 2006 as fasted plasma glucose above 
7.0 mmol/L (126 mg/dL) or 2-hours post 75 g oral glucose challenge plasma 
glucose above 11.1 mmol/L (200 mg/dL) (WHO, 2006). In the United Kingdom, 
the National Institute for Health and Care Excellence (NICE) recommended the 
WHO diagnostic criteria in their ‘Type 2 diabetes: The management of type 2 
diabetes’ guidelines published in 2009, updated in July 2014 (NICE, 2009) and 
they are currently being recommended for the National Health Service (NHS).   
 
1.1.2 Clinical sequelae of type II diabetes mellitus 
Patients with T2DM must balance their diet and clinical interventions to ensure 
glycaemic control and avoid hyperglycaemia or hypoglycaemia (plasma glucose 
below 4.0 mmol/L (DiabetesUK, 2015)) to prevent pathophysiology. People with 
T2DM without appropriate glycaemic control utilise fatty acids instead of glucose 
as an energy source. However, this disturbs the acid-base balance and ketones can 
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accumulate in the bloodstream (ketosis) and if untreated can cause diabetic coma 
(Umpierrez, et al., 2006). Hypoglycaemia is associated with several pathologies 
including a higher risk of cardiovascular disease (CVD) as reviewed in a recent 
meta-analysis with almost one million T2DM participants (Goto, et al., 2013). 
Chronic hyperglycaemia gives rise to a greater risk of microenvironmental defects 
including; retinopathy, neuropathy, nephropathy, microangiopathy and 
mobilopathy (impaired stem cell mobilisation) (Fadini, et al., 2014; Gerstein and 
Werstuck, 2013), and macrovascular complications including; ischaemic heart 
disease, peripheral vascular disease and stroke (Zoungas, et al., 2014). These 
hyperglycaemic and glucose toxicity induced pathologies arise via a myriad of 
cellular mechanisms including altered reduction and oxidation (redox) reactions, 
accumulation of advanced glycated end products, reviewed by Campos (Campos, 
2012), and recently emerging epigenetic mechanisms (Kato and Natarajan, 2014). 
Lipid metabolism is also dysregulated in diabetes causing diabetic dyslipidemia, 
characterised by elevated postprandial triglyceride, also known as triacylglycerol 
(TAG), low levels of high-density lipoprotein (HDL) cholesterol, elevated low-
density lipoprotein (LDL) cholesterol and the predominance of small, dense LDL 
particles, presenting a major cardiovascular risk (Wu and Parhofer, 2014). T2DM 
is therefore associated with reduced quality of life, significant morbidity and 
reduced life expectancy (Jia, et al., 2013).  
 
1.1.3 Epidemiology of type II diabetes mellitus 
The prevalence of T2DM is increasing globally, over the last three decades it has 
more than doubled (Chen, et al., 2012). The International Diabetes Federation 
(IDF) has estimated that worldwide diabetes prevalence will increase from 382 
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million in 2013 to 592 million in 2035 (IDF, 2014). The WHO predicts that 
deaths due to diabetes will double between 2005 and 2030 (WHO, 2011). There 
are variations in prevalence by geographical location, ethnicity, sex and age. 
Geographic variations have been attributed to differences in socio-economic 
status whilst ethnic variations seem to have more profound metabolic causes, 
possibly linked to adipose tissue (WAT) distribution and function (Chan, et al., 
2009). There is a small gender difference in the global numbers of people with 
diabetes, with about 14 million more men than women estimated to have diabetes 
in 2013, and the prevalence increases sharply with age in both sexes (Forouhi and 
Wareham, 2014). 
 
T2DM costs individuals their quality and length of life whilst the clinical 
management of the chronic disease and reduced productivity has considerable 
financial implications. The excess lifetime medical spending of a person 
diagnosed with T2DM at 40 years old compared to without T2DM in the United 
States of America (USA) has been estimated to be $211,400 (Zhuo, et al., 2014). 
People with diabetes require at least two to three times the health-care resources 
compared to people who do not have diabetes, and diabetes care may account for 
up to 15 % of national health care budgets (Zhang, et al., 2010). An inexorable 
increase in the direct medical cost of diabetes and its detrimental economic impact 
through reduced productivity has been recorded (Herman, 2013). The World 
Economic Forum (WEF) have warned in their 2014 Global Risks Report that the 
projected increase in number of people with T2DM and the associated healthcare 
funding will pose ‘a defining challenge for all countries over the next 10 years’ 
(WEF, 2014). Therefore T2DM causes a huge burden on global society, both 
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medically and financially. Understanding the risk factors and causes of T2DM 
will allow development of suitable interventions to reduce this burden on global 
society.   
 
1.1.4 Obesity and type II diabetes mellitus 
There are several risk factors associated with developing T2DM, including 
smoking, adverse developmental origins, and genetic susceptibility (Chan, et al., 
2009). The main aetiological risk factors are age, obesity, family history and 
physical inactivity (Forouhi and Wareham, 2014). However the single most 
important risk factor in contributing to T2DM is obesity (Guh, et al., 2009). 
Obesity is heterogeneous and alone it is not a definitive propensity for T2DM. For 
example, there is a defined subset of obese people who are metabolically healthy 
but obese (MHO) that do not exhibit an increased mortality, increased risk of 
CVD, or an increased risk of T2DM compared to normal weight controls (Seo and 
Rhee, 2014). In obesity there is an expansion of adipose tissue, and where the 
excess adipose tissue is deposited and how it functions influences T2DM risk. 
Excess abdominal adipose tissue, termed ‘central obesity’ poses a greater risk for 
developing T2DM than excess gluteal adipose tissue (Balkau, et al., 2007). 
Paradoxically, obesity is not a prerequisite for T2DM. Indeed there are individuals 
who are not obese on the basis of height and weight, with a body mass index 
(BMI) of less than 30 kg/m2, but are hyperinsulinemic, insulin-resistant and have 
T2DM (Ruderman, et al., 1998). These individuals have been described as 
‘metabolically obese but normal weight’ (MONW) (Ruderman, et al., 1998). 
MHO and MONW populations have been investigated and WAT distribution, 
regulation and function hypothesised as a potential discriminant between the two 
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groups in risk of developing T2DM (Karelis, et al., 2004). WAT dysfunction can 
lead to the accumulation of lipids in tissues not primarily intended for fat storage 
such as liver, pancreas, muscle and kidney. This ectopic fat has 
pathophysiological effects and may in part explain the difference in risk of 
developing T2DM in MHO and MONW (Hill, et al., 2009; Strohle and Worm, 
2014). WAT plays a vital role in systemic metabolism and since T2DM is a 
disease of metabolism, the initiation of insulin resistance and subsequent T2DM 
may arise due to adverse adipose tissue function. 
 
1.2 Adipose tissue heterogeneity 
1.2.1 Brown adipose tissue 
Adipose tissue found in mammals can be broadly split into two categories; white 
adipose tissue (WAT) and brown adipose tissue (BAT) (Peirce, et al., 2014). 
Investigations into BAT over thirty years ago in rats found the tissue has 
important thermogenesis functions that can be cold-induced and diet-induced 
(Rothwell and Stock, 1979). BAT is especially abundant in neonates and in 
hibernating mammals where it serves to generate body heat (Gesta, et al., 2007). 
BAT contains a much higher number of mitochondria per cell and has a more 
extensive capillary network than WAT and therefore it can be distinguished from 
WAT by histology. BAT also has a characteristic protein, uncoupling protein-1 
(UCP-1), which can be used as a marker of the tissue (Cannon and Nedergaard, 
2004). Although BAT had been found in human neonates, evidence confirming 
the presence of BAT in adult humans remained sparse until recently. Paired 
computer tomography (CT) and positron-emission tomography (PET) scans have 
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indicated the presence of BAT in adult humans in the region of anterior neck to 
thorax and were confirmed by immunostaining and histology (Cypess, et al., 
2009). Furthermore, magnetic resonance (MR) imaging has been used to identify 
human BAT (Reddy, et al., 2014). Not only has BAT been identified in adult 
humans, its activity has also been revealed. BAT thermogenesis activity has been 
demonstrated in healthy men when exposed to cold temperatures (16 C) and BAT 
activity was reduced in men who are overweight or obese (van Marken 
Lichtenbelt, et al., 2009). BAT activity in humans has also been 
pharmacologically activated by an orally administered 3-adrenergic receptor 
agonist and shown to increase resting metabolic rate by about 200 kcal compared 
to control (Cypess, et al., 2015). Cellular mechanistic studies have been 
conducted to compare properties of BAT and WAT, however these have been 
mostly restricted to rodent model systems (Rosell, et al., 2014). BAT may play a 
role in adult human metabolism but WAT has a much larger role in metabolism, 
energy storage and energy regulation and WAT comprises the vast majority of 
human AT (Obregon, 2014). Furthermore, WAT is expanded in obesity, the most 
significant risk factor for developing T2DM. Therefore WAT will be considered 
further.  
 
1.2.2 Distinct adipose tissue depots 
WAT, like skeletal muscle, is distributed through the body in discrete depots 
(figure 1.2.2) (Shen, et al., 2003). Subcutaneous adipose tissue (SAT) represents 
about 85 % of all body fat and is unequally distributed through the body, with 
larger depots in the abdomen (Abd SAT), thigh, gluteal, femoral and mammary 
region (Frayn and Karpe, 2014). Visceral adipose tissue (VAT) depots are deeper 
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in the abdomen than SAT and include omental that connects to the stomach. The 
functions and properties of each WAT depot overlap but there are distinct 
differences (White and Tchoukalova, 2014). Accumulation of adipose tissue in 
different depots has differential risk associated with development of T2DM. Early 
clinical observations by Vague suggested upper-body obesity, commonly referred 
to as central obesity, was associated with a much greater incidence of insulin 
resistance than lower-body obesity (Vague, 1956). In central obesity, different 
depths of abdominal SAT are functionally distinct and independently correlate 
with metabolic complications of obesity (Smith, et al., 2001). These observations 
have been supported by several studies, reviewed by Frayn et al. (Frayn, et al., 
2003). The difference in risk of developing T2DM conferred by different WAT 
depots is likely to be due to a combination of WAT properties including lipid and 
carbohydrate metabolism (lipolysis, lipid accumulation and glucose uptake) and 
systemic signalling (protein and lipid secretion and innervation). Lipolysis, TAG 
synthesis and storage, and protein secretion varies between WAT depots as 
reviewed by Lee et al. (Lee, et al., 2013). Hormone secretion varies between 
WAT depots, for example the hormone resistin is secreted from both 
preadipocytes and adipocytes and both gene and protein expression is higher in 
abdominal WAT compared to femoral or mammary WAT (McTernan, et al., 
2002). VAT has been found to secrete more pro-inflammatory molecules like 
interleukin 6 (IL-6) compared to SAT (Fried, et al., 1998). However abdominal 
SAT can also secrete large quantities of pro-inflammatory proteins (Youssef-
Elabd, et al., 2012). WAT depots can have protective effects against T2DM, for 
example increased gluteal and femoral WAT in people with a lower waist hip 
ratio is associated with reduced metabolic risk (Manolopoulos, et al., 2010). The 
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protective phenomenon of gluteal and femoral fat is credited to its beneficial 
secretion profile (Manolopoulos, et al., 2010). WAT distribution therefore plays a 
role in relative risk of developing T2DM. Naturally occurring differences in WAT 
distribution may provide further insight into important depots for developing 
T2DM. 
 
Figure 1.2.2  Major adipose tissue depots 
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Mammary
 
Figure 1.2.2 legend: Major adipose tissue depots. Adipose tissue is distributed 
throughout the body in discrete depots with functionally distinct properties. 
 
1.2.3 Gender and race differences in adipose tissue distribution  
There are sex specific differences in total WAT and its distribution (White and 
Tchoukalova, 2014). Women have generally higher total adiposity than men 
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(Blaak, 2001). Women accumulate more WAT in lower body depots like gluteal 
and femoral, while men accumulate more WAT in central areas, both Abd SAT 
and VAT (Geer and Shen, 2009). Perhaps this is partly why more men develop 
obesity linked T2DM than women. Mechanisms that underlie this sexual 
dimorphism are unclear. Sex steroid hormones androgen and estrogen have been 
investigated. Testosterone-treated men have less adiposity and selective loss of 
central WAT (Allan and McLachlan, 2010), however women with polycystic 
ovary syndrome (PCOS) with a hyperandrogenic state are prone to central obesity 
(Escobar-Morreale and San Millan, 2007). Sex specific differences in lipid and 
glucose metabolism have been investigated and may be an underlying explanation 
for the observed differences in WAT distribution (Varlamov, et al., 2015). Sex 
hormone milieu has been linked to gender and race differences in obesity (Perry 
and Martin, 2014).  
 
Evidence of race disparities in adiposity has been accumulating and these 
differences are becoming apparent from early childhood (Zilanawala, et al., 
2014). Obesity is the most significant risk factor for developing T2DM across 
different ethnicities, however the risk of developing T2DM varies by extent of 
obesity in different ethnicities. For example, a prospective study found that 
Europeans developed T2DM at a much higher obesity, measured by BMI and 
waist circumference, compared to South Asians and Arfican-Caribbeans (Tillin, et 
al., 2015). These differences may be due to altered WAT function in different 
ethnicities. WAT was previously regarded as a dormant energy store, however in 
recent years a plethora of WAT functions has come to light. WAT dysregulation, 
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that is abnormal or impairment in the regulation of metabolic or physiological 
processes, may contribute to T2DM development.  
 
1.2.4 Adipose tissue composition 
WAT is comprised of many cell types that together orchestrate several important 
physiological processes (Trujillo and Scherer, 2006). WAT is a multifaceted 
tissue consisting of preadipocytes, adipocytes, endothelial cells, fibroblasts, 
vascular smooth muscle cells and resident immune cells such as monocytes, 
macrophages, T cells and B cells (Caspar-Bauguil, et al., 2005; Nishimura, et al., 
2013). The precursor cells constitute the stromal vascular fraction of adipose 
tissue. Human WAT is a source of multipotent stem cells (Zuk, et al., 2002). 
Adipocytes are the main cellular component of WAT and the key functional 
energy-storing unit at the interface of energy homeostasis dynamically influenced 
by a number of cues from surrounding cells and distant hormonal and neuronal 
stimuli. To facilitate systemic integration, WAT is supplied with a highly 
regulated and dynamic network of vasculature (Frayn and Karpe, 2014; Yilmaz 
and Hotamisligil, 2013), lymph nodes (Pond and Mattacks, 1995) and is 
innervated by the sympathetic nervous system (SNS) (Bartness and Song, 2007). 
The WAT as a whole is greater than the sum of the individual parts and the parts 
work together to accomplish a multitude of functions. Dysregulation of the WAT 
and consequent suboptimal functionality may contribute to the pathogenesis of 
T2DM. 
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1.3 Integrative adipose tissue functions 
1.3.1 Immune functions 
WAT plays such an extensive role in immunology it has been described as an 
‘immunological organ’ by Grant and Dixit in their recent review (Grant and Dixit, 
2015). WAT serves as a key site for the interaction of adipocytes with other 
specialised effectors of the immune system. This is particularly advantageous in 
SAT immediately below the skin as a first line of defence and may have arisen 
due to the primitive need to both acquire nutrients and defend against pathogens. 
Infiltration of inflamed WAT by immune cells such as eosinophils, macrophages 
and neutrophils bolsters the existing WAT resident immune cell repertoire and is 
an important feature of the immune system to provide host defence against 
pathogens (Exley, et al., 2014). There are several similarities between adipocytes 
and a wide range of immune cells including macrophages, dendritic cells and T 
cells (Wellen and Hotamisligil, 2005). These features include pathogen sensing, 
phagocytic properties, complement activation and production of inflammatory 
mediators (Shoelson, et al., 2006). In vitro studies on human adipocytes have 
shown antigenic stimuli increased the secretion of the adipokine resistin and that 
proinflammatory cytokine levels were increased in response to resistin 
(Kusminski, et al., 2007). Toll like receptors (TLRs) are expressed on human 
adipocytes (Wang and Nakayama, 2010). The TLR family of receptors recognise 
specific components conserved among microorganisms but distinguishable from 
host molecules, collectively referred to as pathogen-associated molecular patterns 
(PAMPs). Examples of conserved features of pathogens include bacterial cell-
surface lipopolysaccharide (LPS), lipoproteins and double stranded RNA of 
viruses. Adipocyte TLRs are thought to be activated by LPS of gram negative 
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circulating gut derived bacteria and therefore stimulate an innate immune 
response (Creely, et al., 2007). Although WAT immune responses and the 
associated local inflammation assist the defence against pathogens they can be 
detrimental if the tissue remains inflamed. Resident WAT regulatory B cells play 
a role in reducing inflammation by secreting anti-inflammatory interleukin-10 
(IL-10) (Nishimura, et al., 2013). WAT inflammation must be regulated to 
prevent adipose tissue dysfunction and subsequent T2DM.  
 
1.3.2 Endocrine functions 
Cells within the WAT secrete several proteins and therefore to perform 
appropriately they require a functional protein secretion system. Given the 
resident cells of WAT secrete signalling proteins the WAT can itself be 
considered as an ‘endocrine organ’ (Galic, et al., 2010). Cloning of the obese gene 
and the identification of its product, leptin (Zhang, et al., 1994), was one of the 
first discoveries of an adipocyte derived signalling molecule and established an 
important role for adipose tissue as an endocrine organ. Since the discovery of 
leptin several other adipokines have been characterised, including chemerin, 
interleukin-6 (IL-6), apelin, visfatin, adiponectin, tumor necrosis factor-alpha 
(TNFα), plasminogen activator inhibitor-1 and retinol binding protein 4 (Ouchi, et 
al., 2011). The term ‘adipokinome’ has been suggested to describe collectively the 
proteins and lipid moieties, such as prostaglandins and fatty acids, released by 
adipocytes (Trayhurn and Wood, 2004). The secreted molecules of the 
adipokinome have diverse roles in lipid metabolism, insulin sensitivity, vascular 
homoeostasis, the alternative complement system, blood pressure regulation, 
angiogenesis and the regulation of energy balance. Obesity-related adipokines and 
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their possible application as a treatment for obesity has been reviewed (Khan and 
Joseph, 2014).  
 
Adiponectin is an adipokine synthesized almost exclusively by adipocytes and is 
the most abundant adipokine in circulation (3 to 30 µg/mL) (Ouchi, et al., 2003). 
However adiponectin levels are decreased in obese individuals compared to lean 
individuals (Ryo, et al., 2004). Consistent with this, the synthesis of adiponectin 
by adipocytes is inhibited by obesity related pro-inflammatory molecules such as 
IL-6 and TNF (Berg and Scherer, 2005) as well as by oxidative stress and 
hypoxia (Hosogai, et al., 2007). An association between adiponectin levels and 
obesity-linked metabolic dysfunction is supported by several clinical 
observations. Namely, high adiponectin levels are associated with a lower risk for 
developing type 2 diabetes, plasma adiponectin levels are decreased in patients 
with type 2 diabetes (Li, et al., 2009), and plasma adiponectin levels negatively 
correlate with VAT accumulation (Ryo, et al., 2004) therefore 
‘hypoadiponectinemia’ is closely associated with the clinical phenotype of the 
metabolic syndrome. Experimental models indicate that adiponectin protects 
against obesity linked metabolic dysfunction. Diabetic mice have been shown to 
reduce hyperglycaemia following administration of adiponectin by enhancing 
insulin activity (Berg and Scherer, 2005), and when given to obese  mice it 
reduced plasma levels of glucose, TAG and free fatty acids (FFAs) by increasing 
fatty acid oxidation in muscle tissue (Fruebis, et al., 2001). Consistent with this, 
transgene mediated overexpression of adiponectin in ob/ob mice (leptin deficient) 
improves glucose metabolism independently of weight loss (Kim, et al., 2007). 
Adiponectin seems to mediate its beneficial effects in part by activating AMP-
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activated protein kinase (AMPK) in liver and skeletal muscle which leads to 
inhibition of gluconeogenesis in the liver and an increase in fatty acid oxidation 
and glucose uptake in muscle tissue (Tomas, et al., 2002; Yamauchi, et al., 2002). 
Adiponectin is synthesised as a 32 kDa monomeric protein and then assembled 
into low molecular weight trimers, medium molecular weight hexamers and high 
molecular weight (HMW) multimers (Galic, et al., 2010). The HMW form has 
insulin sensitising effects (Liu and Liu, 2014).   
 
Leptin is a 16 kDa pro-inflammatory adipokine produced mainly by adipocytes 
and is required for control of bodyweight and reproduction (Lord, 2006). Mice 
defective in leptin or the leptin receptor are hyperphagic, obese, insulin resistant 
and infertile (Lord, 2006). The leptin deficient (ob/ob) mouse has been used 
extensively as an in vivo model of obesity and T2DM (Drel, et al., 2006). Mice 
injected with leptin on a daily basis experienced a fast reduction in food intake, 
body mass and percent body fat, but maintained lean muscle mass, and increased 
energy expenditure and restored reproductive function and euglycemia 
(Pelleymounter, et al., 1995). Leptin is effective at improving metabolic 
dysfunction in patients with congenital leptin deficiency or lipodystrophy 
(Farooqi, et al., 2002; Oral, et al., 2002). Leptin resistance in obesity has been 
suggested since levels in the blood positively correlate with adipose mass and 
obese individuals have high leptin levels without the expected anorexic responses 
(Friedman and Halaas, 1998). Leptin interacts with both the neuronal and immune 
systems and the high levels in obesity may play a role in obese related brain 
diseases (Aguilar-Valles, et al., 2015). 
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The diverse roles of the leptin and adiponectin and their altered expression in the 
obese state demonstrate the complexity of adipokine signalling. The two 
aforementioned adipokines influence the level of WAT inflammation; an 
important factor given increasing evidence indicates that obesity is causally linked 
to a chronic low-grade inflammatory state and T2DM ensues (Hotamisligil, 2006; 
Shoelson, et al., 2006).  
 
1.3.3 Energy homeostasis 
Systemic energy homeostasis requires appropriate function of several 
physiological systems including the digestive, circulatory, musculoskeletal, 
endocrine, and nervous systems. WAT adipocytes play a vital integrative role 
between these systems and are the main energy store in the body (Rosen and 
Spiegelman, 2006). Energy homeostasis is governed by a neuroendocrine system 
that links WAT to the brain. An example of the WAT – hypothalamus axis is the 
reciprocal integration of WAT derived peripheral anorexic signal leptin and 
hypothalamic orexigenic peptide neuropeptide Y (NPY) (Zhang, et al., 2014b). 
The arcuate nucleus (ARC) of the hypothalamus contains NPY neurons that sense 
and integrate peripheral energy signals, such as blood glucose concentration, 
leptin and insulin due to the unique anatomical structure of the ARC in lacking a 
blood brain barrier (Kohno and Yada, 2012). Energy deficiency and greater 
metabolic demand such as increased exercise induces the synthesis of ARC NPY 
(Leibowitz and Wortley, 2004). NPY regulates energy utilisation in WAT by 
promoting adipogenesis and lipid accumulation and inhibiting lipolysis, and 
affects food intake by innervating with other appetite regulatory factors in the 
central nervous system (Zhang, et al., 2014b). WAT also regulates energy 
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homeostasis by influencing liver and muscle metabolism as reviewed by Saltiel 
and Kahn (Saltiel and Kahn, 2001). Adipocytes release FFAs into the circulation 
that reduce glucose uptake in muscle, insulin secretion from pancreatic -cells and 
increase glucose production from the liver (Bergman and Ader, 2000). Adiposity 
influences muscle derived peptide irisin, which may have a central role in 
metabolism given it has been identified in human cerebrospinal fluid (Piya, et al., 
2014). WAT regulation is imperative for systemic energy homeostasis and if it 
becomes dysfunctional then diseases of energy homeostasis, such as T2DM, may 
arise.  
 
1.4 Metabolism in human adipose tissue 
The ability to take up and store energy during a fed state and break down and 
release energy in a fasted state provides an advantage through the ability to 
withstand fluctuations in energy supply. WAT adipocytes undertake anabolic and 
catabolic metabolic processes in response to the needs of the body and contain the 
biggest reserve of energy in the body in the form of lipid TAG; therefore WAT 
plays a vital role in systemic energy regulation. WAT adipocytes are able to take 
up energy from the blood, mostly in the form of carbohydrate (glucose) and lipid 
(nonesterified fatty acids – NEFA), store energy predominantly as lipid (TAG) 
and release energy when required predominantly as lipid (NEFA). WAT 
adipocytes have a very dynamic pattern of metabolism influenced by hormonal 
and neuronal stimuli and consequently rapidly respond to energy requirements. A 
dynamic crosstalk between systemic metabolic organs in which WAT plays a 
prominent role exists to ensure the energy needs of the body are supplied. During 
a fasted state glycogen stores in the liver become depleted triggering a liver-brain-
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adipose neural axis that shifts the energy source from carbohydrate to TAG in 
adipocytes in order to maintain energy balance (Izumida, et al., 2013). 
Conversely, in a fed state glycogen accumulates in the liver and lipogenesis is 
stimulated in adipocytes (Lu, et al., 2014).   
 
Proteins are essential at virtually every stage of systemic energy transfer; 
digestive enzymes, transport proteins in cellular uptake and circulation transfer, 
biochemical enzymes that catalyze anabolic and catabolic reactions, energy 
regulatory hormones, energy storage proteins such as those coating lipid droplets 
and many more function in systemic and WAT metabolism. Therefore functional 
protein metabolism, especially protein synthesis, is vital for systemic energy 
regulation. Thus the intracellular organelle ER that processes proteins plays a vital 
role in energy regulation and impaired ER function can cause several pathologies 
(Kim and Arvan, 1998; Ni and Lee, 2007). In this section about metabolism in 
human WAT, the roles of proteins are presented in an integrated way just as the 
roles of proteins are integrated in WAT metabolism. Excess WAT in obesity is 
the main risk factor for T2DM, a disease of impaired metabolism; therefore 
metabolic processes in WAT may play an important role in the initiation of 
T2DM.  
 
1.4.1 Lipid metabolism 
Dietary fat is absorbed by the gut and transported to the circulation in 
chylomicrons (Mansbach and Gorelick, 2007). Fatty acids from circulating lipids 
are provided to WAT by the albumin-bound NEFA pool, or either TAG 
incorporated in chylomicrons in the postprandial state, or TAG within very low-
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density lipoprotein (VLDL) in the post-absorptive state. TAG must be hydrolyzed 
to fatty acids by extracellular enzyme lipoprotein lipase bound to the wall of 
capillaries before they can be taken up by adipocytes (Mead, et al., 2002). The 
trafficking of fatty acids into and out of adipocytes is regulated by several proteins 
and enzymes and is under control by hormonal and metabolic factors (Thompson, 
et al., 2010). Within adipocytes NEFAs are converted to TAG and stored in lipid 
droplets (LDs), the lipid storage organelles of all organisms. When energy is 
required in other tissues TAG is converted by lipases to NEFA and glycerol and 
both are released into the circulation (Walther and Farese, 2012). During fasting, 
plasma NEFA is almost entirely from hydrolysis of TAG stored in SAT LDs 
(Karpe, et al., 2011). NEFA circulates predominantly bound to albumin and is 
taken up and oxidized in muscle, liver and other tissues. A proportion will be re-
esterified to form new TAG in the liver, which is exported in VLDL and can be 
taken up by adipocytes after being broken down to NEFA by lipoprotein lipase 
(Frayn and Humphreys, 2012). 
 
LDs and their associated proteins in adipocytes play a specific role in maintaining 
systemic energy homeostasis. The cytosolic LD is composed of a core of TAG 
surrounded by a monolayer of phospholipids and lipid droplet-associated proteins, 
including enzyme coactivators and structural proteins. Neutral lipids occupy the 
core of LDs and in human adipocytes are primarily TAG with few sterol esters. In 
mammalian cells TAG synthesis is catalyzed by acyl-coenzyme A:diacylglycerol 
acyltransferase (DGAT) enzymes DGAT1 and DGAT2 (Buhman, et al., 2001). 
DGAT1 and DGAT2 both reside within the ER, although DGAT2 is also found in 
relatively small quantities in mitochondrial-associated membranes (Stone, et al., 
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2009). LD formation requires further clarification, however evidence suggests 
LDs form de novo in mammalian cells from the ER membrane. ER diacylglycerol 
(DAG) enrichment recruits perilipin 3, a LD coat protein (Skinner, et al., 2009), 
LDs are arrested in the ER membrane by tight binding of lipidated apolipoprotein 
B-100 (ApoB) (Ohsaki, et al., 2008), and ER localised fat storage-inducing 
transmembrane proteins 1 and 2 (FIT1 and FIT2) mediate partitioning of cellular 
TG into LDs (Gross, et al., 2010). Lipid droplet formation is tightly regulated 
with cholesterol efflux to maintain intracellular free cholesterol level within a 
narrow range (Martin and Parton, 2006). Studies in macrophages have found that 
increases in ER free cholesterol can lead to the induction of the unfolded protein 
response via changes in the activity of the ER calcium pump sarco(endo)plasmic-
reticulum calcium ATPase-2b (SERCA2b) that lead to the depletion of ER 
calcium stores (Feng, et al., 2003; Li, et al., 2004). Therefore the ER plays a vital 
role in the formation of lipid droplets and ER functional integrity is essential for 
appropriate LD formation and energy storage. 
 
Lipolysis is the catabolism of TAG in LDs. In WAT lipolysis is a key process to 
regulate cellular and systemic energy homeostasis. Lipolytic pathways converge 
on either protein kinase A (PKA) or protein kinase G (PKG), which phosphorylate 
several proteins interacting with the LD, the site of action of lipases and cofactors 
(Arner and Langin, 2014). At the LD surface TAG are sequentially hydrolysed 
into DAG, monoacylglycerol (MAG) and glycerol, releasing one molecule of fatty 
acid (FA) at each step. Three lipases work in sequential fashion in human 
adipocytes to ensure complete hydrolysis of TAG: adipose triglyceride lipase 
(ATGL) (Zimmermann, et al., 2004), hormone-sensitive lipase (HSL) and 
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monoglyceride lipase (Bezaire, et al., 2009). Both ATGL and HSL require 
phosphorylation to become fully active lipases (Krintel, et al., 2008; Pagnon, et 
al., 2012). Key proteins, including perilipin (Brasaemle, 2007) and cell death-
inducing DFFA-like effector A (CIDEA) (Puri, et al., 2008), associate with the 
LD in human adipocytes and seem to play a role in TAG deposition and lipolysis. 
Lipolysis in WAT and the subsequent increase in plasma NEFA has been 
considered inevitable in obesity and was suggested as a mechanism for obesity 
induced T2DM. However many studies have shown that as WAT mass expands, 
NEFA release per kilogram WAT is downregulated. Furthermore, obese T2DM 
subjects can have normal NEFA concentrations and subjects with elevated NEFA 
concentrations do not necessarily have insulin resistance (Karpe, et al., 2011). 
Lipolytic products including FAs and DAGs serve as signalling intermediates and 
may play a role in metabolic regulation (Masoodi, et al., 2014; Zechner, et al., 
2012).  
 
Adipose tissue is the body’s biggest pool of cholesterol. In adipocytes nearly all 
cholesterol (>95 %) exists as free, non-esterified form and resides mostly in the 
LD (Murphy, et al., 2009) and a lower amount in plasma membrane (PM) 
invaginations called caveolae (Pilch, et al., 2011). Adipocyte cytoplasmic 
cholesterol derives mostly from lipoprotein uptake, whereas PM cholesterol is 
predominantly from de novo cholesterol biosynthesis (Musso, et al., 2013). 
Caveolae are important signalling platforms, serving as a concentrating point for 
several signalling molecules, including glucose transporter type 4 (glut4) and 
insulin receptor, and their stability and functionality depends on high PM 
cholesterol content. Decreasing PM cholesterol, as is the case in hyperthrophied 
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adipocytes in dysregulated obesity, dilutes the PM cholesterol across an increased 
cell surface (Le Lay, et al., 2001). Consequently, sterol regulatory element-
binding protein 2 (SREBP2) detects cholesterol PM dilution as cholesterol 
depletion and activates transcription of cholesterol biosynthesis genes, further 
promoting cholesterol accumulation (Bauer, et al., 2011). In addition, PM 
cholesterol depletion disrupts caveolae integrity and function and subsequently 
impairs intracellular insulin signalling (Breen, et al., 2012). The regulation of 
adipocyte lipid metabolism is therefore paramount to ensure appropriate energy 
utilisation. 
 
1.4.2 Carbohydrate metabolism  
Metabolism of carbohydrates in WAT is essential for the transfer of energy to 
quickly available energy via the generation of adenosine triphosphate (ATP) and 
for long-term energy storage via integration with lipid synthesis. WAT stores the 
largest energy reserve in the body, however this is almost exclusively made up of 
TAG and relatively little carbohydrate is stored. The liver and skeletal muscle 
store most of the body’s carbohydrate reserve as glycogen, and glycogen storage 
diseases primarily affect these tissues (Hicks, et al., 2011). Glucose enters 
adipocytes through glut4 responsible for basal (unstimulated) and insulin-
stimulated glucose uptake (Mueckler and Thorens, 2013). In WAT, glucose is 
mostly used for mitochondrial dependent aerobic respiration to generate ATP. 
Mitochondrial dysfunction in WAT has been linked to activation of ER stress 
(Rainbolt, et al., 2014) and progression of T2DM (Kusminski and Scherer, 2012). 
Within adipocytes the interorganellar organisation between the mitochondria and 
ER is important to perform specialised tasks. Bidirectional communications 
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between these two compartments is supported by evidence suggesting the 
regulation of numerous physiological processes including mitochondrial 
metabolism, calcium signalling and cell death (de Brito and Scorrano, 2010). 
Therefore the functional integrity of the ER plays a vital role in cellular energy 
homeostasis and thus in turn systemic energy homeostasis.  
 
In lipogenic tissues, such as WAT, the expression and activity of glycolytic and 
lipogenic pathways are linked. Carbohydrates are utilised in adipocytes both for 
the synthesis of TAG from existing fatty acids, and for the synthesis of new fatty 
acid molecules from non-lipid substrates in de novo lipogenesis (DNL). The 
synthesis of TAG requires glycerol-3-phoshate (G3P) for the initial step of fatty 
acid esterification. G3P is produced in adipocytes either from glucose through the 
first steps of glycolysis or from gluconeogenic precursors through 
glyceroneogenesis (Reshef, et al., 2003). Human DNL contributions from liver 
(1.5 kg) and WAT (12 – 15 kg), on a whole body basis, are comparable between 1 
– 2 g/day for each tissue (Diraison, et al., 2003). DNL in human adipocytes is 
stimulated by glucose and a full stimulation requires the simultaneous presence of 
glucose and insulin (Foufelle, et al., 1992). In the liver glucose acts by 
dephosphorylation of carbohydrate response element binding protein (ChREBP) 
allowing it to enter the nucleus where it binds to a specific response element in the 
promoter of glycolytic (liver pyruvate kinase, L-PK) and lipogenic (fatty acid 
synthase, FAS and acetyl-CoA carboxylase, ACC) genes. The roles of glucose 
and ChREBP in WAT are not as extensively studied as in the liver, however 
evidence suggests signalling is mediated through the activation of the classical 
ChREBP isoform ChREBP- and the expression of a recently identified isoform, 
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ChREBP- (Herman, et al., 2012). This new isoform is a potent stimulator of the 
lipogenic pathway. Therefore carbohydrate metabolism in WAT is essential for 
systemic energy regulation and dysfunction in T2DM can have many adverse 
consequences.  
 
1.4.3 Regulation of adipose metabolism  
Adipocyte metabolism is subject to several levels of regulation, including 
endocrine, metabolic and neuronal that synergistically coordinate appropriate 
energy transfer for the varying needs of the body influenced by diet, physical 
activity and physiological processes. Endocrine and metabolic regulators are 
distributed to adipocytes via the blood flow, hence the regulation of blood flow 
itself can alter the metabolism of WAT (Frayn and Karpe, 2014). Insulin is the 
classical regulator of metabolism in WAT. The hormone is secreted by pancreatic 
-cells and has systemic metabolic effects, altering liver, muscle and WAT 
metabolism. In adipocytes insulin activates several signalling cascades that 
include the activation by phosphorylation of Akt, also known as protein kinase B, 
that result in enhanced glucose uptake and inhibited lipolysis, as reviewed by Guo 
(Guo, 2014). Insulin secretion is stimulated in the post-prandial state by a class of 
gut hormones called incretins that include glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic peptide (GIP) (Kim and Egan, 2008). 
Conversely, in the fasted state insulin secretion is inhibited by a recently 
identified hormone called limostatin which is expressed in -cells and described 
as a ‘decretin’ (Alfa, et al., 2015). Other important endocrine hormones also 
control adipose tissue physiology and metabolism, including growth hormone and 
thyroid hormone as reviewed by Carmean et al. (Carmean, et al., 2014), 
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androgens (O'Reilly, et al., 2014) and glucocorticoids (Lundgren, et al., 2008). 
Metabolic nutrients including glucose, amino acids and fatty acids are capable of 
activating intracellular signalling cascades such as the hexosamine, mammalian 
target of rapamycin (mTOR) and adenosine monophosphate-activated protein 
kinase (AMPK) signalling pathways (Marshall, 2006). The aforementioned 
pathways are interconnected, coupled to insulin signalling and linked to the 
release of metabolic hormones from WAT (Holzer, et al., 2011). Vitamin B12 
deficiency has been linked to an adverse lipid profile in subjects with T2DM in 
multiple populations, therefore micronutrients including vitamin B12 may also 
influence WAT metabolism (Adaikalakoteswari, et al., 2014). WAT is innervated 
by the SNS and adipocyte lipolysis can be stimulated by norepinephrine (NE) 
activating -adrenoceptor and consequent downstream activation of HSL 
(Bartness, et al., 2014). These endocrine, metabolic and neuronal factors interplay 
to coordinate adipocyte metabolism.  
 
Adipocyte metabolism is also influenced by genetic makeup and epigenetic 
mechanisms of genome regulation. Genome wide association studies (GWAS) 
have identified candidate genes such as transcription factor 7-like 2 (TCF7L2) 
with specific alleles that confer an increased relative risk for developing T2DM 
through altered metabolism (Grant, et al., 2006). Not only do certain genes confer 
an increased risk for developing T2DM, but also how genes are regulated. This is 
important during embryonic development, where several factors including the 
nutritional status of the mother influence the genetic regulation of the foetus by 
epigenetic mechanisms, such as DNA methylation, and predict metabolic health 
outcomes of the foetus (Kaijser, et al., 2009). Epigenetic genome regulation is not 
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confined to development; indeed it is a dynamic process that occurs throughout 
life. DNA methylation profiles of several genes biologically relevant to the 
development of adiposity including lipase, hormone sensitive (LIPE) encoding 
HSL, in SAT of adult men and women are associated with extent of adiposity 
(Agha, et al., 2014). Vitamin B12 insufficiency has been shown to induce 
cholesterol biosynthesis by limiting s-adenosylmethionine and modulating the 
methylation of SREBF1 and LDLR genes (Adaikalakoteswari, et al., 2015). A 
further link between genome and metabolic profile has been hypothesised via 
telomere length. Enhanced biological aging in South Asian T2DM men with 
reduced telomere length tracked changes in lipids and BMI (Harte, et al., 2012a). 
Therefore adipocyte metabolism plays a vital role in energy homeostasis and is 
regulated by several mechanisms. In T2DM these regulatory mechanisms fail and 
adipocyte metabolism becomes dysregulated causing considerable pathologies. 
Elucidating the initiation of adipocyte dysregulation will allow development of 
preventive measures and alleviate the burden of T2DM. 
 
 
 
 
 
 
 
 
 
 
50 
Figure 1.4.3  The importance of adipose tissue 
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Figure 1.4.3 legend: The importance of adipose tissue. Adipose tissue is 
multifunctional and integrates several systems in the body to fulfill several vitally 
important roles.  
 
1.5 Adipogenesis 
Adipocytes are specialised cells that synthesise and store fat in WAT and play a 
major role in systemic energy homeostasis. In order to accommodate the energy 
requirements of the body WAT is able to expand and contract during adult life 
despite most development during prenatal and early postnatal life (Poulos, et al., 
2010). WAT expansion occurs primarily in two ways, by increasing adipocyte cell 
number (hyperplasia) or by increasing the size of existing adipocytes 
(hypertrophy). Evidence suggests obesity complications in humans result from the 
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inability of SAT to appropriately expand and store lipids, and consequently 
ectopic fat deposition and lipotoxicity contribute to insulin resistance (Virtue and 
Vidal-Puig, 2010). Impaired WAT expandability is mainly due to defects in 
progenitor cells to fail to supply specialised cells through their differentiation into 
adipocytes, a process termed adipogenesis (Isakson, et al., 2009). Forced 
expansion of WAT via increased hyperplasia induced by transgenic 
overexpression of adiponectin in ob/ob mice normalized glucose and insulin 
levels and prevented insulin resistance despite massive obesity (Kim, et al., 2007). 
Therefore adipogenesis is an important process to maintain WAT metabolic 
function. Adipogenesis is continually required throughout life since about 10 % of 
adipocytes in the body are regenerated annually (Spalding, et al., 2008). In their 
2013 Nature Medicine article, Scherer’s group described understanding the 
underlying mechanisms of adipogenesis as ‘more than an academic exercise’ and 
‘of paramount importance with respect for clinical readouts for the metabolic 
syndrome in the clinic’ (Wang, et al., 2013). Furthermore Peirce et al. have 
proposed in their 2014 Nature Review article that ‘the development of successful 
strategies to target adipose tissues will depend on investigations that elucidate 
their developmental origins and cell-type-specific functional regulators’ (Peirce, 
et al., 2014). Therefore characterising human adipogenesis is vital for gaining 
insight into the pathogenesis of metabolic diseases such as T2DM and for 
identifying potential targets for pharmacological intervention. 
 
1.5.1 Progenitor origin and cell lineage 
Several sites of adipocyte progenitor origin have been explored including 
ectodermal, mesenchymal, endothelial, and hematopoietic, however further 
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clarification is required as reviewed by Hyvonen and Spalding (Hyvonen and 
Spalding, 2014). Adipocytes are thought to derive mostly from mesodermal stem 
cells residing in the AT stroma. Human WAT is an established source if 
multipotent stem cells (Zuk, et al., 2002). Furthermore, analysis of intact human 
SAT revealed adipose derived stem cells distributed in the stroma (Maumus, et 
al., 2011). However, linear tracing studies in mice indicate that a subset of facial 
adipocytes originate from the neural crest and therefore derive from the ectoderm 
(Billon, et al., 2007). Evidence suggests adipocyte precursors may have 
endothelial origin and exist in the AT vasculature, integrated in the walls of blood 
vessels in WAT (Sengenes, et al., 2005; Tang, et al., 2008). This finding is 
supported by reports indicating that angiogenesis and adipogenesis are tightly 
correlated (Cao, 2007). Bone marrow reconstitution studies found that bone 
marrow progenitor-derived adipocytes and AT progenitor-derived adipocytes both 
derive from hematopoietic cells via the myeloid lineage (Majka, et al., 2010). 
These bone marrow progenitor-derived adipocytes accumulated more in women 
compared to men, and more in VAT compared to SAT and therefore may 
contribute to WAT depot heterogeneity.  
 
Adipocyte progenitors in human AT have been found to be depot-specific 
(Tchkonia, et al., 2007) and differences between adipocytes derived from SAT 
and VAT have been documented (Kovsan, et al., 2009). Functional differences 
between mesenchymal stem cell populations are reflected by their transcriptome 
(Jansen, et al., 2010). Adipocyte progenitors may contribute towards regional 
variation in WAT function and development (Baglioni, et al., 2012). This may in 
part explain the depot-specific differences in metabolic function and association 
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with relative risk of developing T2DM (Karastergiou, et al., 2013). With 
nutritional overload VAT expands predominantly by adipocyte hypertrophy 
whereas SAT by adipocyte hyperplasia (Joe, et al., 2009). Hyperplasia allows a 
greater expansion compared to hypertrophy and therefore the difference in 
expansion method between SAT and WAT may partly explain why central 
obesity, characterised by expanded VAT and Abd SAT, confers a greater risk of 
metabolic dysfunction than gluteal and femoral SAT expansion.   
 
1.5.2 Adipogenesis regulation 
Adipogenesis describes the transition of fibroblast-like preadipocytes into 
differentiated, lipid-laden, insulin-responsive adipocytes, highly expressing 
adipocyte-specific genes such as adiponectin (Ouchi, et al., 2003). 
Characterisation of adipogenesis regulatory processes have benefited from the 
discovery of key pathways and transcription factors that contribute to the 
adipogenic process, as reviewed by Lefterova and Lazar (Lefterova and Lazar, 
2009). The transcription factors peroxisome proliferator-activated receptor gamma 
(PPAR) and CCAAT/enhancer-binding proteins (CEBPs) are considered the 
crucial determinants of adipocyte fate. Although other factors including 
extracellular acting wingless-type mouse mammary tumour virus integration site 
family proteins (Wnts) and intracellular cell-cycle proteins also play roles in 
adipogenesis. There are several inhibitors of adipogenesis including CEBP 
homologous protein-10 (CHOP) upregulated in ER stress by the unfolded protein 
response (UPR) (Hou, et al., 2013), and certain T-cell factor/lymphoid enhancer 
factor (TCF/LEF) proteins, activated by Wnt signalling (Farmer, 2006). 
Expression of CHOP in 3T3-L1 adipocytes attenuated adiponectin promoter 
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activity (Hosogai, et al., 2007), therefore ER stress activation of CHOP during 
adipogenesis might suppress adipocyte gene expression. Recently the micro RNA 
(miRNA) miR-540 has been suggested to impair adipogenesis via suppression of 
PPAR (Chen, et al., 2015). Adipogenesis is associated with the UPR, and the 
UPR pathway IRE1 - XBP1s is indispensible for successful murine adipogenesis 
(Sha, et al., 2009). Thus, ER stress activation of the UPR may disrupt 
adipogenesis and consequently limit the expansion of WAT by hyperplasia and 
increase the likelihood of developing insulin resistance. Therefore a network of 
transcription factors and cell-cycle regulators, in concert with transcriptional 
coactivators and corepressors, respond to extracellular stimuli to activate or 
repress adipogenesis.  
 
CEBP, - and - belong to a family of highly conserved basic-leucine zipper 
proteins and were among the first transcription factors to be implicated in 
adipocyte differentiation (Otto and Lane, 2005). CEBP is induced early in 
adipogenesis to transactivate the expression of both CEBP and PPAR (Guo, et 
al., 2015). CEBP is induced late in adipogenesis and is most highly expressed in 
adipocytes where it is essential for insulin-dependent glucose uptake (Wu, et al., 
1999). CEBP-knockout mice with liver abnormalities rescued to prevent death 
fail to accumulate WAT in all depots and have hyperlipidemia and 
hyperinsulinemia (Linhart, et al., 2001). CEBP has been shown to bind to 
several individual genes in adipocytes, however the extent of CEBP binding to 
genomic DNA was unknown until the employment of GWAS. GWAS have 
revealed thousands of CEBP binding sites, many of which have a considerable 
degree of colocalization with PPAR (Lefterova, et al., 2008). Therefore both 
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CEBP and PPAR may be required for the expression of genes at which the two 
transcription factors colocalize.  
 
PPAR induction during adipogenesis is both necessary and sufficient and no 
factor has been identified that can rescue adipogenesis in the absence of PPAR 
(Tontonoz and Spiegelman, 2008). PPAR belongs to the nuclear receptor 
superfamily of ligand-activated transcription factors (Lehrke and Lazar, 2005). 
The endogenous PPAR ligand requires clarification, although lipid metabolites 
such as polyunsaturated fatty acids (PUFAs) and eicosanoids have been 
implicated as ligands (Fu, et al., 2005). GWAS have shown PPAR has 
approximately 5,300 DNA binding sites, several of which are also bound by 
retinoid X receptor (RXR), and related to the DR-1 consensus sequence (Nielsen, 
et al., 2008). This is strengthened by evidence of PPAR binding as a heterodimer 
with RXR on DNA at the DR-1 consensus sequence (Chandra, et al., 2008). 
PPAR can bind to target genes without a ligand bound. In this state several 
corepressors bind that collectively recruit histone deacetylases that repress 
transcription. When a ligand binds PPAR a conformational change occurs that 
allows the binding of coactivators such as steroid receptor coactivators (SRCs) 
(Tontonoz and Spiegelman, 2008). In adipocytes some genes like fatty acid 
binding protein 2 (aP2) are constitutively associated with PPAR and coactivators 
resulting in high transcription levels. However other genes such as glycerol kinase 
(Gyk) and oxidized LDL-receptor 1 (Olr1) require a ligand to bind to PPAR to 
cause the exchange of corepressors for coactivators to activate gene transcription 
(Guan, et al., 2005). Receptor-interacting protein 140 (RIP140) binds to the 
PPAR liganded receptor but represses transcription (White, et al., 2008). RIP140 
56 
antagonizes the effects of PPAR coactivator-1 (PGC-1), a coactivator that 
induces mitochondrial biogenesis and may play a role in systemic metabolism 
(Nautiyal, et al., 2013). UPR is associated with adipogenesis and the UPR 
activated transcription factor X-box binding protein 1 (XBP1) is a novel key 
regulator of PPAR in murine models (Cho, et al., 2014). Elucidating the links 
between human UPR and adipogenesis will provide insight into the regulation of 
adipogenesis and may help derive pharmacological targets with clinical benefit for 
the treatment of obesity and T2DM. 
 
1.5.3 Wnt signalling in adipogenesis 
Wnt proteins comprise a family of highly conserved secreted proteins that exert 
autocrine and paracrine actions via binding to cell-surface receptors (Herr, et al., 
2012). Wnt ligands bind to the frizzled (FZD) and low-density-lipoprotein-related 
protein 5/6 (LRP5/6) coreceptor complex to activate the canonical Wnt signalling 
pathway (figure 1.5.3). The activated receptor complex disrupts or functionally 
inactivates a -catenin destruction complex. The destruction complex consists of 
the scaffold protein Axin, adenomatous polyposis coli (APC), glycogen synthase 
kinase-3 (GSK-3) and casein kinase-1 (CKI). When Wnt is not bound to its 
surface receptors, the destruction complex is active and regulates the 
phosphorylation, ubiquitination and subsequent degradation of -catenin. When 
Wnt is bound to its surface receptors, the destruction complex is inhibited, -
catenin accumulates in the cytoplasm and translocates to the nucleus where it 
engages the TCF/LEF transcription factors to activate the Wnt transcriptional 
program (Li, et al., 2012). Several TCF/LEF targets are linked to cell 
differentiation. For example TCF7 has been shown to regulate a self-
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renewal/differentiation switch that operates in the absence of Wnt signalling (Wu, 
et al., 2012). Negative feedback regulation of the Wnt pathway is thought to be 
mediated through conductin, encoded by the AXIN2 gene and also known as axin2 
(Bernkopf, et al., 2015). 
 
Figure 1.5.3  Wnt signalling pathway 
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Figure 1.5.3 legend: Wnt signalling pathway. Wnt proteins are secreted and exert 
autocrine and paracrine actions via binding to cell-surface receptors and result in 
target cell -catenin translocating to the nucleus to activate Wnt target genes. 
(Wnt; Wingless-type mouse mammary tumour virus integration site family 
protein, LRP; low-density-lipoprotein-related protein, Dvl; dishevelled, APC; 
adenomatous polyposis coli, GSK-3; glycogen synthase kinase-3, CKI; casein 
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kinase-1, -TrCP; beta-transducin repeat containing E3 ubiquitin protein ligase, p; 
phosphorylated, Ub; ubiquitin, TCF; T-cell factor.) 
 
The Wnt and -catenin canonical pathway is well established in morphogenesis of 
bone, intestine and the hematopoietic system (Clevers and Nusse, 2012). The first 
report linking Wnt signalling to adipogenesis demonstrated that activation of the 
Wnt pathway impairs adipogenesis in 3T3-L1 preadipocytes (mouse derived 
preadipocytes with the capacity to undergo adipogenesis into adipocytes (Green 
and Kehinde, 1975)) (Ross, et al., 2000). In a subsequent investigation, -catenin 
was selectively deleted in uterine mesenchyme during early embriogenesis, which 
led to the replacement of uterine smooth muscle with adipocytes. The adipocytes 
were found to originate from the same precursors as smooth muscle cells, 
indicating Wnt proteins influence adipocyte cell fate in vivo (Arango, et al., 2005). 
It has been hypothesised that reciprocal repression might exist between Wnt 
signalling and CEBP or PPAR because activation of these factors can lead to a 
substantial reduction in -catenin levels (Moldes, et al., 2003). More recently it 
has been suggested that Wnt normally inhibits CEBP as a negative feedback 
loop to reduce adipogenesis (Christodoulides, et al., 2009). 
 
Wnt10b has been extensively studied in an adipogenesis context (Rosen and 
MacDougald, 2006). Wnt10b has been shown to impair WAT and BAT formation 
in vivo when overexpressed specifically in mouse adipocytes (Longo, et al., 
2004). Furthermore, increasing Wnt10b levels in WAT leads to decreased 
susceptibility to obesity in both diet-induced (Longo, et al., 2004) and genetic 
mouse models (Wright, et al., 2007). Wnt10b also seems to play a key role in 
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human adipogenesis. Naturally occurring mutations in WNT10B gene are 
associated with early-onset obesity (Christodoulides, et al., 2006). Furthermore, 
Wnt10b has been shown to impair human preadipocyte differentiation (Isakson, et 
al., 2009). And abnormal expression of genes involved in Wnt signalling have 
been recorded in the adipose tissue of PCOS patients (Chazenbalk, et al., 2012). 
Wnt10b may link the UPR with adipogenesis. XBP1s enhances adipogenic 
differentiation in murine cells through downregulation of Wnt10b (Cho, et al., 
2013). Clarifying the links between human UPR and adipogenesis will provide 
insight into the regulation of adipogenesis and may generate pharmacological 
targets with clinical benefit for the treatment of obesity and T2DM. 
 
1.6 Adipocyte endoplasmic reticulum stress 
WAT is comprised of adipocytes integrated in a connective tissue matrix with 
highly regulated vasculature and innervation. A principle function of WAT is to 
appropriately store and release energy. The endoplasmic reticulum is vital for 
adipocyte energy transfer coordination. To store energy, adipocytes synthesise 
TAG and then partition them into LDs, both processes take place at the ER 
membrane and require ER resident enzymes. To utilise energy, adipocytes depend 
on ER and mitochondrial coordination for suitable function. Adipocytes also 
regulate cellular function in distant tissues and organs including muscle, liver and 
the brain. This regulation is predominantly through endocrine mediated 
mechanisms that require functional ER for the synthesis, processing, and secretion 
of adipokines. Impairments in energy regulation and secretory function of WAT 
adipocytes in obesity are associated with the development of insulin resistance 
and T2DM. Although the cellular mechanisms leading to these impairments are 
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complex, accumulating evidence suggests dysregulated ER caused by ER stress 
may play a role. 
 
1.6.1 Endoplasmic reticulum stress and the unfolded protein response 
Virtually all secretory and membrane proteins are assembled into their secondary 
and tertiary structures within the extensive network of membranes that comprise 
the ER. This specialised organelle allows correct folding, maturation, storage and 
transport of these proteins. Misfolded or unfolded proteins are detected, removed 
from the ER and degraded by the 26S proteasome system (Marciniak and Ron, 
2006; Schroder and Kaufman, 2005). The ER can experience perturbations and 
become stressed in a number of situations including the accumulation of unfolded 
proteins, nutrient and energy fluctuations, viral infections, hypoxia, toxins and 
increased demand on the synthetic machinery. When these conditions arise the ER 
activates a complex response system known as the unfolded protein response 
(UPR) (figure 1.6.1) to restore the functional integrity of the organelle (Marciniak 
and Ron, 2006; Schroder and Kaufman, 2005).  
 
In mammals the UPR is comprised of three main branches, signalling through 
which is mediated by inositol-requiring enzyme 1α (IRE1α), PKR-like 
endoplasmic reticulum kinase (PERK) and activating transcription factor 6 
(ATF6) (Harding, et al., 2000b; Harding, et al., 1999). In unstressed ER these 
three transmembrane proteins are bound by a chaperone, Bip/GRP78, in their 
intralumenal domains and rendered inactive (Bertolotti, et al., 2000; Shen, et al., 
2002). Accumulation of improperly folded proteins and increased protein cargo in 
the ER results in the recruitment of Bip away from these UPR sensors. This and 
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potentially other yet to be discovered lumenal events result in oligomerization and 
activation of IRE1α and PERK that engage a complex signalling cascade (Ron 
and Walter, 2007). PERK is activated by homodimerization and 
transphosphorylation, which allows it to phosphorylate the -subunit of the 
translation initiation factor eIF2 (p-eIF2) and subsequently attenuate translation 
initiation. Paradoxically, p-eIF2 leads to selective translation of mRNAs 
containing open reading frames, such as activating transcription factor-4 (ATF4) 
(Schroder and Kaufman, 2005). ATF4 then upregulates the expression of several 
genes including DNA-damage-inducible transcript 3 (DDIT3) that encodes the 
effector protein CHOP (Woo, et al., 2009). The third branch of the UPR requires 
translocation of ATF6 to the Golgi apparatus where it is processed by the serine 
protease site-1 protease (S1P) and the metalloprotease site-2 protease (S2P) to 
produce an active transcription factor (Chen, et al., 2002). In response to ER 
stress ATF6 is reduced and only the reduced monomeric ATF6 can reach the 
Golgi apparatus (Nadanaka, et al., 2007). In combination these three arms 
mitigate ER stress by reducing protein synthesis, facilitating protein degredation, 
and increasing production of chaperones that help proteins in the ER lumen to 
fold. Consequently ER stress is alleviated. If ER stress is not resolved the cell is 
functionally compromised and may undergo UPR mediated apoptosis. 
 
Conserved from yeast to humans, IRE1α is a stress regulated kinase and 
ribonuclease that heads one of the UPR branches (Calfon, et al., 2002). The 
endoribonuclease activity of IRE1α cleaves a 26 base-pair intron between 
nucleotides 531 – 556 from the mRNA of the unspliced X-box binding protein-1 
(XBP1u), creating an alternative mRNA that is translated into the active (spliced) 
62 
form of the transcription factor (XBP1s) (Sidrauski and Walter, 1997; Uemura, et 
al., 2009). XBP1s, alone or in conjunction with ATF6, can initiate transcription of 
chaperones like Bip, and proteins involved in phospholipid synthesis, ER 
biogenesis, ER-associated protein degradation (ERAD), and secretion. Therefore 
XBP1s plays a major role in alleviating ER stress. The adipocyte plays a central 
role in energy homeostasis and in the obese state hypertrophic adipocyte is 
challenged by several insults including inflammation, insulin resistance, surplus 
energy and considerable stress to various organelles. The ER is a vital organelle 
that demonstrates significant signs of stress and dysfunction in obesity and insulin 
resistance.  
 
The ER within a functional adipocyte in a metabolically healthy organism must 
function under unique and testing conditions; adapting to meet the demands of 
energy storage by forming TAG droplets, increased protein synthesis and 
secretion and nutrient sensing. The ER can become overwhelmed when nutrient 
levels are in pathological excess in which case the UPR is activated (Ozcan, et al., 
2004). 
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Figure 1.6.1  Mammalian unfolded protein response pathways  
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Figure 1.6.1 legend: Mammalian unfolded protein response pathways. Unfolded 
protein response signalling pathways originate in the ER lumen and transfer to the 
cytoplasm and nucleus to engage appropriate responses. (ER; endoplasmic 
reticulum, Bip; binding immunoglobulin protein – also known as GRP78; glucose 
regulated protein 78 kDa, PERK; protein kinase RNA-like endoplasmic reticulum 
kinase, p; phosphorylated, eIF2; eukaryotic translation initiation factor 2 A, NF-
B; nuclear factor kappa-light-chain-enhancer of activated B cells, ATF4; 
activating transcription factor 4, CHOP; C/EBP homologous protein, GADD34; 
growth arrest and DNA damage-inducible protein, IRE1; inositol requiring 
enzyme 1 alpha, XBP1u; X-box binding protein 1 unspliced, XBP1s; X-box 
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binding protein 1 spliced, GRPs; glucose regulated proteins, ATF6; activating 
transcription factor 6, MBTPS2; membrane-bound transcription factor peptidase 
site 2.) 
 
1.6.2 Adipose tissue endoplasmic reticulum stress 
Genetically inherited disorders of protein trafficking are almost exclusively 
attributed to mutations in the coding sequence of exportable proteins and result in 
retention of the affected proteins or subunits in the ER (Kim and Arvan, 1998). 
These diseases have revealed the importance of the ER in protein processing. 
Mouse models with specific genetic alterations to genes encoding ER chaperones 
have shown that resident ER chaperones are critical for quality control of proteins 
and for regulating ER signalling in response to ER stress (Ni and Lee, 2007). 
Growing evidence suggests that diseases involving the ER are not restricted to 
genetic disorders and can be acquired in obesity. SAT from the upper thigh in six 
obese insulin-resistant human subjects had significantly higher ER stress gene and 
protein expression compared to six lean insulin-sensitive subjects (Boden, et al., 
2008). In a different investigation WAT was collected from 78 healthy non-
diabetic human subjects with a range of BMIs and UPR gene expression 
positively correlated with increasing BMI (Sharma, et al., 2008). In a third study 
SAT ER stress expression reduced one year after undergoing gastric bypass 
surgery in 11 non-diabetic obese subjects with preoperative mean BMI of 51.3 ± 
3.0 kg/m2 and postoperative mean BMI of 31.4 ± 2.3 kg/m2 (Gregor, et al., 2009). 
Weight loss through calorie restriction in ob/ob mice also reduced ER stress 
expression in SAT (Tsutsumi, et al., 2011).  
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1.6.3 Obesity induces adipocyte endoplasmic reticulum stress 
Several obesity-related perturbations, including hyperglycaemia, endotoxemia, 
elevated circulating FFAs, overnutrition, increased ER demand and local tissue 
hypoxia may serve as initiating factors for ER stress in WAT (Gregor and 
Hotamisligil, 2007; Hotamisligil, 2010). This postulation is supported by murine 
in vivo and in vitro experimental models, for example in WAT of mice fed a high-
fat diet for 16 weeks, indicators of ER stress such as PERK phosphorylation and 
c-Jun N-terminal kinase (JNK) activity are significantly increased compared with 
mice fed with a normal diet (Ozcan, et al., 2004). Furthermore, WAT in ob/ob 
mice displayed signs of ER stress, including increased levels of phosphorylated 
PERK and IRE1α, compared to wild type mice. This was accompanied by an 
increase in JNK activity and XBP1 splicing (Ozcan, et al., 2006). WAT of obese 
mice was characterised by hypoxia and ER stress and in an in vitro model hypoxia 
increased markers of ER stress in 3T3-L1 adipocytes (Hosogai, et al., 2007). 
Thus, dysregulated WAT expansion in obesity may not be served by adequate 
vasculature and therefore the diffusion limit of oxygen may be exceeded, resulting 
in local hypoxia (Yilmaz and Hotamisligil, 2013). Mice with a heterozygous 
deletion of UPR chaperone Bip had an activation of UPR factors including CHOP 
and XBP1s and were protected against diet-induced obesity, hepatic steatosis and 
insulin resistance (Ye, et al., 2010). A mixture of FFAs increased markers of ER 
stress in 3T3-L1 adipocytes (Jiao, et al., 2011). Lipid perturbation-mediated UPR 
activation in mammalian cells revealed the ER lipid bilayer can directly modulate 
UPR signalling independently of changes to protein folding homeostasis in the ER 
lumen (Volmer, et al., 2013). 
 
66 
Human adipocyte experimental models support murine investigations and indicate 
that obesity associated factors induce ER stress. High fat intake leads to acute 
postprandial exposure to circulating lipopolysaccharides in T2DM subjects 
(Harte, et al., 2012b). Obesity associated factors including LPS (100 mg/mL), 
high glucose (25 mM) and saturated FAs (2 mM) increased markers of ER stress 
in primary human adipocytes (Alhusaini, et al., 2010). Adipocytes increase the 
rate of secretion of several proteins in response to adipocyte expansion such as 
leptin, resistin and TNF (Galic, et al., 2010). Thus, the increased demand on the 
ER to process these secreted proteins may lead to accumulation of unfolded 
proteins and activation of the UPR. Therefore many physiological responses to 
obesity can influence adipocyte ER homeostasis and elicit activation of the UPR.  
 
1.7 Endoplasmic reticulum stress induced insulin resistance in adipose 
tissue 
The diversity of ER stress induced UPR signalling likely generates suitable 
outcomes that are specific to the stress imposed and the homeostatic needs of the 
cell. These outcomes include adaptation to restore ER functional integrity, alarm 
to induce an inflammatory response, and apoptosis if there is a failure to resolve 
ER stress (Kim, et al., 2008). Whilst these UPR outcomes may have evolved in 
nutrient scarce environments to improve cellular and tissue function, in obesity-
linked nutrient excess the UPR is chronically activated and metabolic dysfunction 
via insulin resistance and subsequent T2DM can arise (Kammoun, et al., 2014). 
Evidence suggests that ER stress is linked to insulin resistance (Flamment, et al., 
2012). For example, deletion of a key UPR transcription factor XBP1, results in 
the development of insulin resistance in mice (Ozcan, et al., 2004). Further 
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experimental models have indicated that ER stress is essential to the initiation and 
integration of inflammation and insulin action in obesity and type 2 diabetes 
(Wellen and Hotamisligil, 2005). The consequences of UPR activation in WAT 
have been causally linked to the development of insulin resistance through several 
mechanisms including JNK activation, inflammation and oxidative stress 
(Hotamisligil, 2006; Samuel and Shulman, 2012). Hotamisligil has postulated that 
insulin is a crucial anabolic hormone and therefore transient insulin resistance in 
adipocytes may help the ER cope by downregulating metabolic synthetic 
pathways (Hotamisligil, 2010). This may be accurate and explain why chronic 
upregulation of the UPR in obesity is associated with insulin resistance and 
T2DM. 
 
1.7.1 IRE1 activation of JNK and NFB 
ER stress master regulator IRE1 induces insulin resistance via JNK and activates 
inflammation via JNK and NF-B. ER stress induced in rat pancreatic acinar 
AR52J cells by treatment with thapsigargin (Tg) (1 M) that depletes the ER of 
luminal calcium stores, tunicamycin (TM) (2.5 g/mL) that blocks ER protein 
glycosylation, and dithiothreitol (DTT) (10 mM) which interferes with disulfide 
bond formation, all exhibited increased JNK activity (Urano, et al., 2000). The 
cytoplasmic part of UPR master regulator IRE1 was shown to activate JNK via 
TNF receptor associated factor 2 (TRAF2) (Urano, et al., 2000). JNK promotes 
insulin resistance during association with insulin receptor substrate-1 and 
inhibitory phosphorylating key serine 307 (Aguirre, et al., 2000), and induces the 
expression of inflammatory genes by phosphorylating the transcription factor 
activation protein 1 (AP-1) (Davis, 2000). JNK activity is abnormally high in 
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obesity and furthermore, an absence of JNK1 results in decreased adiposity, 
improved insulin sensitivity and enhanced insulin receptor signalling capacity in 
two models of mouse obesity (Hirosumi, et al., 2002). The IRE1-TRAF2 
complex can recruit IB kinase (IKK), which phosphorylates IB, leading to the 
degradation of IB and the nuclear translocation of NF-B (Hu, et al., 2006). NF-
B is a potent activator of inflammation in human adipose tissue (Harte, et al., 
2013). JNK and NF-B influence visfatin expression in primary human SAT, 
therefore these factors can influence adipocyte hormone secretion and may have 
systemic consequences (McGee, et al., 2011). Therefore obesity-induced ER 
stress forms IRE1-TRAF2 complexes, which activate JNK and NF-B leading 
to insulin resistance and inflammation (figure 1.7.1). 
 
Figure 1.7.1 IRE1 activation of XBP1s and JNK 
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Figure 1.7.1 legend: IRE1 activation of XBP1s and JNK. IRE1 is activated by 
several factors (red box, top left), and splices XBP1u mRNA to XBP1s mRNA 
which is translated and the resulting protein transcription factor upregulates genes 
encoding proteins to help restore ER functional integrity. Simultaneously, IRE1 
binds via its cytoplasmic domain to TRAF2 which activates JNK which inhibitory 
phosphorylates IRS1/2 thereby blocking insulin action. JNK also activates AP-1 
to promote transcription of inflammatory genes. (HMW Adipo; high molecular 
weight adiponectin, ER; endoplasmic reticulum, Bip; binding immunoglobulin 
protein – also known as GRP78; glucose regulated protein 78 kDa, p; 
phosphorylated, IRE1; inositol requiring enzyme 1 alpha, XBP1u; X-box 
binding protein 1 unspliced, XBP1s; X-box binding protein 1 spliced, TRAF2; 
TNF receptor associated factor 2, JNK; c-Jun N-terminal kinase, IRS1/2; insulin 
receptor substrate 1/2, AP-1 activation protein 1, GRPs; glucose regulated 
proteins, Wnt10b; Wingless-type mouse mammary tumour virus integration site 
family protein 10b, PPAR; peroxisome proliferator-activated receptor gamma.)  
 
1.7.2 ER stress induced inflammation and subsequent insulin resistance 
The chronic nature of obesity produces tonic low-grade ER stress, inflammation 
and activation of the innate immune system in WAT (Lumeng and Saltiel, 2011). 
This physiological response to cell stress may have arisen due to the integrated 
immune role of WAT as a homeostatic mechanism to restore WAT function 
(Osborn and Olefsky, 2012). The adipocyte ER can be considered as an interface 
between the immune system and metabolism, both of which are incorporated in 
WAT (Unanue and Urano, 2014). The increased ER stress in obesity plays a key 
role in the inflammatory basis of metabolic disease, elegantly reviewed by 
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Hotamisligil (Hotamisligil, 2010). Inflammation is an immune response that 
serves to bolster the local tissue defence by attracting immune cells to prevent or 
engage with pathogens thereby protecting the body. Inflammation is 
predominantly controlled and directed by soluble mediators such as cytokines that 
are released by many cell types including adipocytes. Proinflammatory cytokines 
secreted by adipocytes such as TNF and IL-6 are critically important to attract 
inflammatory leukocytes to WAT (Fantuzzi, 2005). However the secretion of 
these cytokines is increased in obesity-linked ER stress and they interfere with 
insulin action and glucose metabolism (Kammoun, et al., 2014). 
 
Obesity-induced ER stress in adipocytes activates inflammation via several 
mechanisms (Zhang and Kaufman, 2008; Zhang, et al., 2006). IRE1-TRAF2 
complexes activate JNK and NF-B leading to inflammation (section 1.7.1 
above). IRE1 has also been linked to the activation of p38 mitogen-activated 
protein kinase and extracellular-regulated kinase (Hetz and Glimcher, 2009; Hu, 
et al., 2006; Nguyen, et al., 2004). These interactions suggest that IRE1 can 
activate diverse signalling pathways involved in activating inflammation. The 
PERK branch of the UPR can also activate inflammation. Saturated FAs activate 
ER stress and induce the PERK-eIF2-ATF4 UPR pathway that plays a critical 
role in IL-6 production in macrophages, and the same mechanism may exist in 
adipocytes (Iwasaki, et al., 2014). PERK also activates NFK mediated 
inflammation via reduction in the abundance of its inhibitor IK (Wu, et al., 
2004). Protein folding within the ER is an energy-consuming process and 
oxidising conditions are requires for the formation of disulphide bonds (Tu and 
Weissman, 2004). Molecular oxygen is used as the terminal electron recipient to 
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provide a driving force for disulphide bond formation, however this leads to the 
production of reactive oxygen species (ROS), exasperated with increased burden 
on ER in obesity (Tu and Weissman, 2002). ROS are small molecules that are 
highly reactive as the result of the presence of unpaired electrons and induce 
inflammation (Raha and Robinson, 2000). Therefore obesity-induced ER stress in 
adipocytes can initiate secretion of inflammatory cytokines resulting in WAT 
inflammation. 
 
Obesity-induced inflammatory response signalling mediators including FFAs, 
cytokines, adipokines and lipokines interfere with insulin action. Adipocyte ER 
stress may be an important initiator of WAT inflammation, however the release of 
proinflammatory mediators from WAT in obesity is primarily due to immune 
cells (Fain, 2006). The proinflammatory cytokine TNF is produced by 
adipocytes, is highly expressed in adipose tissue and is associated with obesity 
(Hotamisligil, et al., 1993). In rodent cells TNF elevated serine/threonine 
phosphorylation of IRS-1 and IRS-2 and inhibited their binding to the insulin 
receptor and impaired their ability to undergo insulin-induced tyrosine 
phosphorylation (Paz, et al., 1997). Mice lacking TNF or TNF receptors had 
improved insulin sensitivity in dietary and genetic (ob/ob) models of obesity 
(Uysal, et al., 1997). TNF has been shown to inhibit PPAR in several 
experimental systems (Ye, 2008). Therefore TNF may prevent adipogenesis and 
contribute towards WAT dysfunction. Obese human subjects demonstrated 
increased TNF expression in WAT compared to non-obese, and following 
weight loss the cytokine expression reduced (Kern, et al., 1995). Adipose tissue 
IL-6 content correlates with resistance to insulin activation of glucose uptake both 
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in vivo and in vitro (Bastard, et al., 2002). Furthermore, serum levels of IL-6 
decrease in parallel with weight loss and improvement of insulin resistance in 
patients undergoing bariatric surgery (Kopp, et al., 2003). Despite these findings, 
IL-6 has been associated with the resolution of inflammation in certain contexts 
and has versatile functions in metabolism (Mauer, et al., 2015). Nonetheless, IL-6 
expression is increased in obesity and may play a role in the development of 
insulin resistance and T2DM. Therefore WAT derived signalling molecules 
upregulated in response to adipocyte ER stress can interfere with insulin action 
and may contribute towards developing T2DM (figure 1.7.2). 
 
Figure 1.7.2 Unfolded protein response, inflammation and insulin resistance 
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Figure 1.7.2 legend: Unfolded protein response, inflammation and insulin 
resistance. Adipose tissue derived signalling molecules upregulated in response to 
adipocyte ER stress can interfere with insulin action and may contribute towards 
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developing T2DM. (ER; endoplasmic reticulum, IR; insulin receptor, p; 
phosphorylated, JNK; c-Jun N-terminal kinase, IKK; I kappa B kinase, NF-B; 
nuclear factor kappa-light-chain-enhancer of activated B cells, IRS1/2; insulin 
receptor substrate 1/2, AP-1 activation protein 1, PPAR; peroxisome proliferator-
activated receptor, LXR; liver X receptor, FABP; fatty acid-binding protein, FA; 
fatty acid.)  
 
1.7.3 ER stress integration with metabolism 
Adipocytes play a key role in systemic metabolism and require functional ER to 
appropriately orchestrate metabolic processes (Unanue and Urano, 2014). 
Accumulating evidence suggests an integrated role between the UPR and glucose, 
lipid and protein metabolism in adipocytes. For example; ER stress regulates 
branched chain amino acid uptake and metabolism in adipocytes (Burrill, et al., 
2015), the activity of key UPR chaperone Bip, also known as glucose-regulated 
protein 78 (Grp78), responds to metabolic stress (Lee, 2014), and asymmetrical 
dimethylarginine triggers lipolysis and inflammatory response via induction of ER 
stress in cultured adipocytes (Zhou, et al., 2009). ATF6 and XBP1s have been 
linked to lipid biosynthesis and ER membrane expansion via mechanisms that are 
partially distinct (Bommiasamy, et al., 2009; Sriburi, et al., 2004). ATF4 has been 
suggested to play a role in carbohydrate metabolism (Seo, et al., 2009). Therefore 
obesity-induced chronic ER stress may dysregulate adipocyte metabolic processes 
and contribute to insulin resistance and T2DM (figure 1.7.3).  
 
Models of UPR deficiency have shown that the UPR plays an important role in 
metabolism. An investigation into the regulation of eIF2 phosphorylation in the 
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liver revealed complex mechanisms that may be linked to liver glucose 
metabolism during chronic ER stress (Oyadomari, et al., 2008). A further study in 
liver hepatocytes found lipid metabolism is affected by protein misfolding and ER 
stress (Wang and Kaufman, 2014). PERK-deficient mice and animals with a 
homozygous mutation that eliminates eIF2 phosphorylation on serine 51 resulted 
in defective liver gluconeogenesis (Harding, et al., 2000a; Scheuner, et al., 2001). 
Protein kinase RNA-activated (PKR) responds to nutrient signals and ER stress 
and coordinates the activity of other critical inflammatory kinases such as JNK to 
regulate insulin action and metabolism. PKR also directly targets and modifies 
insulin receptor substrate and therefore integrates nutrients and insulin action 
(Nakamura, et al., 2010). The role of ER stress in glucose metabolism in other 
tissues and cells such as adipocytes remains unclear and Hotamisligil expressed 
‘future work should determine whether ER stress also affects glucose metabolism 
in other tissues’ (Hotamisligil, 2010).  
 
Adiponectin links adipocyte ER stress and the UPR to systemic insulin sensitivity. 
Adiponectin is almost exclusively produced by adipocytes (Ouchi, et al., 2003). 
An inverse correlation between adiponectin and insulin resistance has been 
established both in animals and humans (Turer and Scherer, 2012). Adiponectin 
improves insulin sensitivity through various mechanisms involving the liver and 
muscle (Kadowaki and Yamauchi, 2005; Turer and Scherer, 2012). HMW 
adiponectin is thought to confer insulin sensitising effects (Liu and Liu, 2014). 
Functional ER is essential for the synthesis, processing and secretion of 
adiponectin. ER resident proteins ER resident protein-44 (ERp44), ER 
oxidoreductin-1 (Ero1-1) and disulphide bond A oxidoreductase-like protein 
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(DsbA-L) play important roles in adiponectin processing (Liu, et al., 2008; Qiang, 
et al., 2007; Wang, et al., 2007). ER stress has been implicated in diet-induced 
adiponectin downregulation (Liu and Liu, 2014). The treatment of genetically and 
diet induced mouse models of obesity with Tauroursodeoxycholic acid (TUDCA), 
a chemical chaperone that alleviates ER stress, resulted in increased cellular and 
serum levels of adiponectin (Zhou, et al., 2010). This observation is supported by 
another study in ob/ob mice where overexpression of UPR transcription factor 
XBP1s induced adiponectin multimerisation and improved glucose homeostasis 
(Sha, et al., 2014). Therefore, obesity-induced chronic ER dysfunction reduces 
adiponectin levels and may contribute towards decreased systemic insulin 
sensitivity and subsequent development of T2DM.  
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Figure 1.7.3 legend: Balance between nutritional status, unfolded protein 
response activation and adipose tissue function. A balance exists between the 
nutritional status and activation of the unfolded protein response (UPR) and 
influences adipose tissue (AT) function. 
 
1.7.4 ER stress in adipogenesis   
Obesity complications in humans result from the inability of SAT to appropriately 
expand and store lipids, and consequently ectopic fat deposition and lipotoxicity 
contribute to insulin resistance (Samuel and Shulman, 2012; Virtue and Vidal-
Puig, 2010). Impaired WAT expandability is mainly due to defects in 
adipogenesis (Isakson, et al., 2009). Forced expansion of WAT in ob/ob mice via 
increased adipogenesis normalized glucose and insulin levels and prevented 
insulin resistance despite massive obesity (Kim, et al., 2007). Adipogenesis is 
continually required throughout life since about 10 % of adipocytes in the body 
are regenerated annually (Spalding, et al., 2008). Therefore adipogenesis is an 
important process to maintain WAT function. The UPR plays an essential role in 
adipogenesis. The UPR pathway IRE1 - XBP1s is indispensible for successful 
murine adipogenesis (Sha, et al., 2009). Since this discovery, Cho et al. have 
explored the role of XBP1s in adipogenesis further. They revealed that XBP1s 
enhances adipogenesis in 3T3-L1 cells through the downregulation of Wnt10b 
(Cho, et al., 2013). And XBP1s is a key regulator of adipogenic modulator 
PPAR in 3T3-L1 cells (Cho, et al., 2014). XBP1s has been shown to induce 
adiponectin multimerisation (Sha, et al., 2014) and may activate this process 
during adipogenesis since adiponectin expression is almost exclusively from 
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adipocytes (Ouchi, et al., 2003). Thus, obesity induced ER stress may disrupt 
adipogenesis and consequently limit the expansion of WAT and increase the 
likelihood of developing insulin resistance and T2DM. 
 
1.8 Translation to the clinic 
There are currently 14 classes of drugs available to treat T2DM in the USA, 
however only 36 % of patients with T2DM achieve glycaemic control with the 
available therapies (Miller, et al., 2014). New treatment options may improve the 
rate of glycaemic control. Duration of T2DM is independently associated with the 
risk of macrovascular events, microvascular events and death (Zoungas, et al., 
2014). Therefore early intervention to restore glucose homeostasis will provide 
the greatest benefit. Since obesity is the biggest risk factor for T2DM and obesity-
induced ER stress may be an initiating factor in development of insulin resistance 
and TD2M, preventing or treating obesity would reduce the burden of T2DM. 
Weight loss through diet modifications (Gregor, et al., 2009; Seoane-Collazo, et 
al., 2014) and through gastric bypass bariatric surgery in humans (Gregor, et al., 
2009) can reverse ER stress in adipose tissue and improve glucose homeostasis. 
Bariatric surgery has emerged as the most durably effective treatment of T2DM, 
however the mechanisms governing improvement in glucose homeostasis have 
not been fully elucidated (Nguyen and Korner, 2014). Some bariatric procedures 
improve glycaemic control in people with T2DM beyond that expected for weight 
loss alone (Dixon, et al., 2012). The improved glycaemic control in such people 
may be due to improved adipocyte ER regulation and subsequent improved 
metabolic regulation. Targeting the UPR in disease has recently been reviewed by 
Hetz et al. (Hetz, et al., 2013). Given that the adipocyte ER plays important roles 
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in systemic metabolism and energy homeostasis and that obesity-induced ER 
stress leads to insulin resistance, mechanisms for relieving ER stress and 
improving adipocyte ER regulation may improve metabolic regulation and reduce 
the impact of metabolic diseases such as T2DM.  
ER stress may be alleviated through the action of metabolic hormones such as 
GLP-1. GLP-1 receptor (GLP-1R) agonist exendin-4 attenuated translational 
downregulation of insulin and improved cell survival in purified rat pancreatic -
cells following the induction of ER stress in vitro (Yusta, et al., 2006). 
Furthermore, hyperglycaemia induced ER stress in human umbilical vein 
endothelial cells (HUVECs) was prevented by treatment with the GLP-1 analogue 
Liraglutide with maximum activity at 100 nM (Schisano, et al., 2012). 
Investigations into the effects of GLP-1 analogues on adipocyte ER stress will 
provide valuable insight into metabolic regulation and warrant investigation. 
Hotamisligil suggested that ‘a reciprocal relationship may exist wherein some 
hormones, which depend upon the ER for their translation, processing, and 
secretion, may act on target cells in ways that protect the biological function of 
that cell thus ensuring continued hormone action, thereby conferring a self-
preserving activity’ (Hotamisligil, 2010). GLP-1 may be one such hormone and 
there may be undiscovered hormones that have self-preserving and ER regulating 
mechanisms.  
 
Studies have shown that chemicals can reduce ER stress and improve glucose 
regulation. Salicylate is an IB kinase- (IKK) inhibitor (Yuan, et al., 2001) and 
it alleviated ER stress in human adipocytes (Alhusaini, et al., 2010) and improved 
glucose regulation in T2DM subjects (Goldfine, et al., 2010). In addition to kinase 
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inhibitors, salubrinal, a phosphatase inhibitor, might have therapeutic benefits. 
Salubrinal can protect cells against ER stress induced apoptosis by selectively 
inhibiting the dephosphorylation of eIF2α such that further protein synthesis and 
accumulation in the ER is inhibited (Boyce, et al., 2005). Treatment with 
salubrinal leads to protection against ER stress induced cell death in vitro and in 
vivo (Sokka, et al., 2007). Therefore modulating phosphorylation signalling in the 
context of the UPR may provide ER homeostatic benefits.  
 
Chemical chaperones are small molecules that facilitate protein folding and can 
protect against ER stress. TUDCA and 4-phenylbutric acid are chemical 
chaperones, and both reduced phosphorylation of PERK and IRE1 and improved 
glucose tolerance and insulin sensitivity in insulin resistant obese mice (Ozcan, et 
al., 2006). TUDCA also alleviated ER stress and improved glucose homeostasis 
in humans (Kars, et al., 2010). The treatment of genetically and diet induced 
mouse models of obesity with TUDCA resulted in increased cellular and serum 
levels of adiponectin (Zhou, et al., 2010). In addition, another chemical 
chaperone, the resveratrol tetramer vaticanol B, has been shown to inhibit both the 
UPR and the inflammatory response by reducing the protein folding load and 
maintaining ER membrane integrity, preventing ER stress induced apoptosis 
(Tabata, et al., 2007). Therefore assisting protein folding in the ER with chemical 
chaperones may be a potential method for alleviating ER stress.   
 
A recently identified inhibitor of the IRE1-XBP1s UPR pathway may provide a 
suitable agent for modulating ER stress. 4-methyl umbelliferone 8-cabaldehyde 
(48C) is a selective inhibitor of unconventional mRNA splicing by IRE1 
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(Cross, et al., 2012). 48C forms a Schiff base with lysine 907 in the IRE1 
endonuclease domain and blocks substrate access to the active site and selectively 
inactivates XBP1u mRNA splicing. Inhibition of IRE1 endonuclease activity 
does not sensitize cells to the consequences of acute ER stress, but rather 
interferes with the expansion of excretory capacity (Cross, et al., 2012). 48C has 
been used as a pharmacological agent; it attenuated joint inflammation in mice 
and was subsequently suggested as a potential therapeutic intervention for 
inflammatory arthritis (Qiu, et al., 2013). In a cell culture model of ER stress, 
inhibiting IRE1 with 48C blunted UPR gene expression output but did not 
affect ERAD or sensitize cells to apoptosis (Zhang, et al., 2014a). Therefore, 
selectively inhibiting IRE1 with 48C may blunt the expression of secretory 
facilitating genes and consequently reduce cell secretory output. In the context of 
insulin resistance, administering 48C may have beneficial outcomes by reducing 
the secretion of proinflammatory mediators. However, detrimental consequences 
may arise since the secretion of beneficial adipokines such as adiponectin and 
leptin may be reduced and proteins intended for secretion may accumulate in the 
ER, further aggravating ER stress. Additionally, UPR gene output will be 
impaired thus potentially limiting the ability of cells to adapt to conditions of ER 
stress. 48C as a potential pharmacological agent for T2DM requires further 
investigation, although it has been proposed as a potential therapy (Hetz, et al., 
2013). Nonetheless, 48C is a useful tool for inhibiting IRE1 and can be used to 
investigate the UPR in model systems and may provide insight into the initiation 
of insulin resistance and subsequent T2DM.  
 
81 
1.9 Summary  
People with T2DM suffer reduced quality and length of life. The chronic 
metabolic disease presents a huge burden on global society through medical, 
social and financial implications. Obesity, characterised by WAT expansion, is 
the most significant risk factor for developing T2DM. WAT is a multifunctional 
organ that plays a key role in metabolic health and regulating energy homeostasis. 
An inability of WAT to expand to accommodate excess nutrients is predominantly 
due to impaired adipogenesis and results in ectopic fat deposition, lipotoxicity and 
insulin resistance. Adipogenesis is influenced by several extracellular and 
intercellular factors and the IRE1-XBP1s UPR pathway is indispensible for 
successful murine adipogenesis. Obesity associated factors such as 
hyperglycaemia, endotoxemia, elevated circulating FFAs, and local hypoxia 
induce adipocyte ER stress via several mechanisms including increased demand 
on the ER for protein synthesis and processing, lipid droplet formation and lipid 
partitioning, and elevated ROS production. ER stress is a key factor in the 
initiation of insulin resistance through inhibiting insulin action and inducing WAT 
inflammation and may interfere with adipogenesis. Interventions that alleviate ER 
stress may be suitable first-line treatments to restore ER function and metabolic 
regulation in metabolic diseases such as T2DM.  
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1.10 Research hypothesis, aims and objectives 
1.10.1 Research hypothesis 
The research hypothesis is that ER stress in human WAT is an important player in 
inducing WAT dysfunction, which can then lead to overall insulin resistance and 
T2DM. 
 
1.10.2 Research aims 
1. To elucidate interactions of ER stress in human WAT.  
2. To characterise the role of ER stress in human adipogenesis.  
 
1.10.3 Research objectives 
1. Some bariatric procedures improve glycaemic control in people with 
T2DM beyond that expected for weight loss alone (Dixon, et al., 2012). 
And ER stress in adipose tissue can be reversed with gastric bypass 
bariatric surgery in humans (Gregor, et al., 2009). Therefore the WAT in 
T2DM subjects before and after different bariatric surgeries may provide 
useful information about interactions of ER stress. Thus, to elucidate the 
interactions of ER stress in human WAT, SAT biopsies and anthropometry 
will be collected before and six months after T2DM subjects undergo 
malabsorptive or restrictive bariatric surgeries. SAT ER stress and 
inflammation will be measured by western blotting and qRT-PCR and 
analysed with anthropometric data.  
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2. In order to accommodate the energy requirements of the body WAT is 
able to expand and contract during adult life despite most development 
during prenatal and early postnatal life (Poulos, et al., 2010). Evidence 
suggests obesity complications in humans result from the inability of SAT 
to appropriately expand and store lipids, and consequently ectopic fat 
deposition and lipotoxicity contribute to insulin resistance (Virtue and 
Vidal-Puig, 2010). Impaired WAT expandability is mainly due to impaired 
adipogenesis (Isakson, et al., 2009). The ER stress activated IRE1α - 
XBP1s pathway has been linked to adipogenesis in mouse studies (Sha, et 
al., 2009). In order to characterise the role of ER stress in human 
adipogenesis WAT samples will be collected and primary human 
preadipocytes will be extracted and grown to confluence and then fully 
differentiated into adipocytes by standardised methods (Alhusaini, et al., 
2010). They will be assessed for lipogenesis, lipolysis, glucose uptake and 
insulin sensitivity, ER stress and adipogenesis markers in control cells 
without any treatment and with agents known to induce ER stress. ER 
stress pathways and adipogenesis markers will be investigated by western 
blotting and qRT-PCR and where required siRNA.  
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Chapter 2: Subjects, methods and 
materials 
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2.1 Ethical approval  
2.1.1 Bariatric study 
The Ethics Committee of the Institute of Endocrinology, Prague, Czech Republic 
provided ethical approval for the bariatric study. All participants provided written 
and informed consent in accordance with the Declaration of Helsinki and 
underwent bariatric surgery at the OB Clinic, Prague, Czech Republic. The 
European Foundation for the Study of Diabetes (EFSD) funded the study through 
the New Horizons Collaborative Research Initiative (EFSD New Horizons 
research grant no. 1113 09). 
 
2.1.2 Human adipose tissue collection 
The University Hospitals Coventry and Warwickshire NHS Trust Research and 
Development Department provided ethical approval for the collection of human 
adipose tissue and issued the following approval number: SK06/9309. All 
participants provided written and informed consent in accordance with the 
Declaration of Helsinki and had adipose tissue collected at University Hospitals 
Coventry and Warwickshire. 
 
2.2 Subjects 
2.2.1 Subjects who underwent bariatric surgery 
For the bariatric study, a female cohort of thirty Caucasian adult women with 
morbid obesity (BMI ≥35 kg/m2) and T2DM were recruited who underwent 
bariatric surgery (figure 2.2.1): laparoscopic adjustable gastric banding (LAGB; 
n=8) (Kormanova, et al., 2004; Zinzindohoue, et al., 2003) or laparoscopic greater 
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curvature plication (LGCP; n=13) (Bradnova, et al., 2014; Fried, et al., 2012) or 
biliopancreatic diversion (BPD; n=9) (Scopinaro, et al., 2011) at the OB Clinic, 
Prague, Czech Republic. Abdominal SAT was collected by biopsy on the day of 
surgery and at six months post-surgery. For the purposes of this study all patients 
were prospectively investigated before the surgery (baseline) and 6 months 
following the procedure; both anthropometry and biochemical analysis were 
undertaken at both visits. Patients on incretin mimetics and/or insulin for T2DM 
treatment were excluded from this study (Bradnova, et al., 2014). Fat mass was 
measured with bioimpedance method (Tanita TBF-300). 
 
Figure 2.2.1  Bariatric surgery procedures under investigation 
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Figure 2.2.1 legend: Bariatric surgery procedures under investigation. Schematic 
diagram representing laparoscopic adjustable gastric banding (LAGB), 
laparoscopic greater curvature plication (LGCP) and biliopancreatic diversion 
(BPD) bariatric surgery procedures. 
 
2.2.2 Adipose tissue collection  
WAT was collected exclusively from non-smoking, non-diabetic, pre-
menopausal, Caucasian women undergoing elective cesarean section at University 
Hospitals Coventry and Warwickshire (UHCW). Paired abdominal SAT and 
omental VAT was collected. Lean was considered pre-pregnant body mass index 
(BMI) of less than 25.0 kg/m2 and obese was considered pre-pregnant BMI over 
30.0 kg/m2. The WNT10B C256Y subject consented to an abdominal 
subcutaneous adipose tissue biopsy and the biopsy was collected at the 
Warwickshire Institute for Diabetes, Endocrinology and Metabolism (WISDEM), 
at UHCW. 
 
2.3 Tissue culture 
2.3.1 Extracting primary human preadipocytes 
Adipose tissue-derived stromal cell isolation was collected as previously reviewed 
(Schaffler and Buchler, 2007). Sterile conditions in a category 2 tissue culture 
room were used and to minimise lysis of fat the procedure was carried out as soon 
possible after collecting the adipose tissue (within 1 hour). Between 3 cm3 and 10 
cm3 of WAT was placed in a 50 mL falcon containing 10 mL 2 mg/mL 
collagenase (Worthington, UK), pre-warmed to 37 C. The WAT was cut with 
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autoclaved and 70 % industrial methylated spirit cleaned scissors until the fat 
pieces were no bigger than 2 mm in diameter. The falcon was placed in a rack in a 
shaking water bath at 37 C for 30 minutes and shaken vigorously by hand at 10 
minute intervals to form a smooth lipid and collagenase mixture. This mixture 
was filtered through sterile cotton mesh into a sterile 50 mL falcon and 
centrifuged at 2000 rpm for 5 minutes. The supernatant was discarded then the 
preadipocyte pellet was resuspended in 5 mL lysis buffer, incubated at room 
temperature for 5 minutes and then centrifuged at 2000 rpm for 5 minutes. The 
supernatant was discarded and the remaining pellet was resuspended in 5 mL 
primary adipocyte growth media and transferred to a 75 cm2 tissue culture flask 
(T75) (corning, UK) containing 15 mL primary adipocyte growth media that had 
been pre-incubated in a 37 C, 5 % CO2 humidified incubator for 15 minutes. The 
flask was labelled and stored in a 37 C, 5 % CO2 humidified incubator and the 
media was changed every 48 hours. 
 
Collagenase: 
• 50 mL Hank’s balanced salt solution (HBSS) 
• 445 mL sterile water 
• 5 mL Penicillin/streptomycin 
Pipetted 20 mL of the above solution into a bottle of 1 g collagenase then mixed 
up and down and put back into the solution and repeated three times and mixed 
until all collagenase was dissolved. Aliquoted 10 mL into 50 mL falcons, labelled 
with collagenase and the date and stored until use at -20 C. 
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Lysis Buffer: 
• 1.001 g  Potassium bi-carbonate (KHCO3) 
• 8.29 g Ammonium chloride  (NH3Cl)        
• 0.0372 g Ethylenediaminetetraacetic acid (EDTA)    
• Made up to 1 L with sterile deionised water 
2.3.2 Human preadipocyte ChubS7 cell line 
The ChubS7 cell line (Nestlé Research Centre, Lausanne, Switzerland) was 
derived from a preadipocyte extracted from Abd SAT of an obese female subject 
with a BMI of 54 kg/m2 by coexpression of human telomerase reverse 
transcriptase (hTERT) and papillomavirus E7 oncoprotein (HPV-E7) genes 
(Darimont, et al., 2003). ChubS7 retain the ability to undergo adipogenesis and 
have been used to study adipocyte metabolic function including glucose uptake 
(Gathercole, et al., 2007) following a previously described glucose uptake assay 
method (Liu, et al., 2001). 
 
2.3.3 Cell culture media composition 
Cell culture media was used as previously described (Alhusaini, et al., 2010). 
ChubS7 growth media: 
• DMEM/Ham’s F-12 phenol-free medium 500 mL (Invitrogen #11039047) 
• Penicillin/streptomycin/L-glutamine 100x, 5 mL (1 %) (Invitrogen 
#10378-016) 
• Fetal bovine serum 50 mL (10 %) (Biosera #S1810) 
Primary adipocyte growth media: 
• DMEM/Ham’s F-12 phenol-free medium 500 mL (Invitrogen #11039047) 
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• Penicillin/streptomycin/L-glutamine 100x, 5 mL (1 %) (Invitrogen 
#10378-016) 
• Fetal bovine serum, 50 mL (10 %) (Biosera #S1810) 
• Fibroblast growth factor-basic (FGF-basic), recombinant human 5 ng/mL 
(Fisher Scientific #VXPHG0026) 
• Transferrin, human 5 g/mL (Fisher Scientific #VX0030124SA) 
 Differentiation media (PromoCell Supplements):  
• DMEM/Ham’s F-12 phenol-free medium 500 mL (Invitrogen #11039047) 
• Fetal bovine serum, 15 mL (3 %) (Biosera #S1810) 
• Preadipocyte differentiation supplement pack x1 (Promocell #C39436) 
The media contained the following supplements at their final concentration: 
• Insulin, recombinant human 0.5 g/mL 
• Dexamethasone 400 ng/mL 
• D-biotin 8 µg/mL 
• Isobutylmethylxantine (IBMX) 44 µg/mL 
• L-thyroxine 9 ng/mL  
• Ciglitazone 3 µg/mL 
Nutrition media (PromoCell Supplements): 
• DMEM/Ham’s F-12 phenol-free medium 500 mL (Invitrogen #11039047) 
• Adipocyte nutrition supplement pack x1 (Promocell #C39439) 
The media contained the following supplements at their final concentration: 
• Insulin, recombinant human 0.5 µg/mL 
• Dexamethasone 400 ng/mL 
• D-biotin 8 µg/mL 
• Fetal calf serum 0.03 mL/mL (3 %) 
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2.3.4 Propagation and differentiation of preadipocytes  
The volume of media used in experiments was always the same in control and 
treatment flasks because adipocyte differentiation is affected by media height 
above the cell layer (Sheng, et al., 2014). Primary human preadipocytes were 
isolated and cultured in T75 flasks as described above. When the T75 was 80 % 
confluent the cells were passaged into 3 further T75 flasks. Trypsinization and 
passage of cells: media was aspirated and cells were washed three times with 
sterile phosphate buffered saline (PBS) pre-warmed to 37 C, and incubated with 5 
mL 0.05 % trypsin – EDTA (Life Technologies #25300-062) for 5 minutes. Cells 
were dislodged from the bottom of the flask by gentle tapping and trypsin was 
neutralized with 15 mL growth media, centrifuged at 1000 rpm for 5 minutes to 
form a pellet of cells. Supernatant was removed, cells resuspended in 5 mL 
growth media and transferred to 3 new T75s. Once 80 % confluent, preadipocytes 
were counted with a hemocytometer and seeded at a density of 4000 cells/cm2 
onto treated polystyrene six well culture plates (Corning) with 2 mL primary 
adipocyte growth media in each well. Growth media was changed every 48 hours, 
and once confluent, cells were incubated in growth media for a further 2 days. 
Differentiation was then initiated (day 0) by changing the media to differentiation 
media. During day 0 to day 6 of adipogenesis media was always changed every 48 
hours with differentiation media. The media was then changed to nutrition media 
every 48 hours from day 6 to day 14. 
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2.3.5 Treatments 
Prior to optimisation treatments, media were switched to detoxification media 
(DMEM/Ham’s F-12 phenol-free medium containing only 3 % serum) for 24 
hours to remove effects of growth factors and other components in nutrition 
media. The treatments including control were placed in the fresh detoxification 
media made on the day of treatment. Tunicamycin (TM) (Sigma #7765) treatment 
concentration was chosen based on previous reports investigating ER stress that 
used between 0.5 g / mL and 2.0 g / mL (Alhusaini, et al., 2010; Ozcan, et al., 
2004). The concentration of 48C was optimised based on the range of 
concentrations (1 M to 64 M) used by Cross et al. (Cross, et al., 2012). TM and 
48C were diluted in dimethyl sulfoxide (DMSO) (Sigma #D8418). Where TM or 
48C treatments were used, the control always had the same volume of DMSO 
added as the volume needed to dissolve the treatment. All treatment media 
including control was filtered through a 0.22 M filter before use.  
 
2.3.6 Small interfering RNA transfection 
ChubS7 cells were used for siRNA studies because of their consistency and 
reliability. Cells were grown to confluence on 12 well plates (Corning), media 
changed to detoxification media (DMEM/Ham’s F-12 phenol-free medium 
containing only 3 % serum) for optimisation and differentiation media for 
adipogenesis experiment, for 30 minutes. SMARTpool: ON-TARGETplus 
Human XBP1 siRNA (Thermo Fisher Scientific Bioscience #L009552000005) 
and ON-TARGETplus non-targeting pool (control) (Thermo Fisher Scientific 
Bioscience #DZD18101020) were reconstituted with 5x siRNA buffer (Thermo 
Fisher Scientific Bioscience #B002000UB100) and vortexed for 30 minutes. 
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siRNA was diluted to a final concentration of 25 – 100 nmol in 1x Opti-MEM1 
(Life Technologies #31985062), mixed with a final concentration of 0.5 % or 1.0 
% DharmaFECT Duo (Thermo Fisher Scientific Bioscience #DZT201003), added 
to detoxification media or differentiation media as appropriate, mixed and then 
added to cells for 16 hours. Media was then aspirated and fresh appropriate media 
without siRNA was added. 
 
2.3.7 Collection of conditioned media, protein and RNA 
Conditioned media (1.5 mL), was collected from six separate wells for every 
sample time point and stored at -80 C until use for free glycerol assay. To collect 
protein, a lysis buffer was made with 5 mL 1x radioimmunoprecipitation (RIPA) 
(Millipore UK) with 100 L of dissolved protease and phosphatase inhibitors (2 
Roche Complete Mini protease inhibitor cocktail tablets and 8 mg sodium fluoride 
(NaF, Fisher Scientific) and 20 mg sodium vanadate (Na3VO4, Acros Organics) 
in 2 mL 1x RIPA). 250 l of the protein lysis buffer was added to each well at 4 
C, cells were scraped with sterile scrapers in each well for 60 seconds, the well 
contents was collected and stored at -80 C. The same method was used to harvest 
total RNA except 350 L Buffer RLY (Bioline) and 3.5 L -mercaptoethanol 
(-ME) (Sigma) were added per well instead of protein lysis buffer. Both protein 
and RNA were collected in triplicate for every time point. 
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2.4 Analysis of samples 
2.4.1 Analysis of blood samples 
All patients were examined in the morning after a 10 hour overnight fast and 
venous blood was sampled. All blood samples were collected into chilled 
ethylenediaminetetraacetic acid (EDTA) containing tubes with aprotinin as well 
as without for the measurements of glucose, insulin and C-peptide levels. The 
samples were aliquoted and stored at -80 C until assayed. Circulating glucose, 
insulin, HbA1c and lipids were measured using the Cobas 6000 analyzer. The 
homeostatic model assessment method was used to assess insulin resistance 
(HOMA-IR) as previously described, (Matthews, et al., 1985), according to the 
following equation: HOMA-IR = [fasting glucose (mmol/L) x fasting insulin 
(U/L)] / 22.5. LDL cholesterol was calculated according to the Friedewald 
formula (Friedewald, et al., 1972). 
 
2.4.2 RNA analysis 
Total RNA was extracted from WAT samples using RNeasy lipid tissue kit 
(Qiagen, #74104) and from cell culture samples using Isolate II RNA Mini Kit 
(Bioline, #BIO-52073) according to the manufacturer’s instructions. RNA was 
quantified using a spectrophotometer (Nanodrop ND-1000, Labtech, UK), 
measuring at an absorbance of 260 nm. The ratios between absorbances 260/280 
nm and 260/230 nm were measured to give an estimate of RNA purity. A value 
between 1.8 and 2.1 for both ratios was accepted as suitable RNA purity for use.  
RNA integrity was assessed by ethidium bromide incorporated agarose gel 
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electrophoresis and two sharp distinct bands representing 18S and 28S were 
considered acceptable RNA integrity for use. 
 
Complimentary DNA (cDNA) was synthesised as described elsewhere (Alhusaini, 
et al., 2010). Briefly, a Bioline kit (#BIO-65026) was used. 200 ng RNA per 
sample, based on spectrophotometer (Nanodrop, Labtech) quantification, was 
used to make cDNA. RNA was pipetted into a sterile microcentrifuge tube (200 
µL capacity), with 1 µL of random hexamers 50-250 ng (Bioline, UK) and 1 µL 
10 mM dNTP mix (Invitrogen, UK), and mixed in RNase free water (Qiagen) to 
give a total volume of 10 µL.  Samples were then vortexed, centrifuged briefly 
and heated to 70 C for 5 minutes and chilled on ice at 4 C for 2 minutes. Samples 
were then vortexed thoroughly and mixed with 10 µL reverse transcription 
mastermix (4µl of 5X reaction buffer, 1 µL RNase inhibitor, 0.5 µL reverse 
transcriptase (200 U/μL) made up to 10 µL by adding RNase free water) giving a 
final volume of 20 µL. Each sample was mixed thoroughly, briefly centrifuged 
and incubated at room temperature for 5 minutes and then transferred to a 
thermocycler (Biorad, UK).  Samples were heated to 37 C for 5 minutes, 42 C for 
55 minutes, and then 70 C for 15 minutes and stored at -20 C until use. 
 
Quantitative real-time PCR (qRT-PCR) was performed using an ABI 7500 
standard Sequence Detection System (Applied Biosystems, UK).  Reactions were 
carried out at 50 C for 2 minutes, 95 C for 10 minutes, and then 40 cycles of 95 C 
for 15 seconds then 60 C for 1 min. Reactions were prepared to 25 µL volumes in 
a 96 well plate. Pre-designed gene specific Taqman probes and primers were used 
(Applied Biosystems, UK, ATF4: Hs00909569_g1; CHOP (DDIT3): 
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Hs00358796_g1; IRE1 (ERN1): Hs00176385_m1; ATF6: Hs00232586_m1; 
IL10: Hs00961622_m1; CCL2: Hs00234140_m1; CD68: Hs02836816_g1, CD14: 
Hs02621496_s1, IL6: Hs00185926_m; CEBP: Hs00269972_s1; PPAR: 
Hs01115513_m1; Adiponectin (ADIPOQ): Hs00605917_m1; GLUT4 (SLC2A4): 
Hs00168966_m1; TCF7: Hs00175273_m1; AXIN2: Hs00610344_m1) in a 
reaction mix containing TaqMan universal PCR master mix (Applied Biosystems, 
UK). All reactions were multiplexed with the housekeeping gene 18S, provided as 
a pre-optimised control probe (Applied Biosystems, UK) enabling calculation of 
delta threshold cycle (∆Ct) values (where ∆Ct = Ct of 18S subtracted from Ct of 
gene of interest). Data is expressed as 2 raised to the power of the difference 
between control ∆Ct and test ∆Ct (∆∆Ct method). For the bariatric study all gene 
expression was calculated for each individual relative to her pre-surgery gene 
expression. The inverse of ∆Ct values were used for correlation analysis.  
Measurements were carried out in triplicate for each sample. A Bioline 
SensiMixTM SYBR Low-ROX Kit (#QT625-02) was used to measure mRNA 
expression using specific primers (Invitrogen UK) for XBP1s: Forward: 5’-
GGTCTGCTGAGTCCGCAGCAGG-3’, Reverse: 5’-
GGGCTTGGTATATATGTGG-3’, (Cho, et al., 2014; Gregor, et al., 2009; Lee, 
et al., 2011); XBP1u: Forward: 5’-CAGACTACGTGCACCTCTGC-3’, Reverse: 
5’-GTTCATTAATGGCTTCCAGCT-3’, designed such that the forward primer is 
complementary to nucleotides 549 – 569 of XBP1u and spans the 3’ end of the 26 
nucleotide intron located at 531 – 556 and therefore exclusively amplifies XBP1u 
mRNA (Uemura, et al., 2009);   18S: Forward: 5’-
GTAACCCGTTGAACCCCATT-3’, Reverse: 5’-
CCATCCAATCGGTAGTAGCG-3’, (Gregor, et al., 2009); WNT10B: Forward: 
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5’-CAGTCGGGCTCTAAGCAATGA-3’, Reverse: 5’-
CTTGCTCAGGCCGGACAG-3’, (Isakson, et al., 2009). The following were 
added per well: 12.5 µL SensiMixTM SYBR Low-ROX, 0.5 µL 10 µM forward 
primer, 0.5 µL 10 µM reverse primer, 10.5 µL nuclease free water and 1 µL 
cDNA template. 
 
2.4.3 Protein analysis 
Human WAT was homogenized and resuspended in 250 L protein lysis buffer 
made with 5 mL 1x radioimmunoprecipitation (RIPA) (Millipore UK) with 100 
L of dissolved protease and phosphatase inhibitors (2 Roche Complete Mini 
protease inhibitor cocktail tablets and 8 mg sodium fluoride (NaF, Fisher 
Scientific) and 20 mg sodium vanadate (Na3VO4, Acros Organics) in 2 mL 1x 
RIPA). Protein concentrations were determined using the Bio-Rad detergent 
compatible protein assay kit (Bio-Rad Laboratories, CA) with standard 
concentrations of albumin from bovine serum (BSA) (Sigma #A9647) and 
quantified using a nanospectrophotometer (GeneFlow, UK). Western blot analysis 
was performed using a method previously described (Alhusaini, et al., 2010). For 
Western blotting, in brief, 20 μg of protein samples were loaded onto a 10 % 
denaturing polyacrylamide gel (GeneFlow, UK), separated by electrophoresis and 
transferred at 4 C and 100 V for 60 minutes to membrane filter Immobilon-P 
transfer membranes 0.45 µm pore size (Fisher), blocked for 60 minutes in 0.2 % I-
Block PBS-tween (PBST) and incubated in primary rabbit-derived antibody 
diluted in 0.2 % I-Block PBST (p-IRE1α 1:500, total IRE1α 1:200, Calnexin 
1:1000, BiP/Grp78 1:750, -actin 1:1000, Cell Signalling; XBP1s and XBP1u 
1:250, glut4 1:80,  Abcam; ATF6 1:250 Abnova; p-Akt 1:1000, total Akt 1:1000, 
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p--catenin 1:500, unphosphorylated -catenin 1:500, Millipore, UK) at 4 C 
overnight. Equal protein loading was confirmed by examining β-actin protein 
expression. Membranes were washed three times for ten minutes in PBST and 
incubated in anti-rabbit IgG (whole molecule), horseradish peroxidase antibody 
produced in goat, IgG fraction of antiserum, buffered aqueous solution (Sigma 
#A9169). A chemiluminescent detection system, ECL/ECL+ (GE Healthcare, 
UK), enabled visualization of bands on hyperfilm MP (Fisher), and intensity was 
determined using densitometry (Genesnap, Syngene, UK). 
 
2.4.4 Agarose gel electrophoresis 
Agarose gel (2.5 % for resolving qRT-PCR products, 1 % for assessing extracted 
RNA integrity) was made by adding agarose (Fisher Scientific) to 1x TAE (Tris 
base, acetic acid and EDTA). The agarose was dissolved by heating for 60 
seconds in a 900 Watt microwave. The solution was cooled before adding 
ethidium bromide to a final concentration of 1 ng/mL. After the gel had set, 
appropriate ladders and test samples were loaded. 1x TAE was used as a buffer 
and electrophoresis was carried out for 30 – 60 minutes at 100 V. The gel was 
viewed under UV light to show ethidium bromide incorporated DNA or RNA and 
digital images were taken (ChemiGenius). 
 
2.4.5 Lipolysis assay 
Lipolysis was measured by free glycerol in conditioned media using a free 
glycerol assay kit (Sigma) and following the manufacturers guidelines. Glycerol 
standard solution (Sigma #G7793) was serially diluted to make eight 
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concentrations ranging from 4 – 130 µg/mL. Free glycerol reagent (Sigma 
#F6428) was reconstituted in 40 mL sterile water. 25 µL of each calibration 
solution and test condition media were added to wells in a 96 microwell plate 
(Sterlin, UK) in triplicate. Then 200 µL reconstituted free glycerol reagent was 
added per well. Adhesive film was placed over the plate and incubated plate on 
shaker for 15 minutes. Absorbance was read at 540 nm using a spectrophotometer 
(Infinite 200 PRO NanoQuant, TECAN). Appropriate cell culture media was used 
as a blank because the media contains fetal bovine serum with lipids in (Boone, et 
al., 1971).  
 
2.4.6 Adipocyte staining 
Adipocytes were grown on 6 well plates (corning), media was removed and the 
cells washed with PBS twice. The cells were fixed with 10 % formalin for 60 
minutes at room temperature. Excess formalin was washed off with PBS and the 
wells were air dried completely for 30 minutes.  
 
Hematoxylin and eosin staining: Stained in haematoxylin (Gill’s haematoxylin 
number 3, Sigma #GHS380) for 45 seconds then washed 3 times in water. Stained 
in eosin (Eosin yellowish: 1 % solution in water, Gurr Certistain, BDH, VWR 
#341973R) for 1 minute and washed 3 times in water. Dehydrated in 50 %, 70 % 
and 90 % ethanol for 45 seconds in each, then 1 min in 100 % ethanol. Left to dry 
overnight lying upside down on tissue. 
 
Oil Red-O staining: Stock Oil Red-O (ORO) solution was made by dissolving 0.5 
g ORO powder (Sigma, UK) in 100 mL absolute propan-2-ol and stirring 
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overnight. Working ORO solution was made by diluting the stock ORO with 
distilled water 3:2, stirring for 10 minutes and then filtering through a 0.22 µm 
filter. Enough working ORO was made for the whole experiment to ensure all the 
dye used was exactly the same concentration. 500 μL working ORO was added to 
each well and incubated at room temperature for 60 minutes. All unbound ORO 
was washed off with distilled water before viewing under a light microscope to 
assess lipid accumulation. Digital photographs were taken. The wells were then 
air dried completely for 30 minutes. The bound ORO was eluted by adding 300 
μL absolute propan-2-ol per well and shaking on an orbital shaker at 100 rpm for 
20 minutes. To quantify the ORO in each well, 200 μL of eluted solution was 
transferred to individual wells of a 96 microwell plate (Sterlin, UK) and the 
absorbance at 520 nm was measured using a spectrophotometer (Infinite 200 PRO 
NanoQuant, TECAN). Two wells with only isopropanol 200 µL were used as 
blanks in the microwell plate.  
 
2.4.7 Glucose uptake assay 
Glucose uptake was carried out as previously described (Adaikalakoteswari, et al., 
2015; Gathercole, et al., 2007; Liu, et al., 2001). Measurement of 2-deoxy-D-[1-
3H] glucose uptake: Cells were grown on 6 or 12 well plates (Corning), washed 
with PBS and incubated at 37 C for 3 hours in Krebs-Henseleit buffer (KHB) with 
0.01 % BSA and 5 mmol/L glucose for insulin and serum starvation. Adipocytes 
were incubated for 30 minutes at 37 C with KRH buffer without glucose or BSA, 
then treated with DMSO (basal control) or 100 nm insulin (insulin solution, 
human, chemically defined, recombinant from Saccharomyces cerevisiae, sterile-
filtered, (Sigma # I9278)). 1 μCi/mL of 2-deoxy-D-[1-3H]glucose (PerkinElmer) 
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was added and incubated for 10 minutes. Cells were washed three times with ice-
cold PBS and harvested in 500 L RIPA per well. 400 L cell lysate was 
transferred to 4 mL scintillation fluid and radioactivity (becquerels, Bq) was 
counted using a scintillation counter. The remaining 100 L cell lysate was used 
to quantify protein and glucose uptake was expressed as Bq/mg protein.  
 
To make 1 L 5x KHB, the following reagents were added separately in the listed 
order to 900 mL distilled and autoclaved water (dH2O) in a 1 L beaker containing 
a sterile magnet stir bar. The final volume was adjusted to 1000 mL with dH2O, 
and stored at 4 C for later use. 
Chemical  5X (mM)  5X (g/L) 
NaCl   555  32.532 
KCl   23.5   1.752 
MgSO4 10  1.204 
Na2HPO4 6  0.852 
On the day before the assay, 500 mL of the following two reagents were prepared 
and filter sterilized: 
1. 1x KHB, low glucose – 5 mM (450 mg), 0.01 % BSA (50 mg), 10 mM 
Hepes (1.1915 g), pH 7.4  
2. 1x KHB, no glucose, no BSA, 10 mM Hepes (1.1915 g), pH 7.4 
 
2.4.8 Cell viability assay 
Cell viability assay measured the activity of living cells via the activity of 
mitochondrial dehydrogenases as previously described (Denizot and Lang, 1986; 
Sharma, et al., 2014). An in vitro 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
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tetrazolium bromide (MTT) toxicology assay kit (Sigma # TOX1-1KT) was used 
according to the manufacturers protocol. Briefly, cells were grown to confluence 
on 96 well tissue culture plates (Corning) and treatments conducted. Following 
treatment, MTT was reconstituted and added to culture medium as described in 
the protocol and cells were returned to incubate for 4 hours. Following incubation, 
formazan crystals were dissolved by adding MTT solubilization solution and 
gentle mixing. Absorbance was measured at 570 nm and background absorbance 
at 690 nm was subtracted from the 570 nm measurement. Complete medium 
without cells was used as a blank. 
 
2.5 Statistical Analysis 
Statistical analysis was undertaken using Microsoft Excel, IBM SPSS Statistics 
21.0 and online computer software (Preacher, 2002, May). Data were examined 
for normality using the Shapiro-Wilk test. Parametrically distributed data were 
analysed using the two-tailed paired sample t-test and non-parametrically 
distributed data were analysed with the Wilcoxon Signed Rank Test. Correlations 
between variables were tested using univariate analyses (Pearson’s or Spearman’s 
correlation where appropriate) then calculations to test the difference between two 
independent correlation coefficients were performed. All data is expressed as 
mean value ± standard error of the mean (SE). P<0.05 was considered statistically 
significant and significance levels are indicated as follows; *P<0.05, **P<0.01, 
***P <0.001 and where more than one comparison was made: +P<0.05, 
++P<0.01, +++P <0.001. 
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Chapter 3: Endoplasmic reticulum stress 
in human adipose tissue 
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3.1 Introduction 
The endoplasmic reticulum (ER) is a multifunctional organelle that plays a key 
role in the folding, maturation, storage and transport of proteins. However, in 
conditions of obesity the ER functions can become dysregulated which manifests 
in misfolded and unfolded proteins, often referred to as ‘ER stress’ (Hotamisligil, 
2006; Hotamisligil, 2010; Schroder and Kaufman, 2005). Several factors appear 
to heighten ER stress in obesity including hyperglycaemia and inflammation, as 
well as hypertrophic adipocyte conditions (Alhusaini, et al., 2010; Gregor and 
Hotamisligil, 2007; Ozcan, et al., 2004; Ozcan, et al., 2006). Whilst the adipocyte 
continues to adapt to such stresses, often this leads to the point where the 
dysregulated ER initiates a complex response system known as the unfolded 
protein response (UPR) (figure 1.6.1) to restore the functional integrity to the 
organelle (Marciniak and Ron, 2006; Schroder and Kaufman, 2005). In mammals 
the UPR is comprised of three main branches, signalling through which is 
mediated by inositol-requiring enzyme 1α (IRE1α), PKR-like endoplasmic 
reticulum kinase (PERK) and activating transcription factor 6 (ATF6) (Harding, et 
al., 2000b; Harding, et al., 1999). In unstressed conditions, the UPR sensing 
transmembrane proteins are bound by a chaperone, BiP/Grp78, in their 
intraluminal domains and rendered inactive. In cases of accumulating unfolded 
proteins and increased protein cargo in the ER, BiP/Grp78 is recruited releasing 
the IRE1α, PERK and ATF6 (Bertolotti, et al., 2000; Shen, et al., 2002). Upon 
activation IRE1α with its endoribonuclease activity splices and excises a specific 
26 nucleotide fragment from X-box binding protein-1 (XBP1) mRNA to form 
XBP1s (spliced) mRNA encoding a potent transcription factor. PERK 
phosphorylates the eukaryotic translation initiation factor 2α (eIF2α) (Harding, et 
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al., 1999) and ATF6 is enzymatically processed into its active form (Chen, et al., 
2002; Nadanaka, et al., 2007). Collectively, these factors attenuate protein 
synthesis and reduce ER protein overload to restore ER integrity (Calfon, et al., 
2002; Ruggiano, et al., 2014; Sidrauski and Walter, 1997; Wek, et al., 2006). 
 
Obesity appears to have a particular effect on activating UPR, highlighted by mice 
fed a high fat diet or ob/ob mice, which initiates a raised UPR response in adipose 
tissue (Gregor and Hotamisligil, 2007; Ozcan, et al., 2004; Ozcan, et al., 2006). 
Further studies have also indicated that ER stress in adipose tissue can be reversed 
with diet induced weight loss (Gregor, et al., 2009; Seoane-Collazo, et al., 2014) 
as well as through gastric bypass bariatric surgery in humans (Gregor, et al., 
2009). Bariatric surgery has proven to be highly effective method for prevention 
as well as remission of type 2 diabetes (T2DM) in obese patients, however the 
rate of remission varies between different surgical procedures (Schauer, et al., 
2012). Each surgery type induces changes in metabolic profiles and 
anthropometry which may have differential impact on ER stress resolution in 
WAT although studies to date have not examined this (Madsbad, et al., 2014). 
Bradley et al. (Bradley, et al., 2012) compared malabsorptive, Roux-en-Y gastric 
bypass (RYGB), and laparoscopic adjustable gastric banding (LAGB) and 
concluded that marked weight loss itself was primarily responsible for increased 
insulin sensitivity, β-cell function and oral glucose tolerance in non-diabetic obese 
adults and not the surgery type. They also suggested that additional studies on 
obese T2DM subjects were required to confirm their observations. Therefore, the 
aim of this study was to investigate the effect of malabsorptive versus restrictive 
surgeries on the clinical parameters related to metabolic health of obese type 2 
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diabetics. For this study patients undergoing three types of bariatric surgeries 
were recruited: BPD (malabsorptive) (Scopinaro, et al., 2011), LAGB (restrictive) 
(Kormanova, et al., 2004) and laparoscopic greater curvature plication (LGCP; 
restrictive) (Bradnova, et al., 2014; Fried, et al., 2012). The effects of surgery 
induced weight loss on ER stress in abdominal SAT as well as the effects of each 
surgery type on this pathway were investigated. All measurements were carried 
out in obese T2DM subjects before undergoing LAGB or LGCP or BPD surgery 
and after 6 months, in order to understand the rate of improvements in each 
surgery type. 
 
3.2 Results 
3.2.1 Body composition, basal metabolic variables and sample analyses 
There were significant changes observed in all subjects 6 months post-surgery 
independent of surgery type. Individual BMI (P<0.001), fasting blood glucose 
(P<0.001), insulin (P<0.001), HOMA-IR (P<0.001), TG (P<0.05), cholesterol 
(P<0.001) and LDL-cholesterol (P<0.05) were all significantly improved (Table 
3.2.1). According to surgery types, body weight loss post-surgery varied from 
10.5 ± 1.0 % observed for LGCP, 11.4 ± 1.6 % for LAGB to 16.8 ± 0.5 % for 
BPD. Additionally, BPD resulted in a significantly higher rate of weight loss 
measured as pre body weight (PBW) loss per 100 days compared to LAGB and 
LGCP. The PBW loss per 100 days for BPD was 11.2 ± 0.7 %, for LGCP it was 
5.9 ± 0.7 % and for LAGB it was 7.3 ± 1.2 % (Table 3.2.1). BPD subjects had 
lower HbA1c and HDL cholesterol compared to LAGB subjects and lower total 
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cholesterol and HDL cholesterol compared to LGCP subjects. BPD subjects also 
had a higher TAG/HDL ratio compared to LAGB subjects. 
 
Table 3.2.1  Body composition and metabolic characteristics before and after  
  bariatric surgery (following page, whole page table) 
 
Table  3.2.1 legend: Body composition and metabolic characteristics before and 
after bariatric surgery. Anthropometric measurements were taken for 30 female 
subjects at the time of either laparoscopic adjustable gastric band (LAGB), 
laparoscopic greater curvature plication (LGCP) or biliopancreatic diversion 
(BPD) bariatric surgery (pre) and six months after surgery (post). Data is 
expressed as mean ± SE. Pre and post values were compared and P<0.05 was 
considered statistically significant and significance levels are indicated as follows; 
*P<0.05, **P<0.01, ***P <0.001. 
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Table 3.2.1 LAGB (n=9) LGCP (n=13) BPD (n=8) 
  Pre Post Pre Post Pre Post 
Excess BMI Lost  
(% Excess BMI Lost)   
31.85 
± 5.95   
29.86  
± 3.18   
40.96  
± 1.99 
Time Between Biopsies  
(Days)   
162.22  
± 6.83   
184.62  
± 5.38   
152.50  
± 8.18 
Weight Loss Rate  
(% Lost per 100 Days)   
7.30  
± 1.17   
5.87  
± 0.70   
11.24  
± 0.74 
Age 
(Years) 
53.89  
± 1.99 
54.33*** 
± 3.70 
55.38  
± 1.07 
55.89***  
± 1.65 
52.38  
± 0.63 
52.79***  
± 1.24 
Body Weight 
(kg) 
113.03  
± 6.63 
100.52*** 
± 6.98 
106.23  
± 4.27 
94.82***  
± 3.36 
120.01  
± 4.90 
99.95***  
± 4.32 
BMI  
(kg/m
2
) 
41.92  
± 2.29 
37.26*** 
± 2.46 
39.43  
± 1.44 
35.16***  
± 1.14 
43.30  
± 0.90 
35.98***  
± 0.92 
Fat Free Mass  
(kg) 
57.16  
± 2.24 
54.53* 
± 3.50 
54.62  
± 1.39 
52.39** 
± 1.51 
59.93  
± 1.78 
53.89**  
± 1.90 
Fat Mass 
(kg) 
55.87  
± 4.57 
46.00*** 
± 3.93 
51.61  
± 3.15 
42.43***  
± 2.28 
60.09  
± 3.80 
46.06***  
± 3.48 
Fat Mass  
(% Body Weight) 
48.91  
± 1.31 
45.34** 
± 1.51 
48.18  
± 1.10 
44.51***  
± 1.06 
49.80  
± 1.30 
45.74**  
± 1.80 
Waist Circumference  
(cm) 
118.19  
± 4.34 
113.83*  
± 5.18 
113.81  
± 2.66 
105.97**  
± 2.48 
122.88  
± 2.78 
112.38*  
± 5.06 
Hip Circumference  
(cm) 
131.13  
± 4.11 
125.00**  
± 4.45 
128.65  
± 4.02 
119.82**  
± 2.82 
135.44  
± 4.26 
124.63*  
± 3.79 
Waist / Hip Ratio 
 
0.90  
± 0.01 
0.91  
± 0.02 
0.89  
± 0.03 
0.89  
± 0.02 
0.91  
± 0.03 
0.90  
± 0.02 
HbA1c  
(mmol/mol) 
53.44 
± 3.30 
46.00*  
± 2.26 
56.77  
± 2.80 
47.77**  
± 2.95 
58.63  
± 2.92 
40.25**  
± 0.86 
Plasma Glucose 
(mmol/L)  
9.60  
± 0.86 
7.10***  
± 0.54 
9.27  
± 0.60 
7.38**  
± 0.48 
9.28 
± 1.09 
7.23**  
± 0.65 
Plasma Insulin 
(mU/L) 
26.69  
± 2.44 
15.70**  
± 1.88 
27.19  
± 5.85 
16.13**  
± 3.27 
35.26  
± 8.77 
16.39*  
± 3.10 
HOMA-IR 
 
10.70  
± 1.63 
5.29**  
± 1.02 
11.40  
± 2.60 
4.98**  
± 1.01 
13.68  
± 3.93 
4.80*  
± 1.05 
Total Cholesterol 
(mmol/L) 
4.83  
± 0.28 
4.35  
± 0.22 
4.89  
± 0.19 
4.76  
± 0.23 
5.15  
± 0.42 
3.84***  
± 0.36 
LDL Cholesterol 
(mmol/L) 
2.98 
± 0.24 
2.72  
± 0.18 
2.81  
± 0.20 
2.96  
± 0.23 
3.41  
± 0.43 
2.31**  
± 0.27 
HDL Cholesterol 
(mmol/L) 
1.06  
± 0.09 
1.08  
± 0.09 
1.09  
± 0.08 
1.15  
± 0.09 
1.00  
± 0.08 
0.76**  
± 0.04 
Triglyceride (TAG)  
(mmol/L) 
1.72  
± 0.25 
1.19*  
± 0.16 
2.15  
± 0.41 
1.43  
± 0.21 
1.60  
± 0.27 
1.67  
± 0.26 
HDL/LDL Ratio 
 
0.37  
± 0.04 
0.42  
± 0.05 
0.42  
± 0.05 
0.43  
± 0.06 
0.33  
± 0.05 
0.36  
± 0.04 
TAG/HDL Ratio 
 
1.78  
± 0.32 
1.23* 
± 0.23 
2.32 
± 0.52 
1.41  
± 0.25 
1.75  
± 0.37 
2.27*  
± 0.43 
C-Reactive Protein  
(ng/L) 
4.65 
± 1.55 
4.41 
± 1.47 
8.61 
± 2.49 
5.10  
± 1.47 
4.47  
± 1.69 
3.87  
± 1.46 
109 
3.2.2 Adipose tissue expression of UPR related genes and proteins were 
reduced post bariatric surgery 
Abdominal SAT mRNA and protein expressions of key UPR genes and proteins 
were evaluated in all 30 subjects before and 6 months after surgery. This was to 
assess the effect of weight loss alone. All the three UPR pathways; PERK, IRE-1α 
and ATF6 were assessed for changes in gene and protein expression. mRNA 
expression of downstream targets of PERK, ATF4 and CHOP, were both 
significantly reduced post-surgery (P<0.01; Figure 3.2.2 A). Both IRE-1α and 
ATF6 regulate expression of spliced XBP1 (XBP1s) (Guo, et al., 2014). The IRE-
1α mRNA and phospho-IRE-1α protein expressions were significantly reduced 
post-surgery (Figure 3.2.2 B and C). The mRNA and protein expressions of ATF6 
and XBP1s were also significantly reduced 6 months after surgery (P<0.05; 
Figure 3.2.2 B and C). The protein expressions of important protein chaperones, 
BiP1/Grp78 and calnexin were also significantly reduced 6 months post-surgery 
(Figure 3.2.2D). 
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Figure  3.2.2  ER stress in abdominal subcutaneous adipose tissue was reduced  
  six months after bariatric surgery in obese T2DM subjects 
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Figure 3.2.2 legend: ER stress in abdominal subcutaneous adipose tissue was 
reduced six months after bariatric surgery in obese T2DM subjects. ER stress 
markers from all three ER stress pathways and chaperones were measured in all 
subjects before (pre) and after (post) bariatric surgery. Gene expression of ATF4 
and CHOP (A), ATF6, IRE1α and XBP1s (B). Protein expression of ATF6, 
pIRE1α, XBP1s (C), calnexin and bip (D). Data is expressed as mean ± SE. Pre 
and post values were compared and P<0.05 was considered statistically significant 
and significance levels are indicated as follows; *P<0.05, **P<0.01, ***P <0.001. 
 
 
3.2.3 Regulation of UPR markers was improved in adipose tissue 6 months 
post-surgery 
The UPR is activated in response to an accumulation of unfolded or misfolded 
proteins in the ER in order to restore normal cellular functions and this process is 
tightly regulated. In obesity this activation could be prolonged leading to 
increased inflammation or cellular dysfunction. PERK regulates expression of 
ATF4 and CHOP while IRE1α regulates synthesis of active form of XBP1, 
XBP1s by splicing inactive XBP1u (XBP1 unspliced) through its 
endoribonuclease activity. To investigate whether this regulation is improved after 
surgery, correlation studies were carried out. A significant correlation was 
observed between changes in ATF4 and CHOP mRNA expression post-surgery 
(Figure 3.2.3 A). There were significant correlations between the change in 
expression of XBP1s vs CHOP (Figure 3.2.3 B), XBP1s vs ATF4 (Figure 3.2.3 C) 
and pIRE1α vs calnexin (Figure 3.2.3 D; P<0.001). These association studies 
highlight the overall improved regulation of UPR pathways post-bariatric surgery. 
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Figure  3.2.3 ER stress signalling regulation in abdominal subcutaneous   
  adipose tissue was improved six months after bariatric surgery  
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Figure  3.2.3 legend: ER stress signalling regulation in abdominal subcutaneous 
adipose tissue was improved six months after bariatric surgery. Correlation 
analysis for all subjects was undertaken between the change in ER stress 
signalling markers and chaperones at gene and protein expression level before and 
after surgery. ATF4 mRNA and CHOP mRNA (A), XBP1s mRNA and CHOP 
mRNA (B), XBP1s and ATF4 mRNA (C), pIRE1α protein and calnexin protein 
(D). P<0.05 was considered statistically significant and significance levels are 
indicated as follows; *P<0.05, **P<0.01, ***P <0.001. 
 
3.2.4 Effect of surgery type on ER stress (Restrictive versus Malabsorptive) 
Bariatric surgery is highly effective for prevention as well as for resolving T2DM 
but the remission rates have been shown to vary between different surgical 
procedures. Therefore, the effect of each surgery type on ER stress markers in 
adipose tissue 6 months after each surgery was investigated. Overall the mRNA 
expression of XBP1s was significantly reduced across all surgery types. While all 
other markers studied were significantly reduced either in LAGB or LGCP 
surgery types but not in BPD, even though the overall trend was towards 
reduction for all the markers in all surgery types (Figure 3.2.4 A-D). It did not 
reach significance for some markers probably due to the smaller sample size for 
individual surgery types.  
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Figure  3.2.4 Post-surgery ER stress improvements in abdominal subcutaneous  
  adipose tissue varied by bariatric surgery type  
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Figure  3.2.4 legend: Post-surgery ER stress improvements in abdominal 
subcutaneous adipose tissue varied by bariatric surgery type. XBP1s, ATF4, 
ATF6, CHOP, and IRE1α gene expressions were measured before (pre) and after 
(post) bariatric surgery, stratified by restrictive (LAGB and LGCP) (A), 
malabsorptive (BPD) (B), LAGB (C), and LGCP (D) surgery types. Data is 
expressed as mean ± SE. Pre and post values were compared and P<0.05 was 
considered statistically significant and significance levels are indicated as follows; 
*P<0.05, **P<0.01, ***P <0.001. 
 
3.2.5 Adipose tissue inflammation and macrophage infiltration 
Adipose tissue inflammation and macrophage specific markers were assessed pre 
and post bariatric surgery. The pro-inflammatory markers IL-6 and CCL2 mRNA 
expressions were significantly reduced post-surgery (Figure 3.2.5; P<0.05) whilst 
there was no significant change in the anti-inflammatory IL-10 mRNA 
expression. The macrophage specific surface markers CD68 and CD14 mRNA 
expressions appeared to reduce post-surgery, although this did not reach 
significance. Further assessment of the potential link between IL-6 mRNA 
expression and macrophage markers showed there was no significant correlation 
with either CD68 or CD14. 
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Figure  3.2.5 Adipose tissue inflammation reduced after bariatric surgery  
  independently of macrophage expression  
 
Figure  3.2.5 legend: Adipose tissue inflammation reduced after bariatric surgery 
independently of macrophage expression. Pro-inflammatory cytokine IL-6, anti-
inflammatory cytokine IL-10, macrophage recruitment chemokine CCL2 and 
macrophage surface markers CD68 and CD14 gene expressions were measured 
for all subjects before (pre) and after (post) bariatric surgery. (IL-6; interleukin – 
6, IL-10; interleukin – 10, CCL2; C-C motif ligand 2, CD68; cluster of 
differentiation 68, CD14; cluster of differentiation 14). Data is expressed as mean 
± SE. Pre and post values were compared and P<0.05 was considered statistically 
significant and significance levels are indicated as follows; *P<0.05. 
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3.3 Discussion 
This study was designed to investigate the effect of bariatric surgery types on 
metabolic health of obese T2DM patients. Both restrictive (LAGB and LGCP) as 
well as malabsorptive (BPD) surgery types were assessed for the outcome. Recent 
studies suggest an important role for ER stress in underlying mechanisms for 
insulin resistance and T2DM in obese subjects (Hummasti and Hotamisligil, 
2010). The results of this study show that ER stress is activated in obese T2DM 
subjects and is significantly reduced after bariatric surgery. Surgery specific 
effects on ER stress and other metabolic parameters were observed. 
 
The results of this study agree with previous findings in obese T2DM patients, 
showing that the significant weight loss six months post-bariatric surgery, 
comprising predominantly from reduced fat mass, resulted in marked 
improvements in both insulin and glucose homeostasis. More specifically, fasting 
insulin and glucose and HbA1c all significantly decreased suggesting a major role 
for excess adipose tissue in obesity-linked pathogenesis of T2DM (Bradnova, et 
al., 2014; Nguyen and Korner, 2014). In addition, the significant weight loss post-
surgery was also found to be associated with improvements in other obesity-
related metabolic factors including significantly decreased LDL and TAG levels. 
Patients who underwent BPD had achieved higher percent excess BMI lost (% 
EBL) compared to the other bariatric interventions. BPD patients also had lower 
HbA1c, total cholesterol and HDL compared to restrictive surgeries, possibly due 
to their higher % EBL. There were no significant differences between surgery 
types in other metabolic parameters including body weight, BMI, fat mass, fasting 
plasma glucose, plasma insulin, or TAG.  
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The present study demonstrated that in obese T2DM subjects, UPR regulation in 
adipose tissue improved six months after bariatric surgery. In agreement with 
previous studies (Gregor, et al., 2009) the expression of UPR markers at the level 
of master regulators (IRE1 and ATF6), downstream signalling effector 
molecules (XBP1s, ATF4 and CHOP) and key protein chaperones (Bip and 
Calnexin) were significantly decreased. UPR in WAT has been directly linked to 
insulin resistance via activation of JNK protein kinases by IRE1 (Urano, et al., 
2000). In this study expression of IRE1 in its active phosphorylated form and its 
immediate downstream target XBP1s were both significantly decreased. 
Furthermore, the correlation between their expressions was highly significant 
post-surgery (P<0.001), suggesting a tighter regulation. 
 
In addition to the IRE1 pathway, the regulation of the PERK pathway was also 
improved following bariatric intervention. The association between the 
downstream targets of PERK, ATF4 and CHOP, significantly increased post-
surgery suggesting improved regulation of this UPR pathway in addition to 
IRE1α-XBP1s pathway. The hypothesis that the ER in WAT is under a reduced 
demand post-surgery is supported by the finding in this study that the expression 
of protein chaperones BiP/Grp78 and calnexin are significantly reduced post-
surgery compared to baseline and are significantly associated (Gulow, et al., 
2002). The expression of BiP/Grp78 protein coincides with the level of ER stress; 
therefore a reduction in BiP protein expression in the patients WAT post-surgery 
is indicative of a reduction in ER stress. 
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Gregor et al. (Gregor, et al., 2009) have reported similar observations with 
regards to ER stress following malabsorptive bariatric surgery, i.e. gastric bypass, 
except for one notable difference. In their study, Gregor et al. observed no change 
to CHOP mRNA expression in spite of changes to upstream regulator p-eIF2α, in 
the PERK pathway and argued that CHOP expression was probably regulated by 
additional signals which do not respond to changes in body weight. On the 
contrary, this study documented significant reduction to CHOP as well as ATF4 
mRNA expressions after weight loss at 6 months post-surgery. Upon further 
investigation CHOP expression was significantly reduced only in restrictive 
surgery samples (LAGB and LGCP) and not in malabsorptive surgery (BPD) 
(Figure 3.2.4). Therefore, our results indicate that CHOP expression is also 
probably affected by the type of the bariatric procedure and is regulated by yet 
another confounding factor that requires further investigation. In general almost 
all the ER stress markers were significantly reduced in restrictive compared to 
malabsorptive surgery. 
 
Glucose homeostasis and WAT UPR regulation were both improved after 
bariatric induced weight loss and may be linked. This observation is supported by 
another study in ob/ob mice where overexpression of XBP1s has been shown to 
induce adiponectin multimerisation and improve glucose homeostasis (Sha, et al., 
2014). Another bariatric study using Roux-en-Y gastric bypass (RYGB) and 
LAGB samples by Bradley et al. (Bradley, et al., 2012) has shown improved 
insulin sensitivity, oral glucose tolerance and beta cell function after surgery but 
does not provide a mechanism. The IRE1α-XBP1s pathway has now been linked 
to adipogenesis (Sha, et al., 2009), differentiation of secretory cell types, such as 
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pancreatic and salivary exocrine cells and regulation of lactation (Gregor, et al., 
2013) in addition to regulation of glucose homeostasis. 
 
Furthermore, since chronic inflammation of WAT has been linked to metabolic 
dysregulation (Wellen and Hotamisligil, 2003; Xu, et al., 2003), the inflammatory 
status of patients’ WAT was investigated. The expression of pro-inflammatory 
cytokine IL-6 was significantly reduced after bariatric surgery compared to 
baseline while no significant change was observed in mRNA expression of anti-
inflammatory IL-10. IL-6 expression has been linked to macrophage infiltration in 
adipose tissue (Di Gregorio, et al., 2005), therefore to establish whether 
macrophage played any role in the observed changes, macrophage surface 
markers (CD14 and CD68) and macrophage chemoattractant chemokine ligand 2 
(CCL2), also referred to as monocyte chemotactic protein 1 (MCP1), were 
measured. There were no significant changes in CD14 or CD68 expression before 
and after surgery, although there was a significant reduction in CCL2 expression 
(figure 3.2.5). However, none correlated with IL-6 expression, therefore the IL-6 
reduced expression was likely to be independent of macrophages. 
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3.4 Conclusions 
This study has demonstrated that both restrictive and malabsorptive bariatric 
interventions are effective weight loss interventions for obese T2DM patients 
resulting in significantly improved glucose and insulin levels six months after 
surgery. While malabsorptive bariatric surgery involves more complicated 
procedures and requires long-term vitamin and other supplementation, the 
restrictive bariatric procedures are less complicated and induce almost equal 
benefits. In this study adipose tissue health was better following the two 
restrictive procedures (LAGB and LGCP) compared to BPD as shown by higher 
reduction of ER stress markers as well as improved regulation of CHOP. The data 
from Bradley et al. (Bradley, et al., 2012) obtained from non-diabetic obese 
patients did not specifically support malabsorptive (RYGB) over restrictive 
surgery type (LAGB) and suggested that further studies were required which 
could apply to obese patients with T2DM. This study offers novel data in that 
direction indicating that while the clinical outcomes regarding parameters, such as 
% EBL and HbA1c, were better following BPD, the adipose tissue health was 
significantly improved following the restrictive procedures. The clinical 
implications of these findings in the longer term require further investigations. 
Overall, all the surgery types investigated significantly improved the metabolic 
health of obese diabetics included in this study irrespective of surgery type. 
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Chapter 4: Regulation of ER stress 
during adipogenesis 
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4.1 Introduction 
Obesity, characterised by expansion of WAT, is the biggest risk factor for 
developing the metabolic disease T2DM (Guh, et al., 2009). WAT is a 
multifunctional organ that plays a key role in energy regulation and metabolism. 
People with T2DM who lost weight predominantly through a reduction in WAT 
mass following bariatric surgery improved their glucose and lipid metabolic 
profile (table 3.2.1). Therefore excess WAT in obesity may lead to dysregulation 
and impaired metabolic health. However, not all WAT is equal. WAT, like 
skeletal muscle, is distributed through the body in discrete depots (Shen, et al., 
2003). SAT represents about 85 % of all body fat and is unequally distributed 
through the body, with larger depots in the abdomen, thigh, gluteal and mammary 
region (Frayn and Karpe, 2014). Abdominal VAT depots are deeper in the body 
than SAT and include omental that connects to the stomach. The functions and 
properties of each WAT depot overlap but there are distinct differences (White 
and Tchoukalova, 2014). Accumulation of adipose tissue in different depots has 
differential risk associated with development of T2DM. Accumulation of VAT 
and SAT in the abdomen is referred to as ‘central obesity’ and confers a higher 
risk of developing T2DM compared to lower body accumulation of fat. Therefore 
abdominal WAT was investigated. In central obesity, different depths of 
abdominal SAT are functionally distinct and independently correlate with 
metabolic complications of obesity (Smith, et al., 2001). These observations have 
been supported by several studies, reviewed by Frayn et al. (Frayn, et al., 2003). 
Lipolysis, TAG synthesis and storage, and protein secretion varies between WAT 
depots as reviewed by Lee et al. (Lee, et al., 2013). The difference in risk of 
developing T2DM conferred by different WAT depots is likely to be due to a 
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combination of WAT properties including lipid and carbohydrate metabolism 
(lipolysis, lipid accumulation and glucose uptake) and systemic signalling (protein 
and lipid secretion and innervation).  
 
In order to accommodate the energy requirements of the body WAT is able to 
expand and contract during adult life despite most development during prenatal 
and early postnatal life (Poulos, et al., 2010). WAT expansion occurs primarily in 
two ways, by hyperplasia or hypertrophy. Evidence suggests obesity 
complications in humans result from the inability of SAT to appropriately expand 
and store lipids, and consequently ectopic fat deposition and lipotoxicity 
contribute to insulin resistance (Virtue and Vidal-Puig, 2010). Impaired WAT 
expandability is mainly due to impaired adipogenesis (Isakson, et al., 2009). 
Adipocyte progenitors in human AT have been found to be depot-specific 
(Tchkonia, et al., 2007) and differences between adipocytes derived from SAT 
and VAT have been documented (Kovsan, et al., 2009). Adipocytes are central to 
metabolic regulation (Rosen and Spiegelman, 2006) and therefore differences in 
adipocyte progenitors may contribute towards regional variation in WAT function 
and development (Baglioni, et al., 2012). This may in part explain the depot-
specific differences in metabolic function and association with relative risk of 
developing T2DM (Karastergiou, et al., 2013). However the underlying reasons 
why depot specific differences in adipocytes exist requires clarification.  
 
Within adipocytes the ER plays a key role in metabolic regulation. ER stress can 
impair ER integrity and influence metabolism and function of adipocytes. Weight 
loss reduced ER stress and improved metabolic profile in humans (chapter 3). ER 
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stress might be directly linked to metabolism since abdominal SAT XBP1s 
correlated with plasma glucose after bariatric surgery induced WAT loss in 
humans (figure 3.2.3). Furthermore, the IRE1-XBP1s UPR pathway is essential 
for adipogenesis in mouse cells (Sha, et al., 2009). However XBP1s has not been 
studied in human adipogenesis. The underlying differences between WAT depots 
may be due to different levels of IRE1 and or XBP1s expression in 
adipogenesis. Scherer’s group have expressed an urgency for understanding the 
underlying mechanisms of adipogenesis and highlighted that it will bring potential 
clinical benefit for combating metabolic disease (Wang, et al., 2013).  
 
Therefore the aims of this study were to investigate the extent of adipogenesis and 
expression of IRE1 and XBP1s during adipogenesis in preadipocytes from 
paired human abdominal SAT and VAT depots and whether the IRE1-XBP1s 
UPR pathway is essential in human adipogenesis. To assess depot specific 
differences in adipogenesis paired primary human abdominal SAT and VAT from 
lean and obese non-diabetic subjects were collected. Preadipocytes were extracted 
from WAT depots, cultured and adipogenesis initiated. To assess the effect of ER 
stress on adipogenesis, TM was administered during early adipogenesis. To assess 
whether the IRE1-XBP1s pathway is essential during human adipogenesis, 
IRE1 endonuclease activity was selectively blocked with the small molecule 
inhibitor 48C during early adipogenesis. In order to further assess the role of ER 
stress on adipogenesis a human adipocyte cell line Chub-S7 was used (Darimont, 
et al., 2003). Functional differences between mesenchymal stem cell populations 
are reflected by their transcriptome (Jansen, et al., 2010). Therefore IRE1 and 
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XBP1s mRNA expressions were measured during adipogenesis in control 
conditions and following ER stress induction and XBP1s inhibition.  
 
4.2 Results 
4.2.1 Cultured primary human preadipocytes had depot and BMI specific 
differences in lipid metabolism during adipogenesis 
Preadipocytes were extracted from primary human tissue, cultured and 
adipogenesis stimulated. On day 14 after induction of adipogenesis staining was 
performed (figure 4.2.1 A). Hematoxylin staining dyed the basophilic nucleus 
dark blue (blue arrows in figure 1.4.1 A) and indicated that lipid droplets (white 
arrows in figure 1.4.1 A), brightly reflecting circular shapes, formed in the 
cytoplasm (black arrows in figure 1.4.1 A) around the nucleus. Eosin staining 
dyed the acidophilic cytoplasm pink and in combination with hematoxylin 
staining it showed that lipid droplets can occupy virtually the entire adipocyte 
cytoplasm. ORO staining dyed TAG and lipids red and provided a clearer 
indication of lipid accumulation compared to HE staining. Therefore ORO 
staining was used as an indicator of adipogenesis during subsequent adipogenesis 
experiments. Preadipocytes derived from lean and obese Abd SAT and VAT 
depots had adipogenesis induced and ORO staining was performed every 48 hours 
up to 14 days (figure 4.2.1 B – D). Preadipocytes from obese subjects 
accumulated more lipids during adipogenesis than from lean. Preadipocytes 
derived from VAT accumulated more lipids than derived from SAT. Lipolysis, an 
indicator of adipocyte function, was assessed during adipogenesis every 48 hours 
by measuring free glycerol in conditioned media (figure 4.2.1 E). In preadipocytes 
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derived from SAT, those derived from obese subjects underwent more lipolysis 
than from lean. However in VAT derived preadipocytes, those derived from lean 
subjects underwent more lipolysis than from obese. 
Figure  4.2.1 Primary human adipocytes had depot and BMI specific  
  differences in lipid accumulation and lipolysis during   
  adipogenesis  
A        Adipocyte staining 
 Hematoxylin only              20x                    40x 
Hematoxylin and Eosin 
 Oil Red-O 
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Lipid accumulation during lean and obese abdominal 
subcutaneous adipocyte adipogenesis 
     Lean, Abd SAT       Obese, Abd SAT 
Day      20x   40x        20x  40x 
 
B 
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Lipid accumulation during lean and obese  
visceral adipocyte adipogenesis 
           Lean, VAT              Obese, VAT 
Day          20x     40x             20x      40x 
 
C 
133 
 
 
0.0
1.0
2.0
3.0
4.0
5.0
0 2 4 6 8 10 12 14
L
ip
id
 a
cc
u
m
u
la
te
d
 (
O
R
O
 r
el
at
iv
e 
fo
ld
 t
o
 d
ay
 0
)
Days after initiation of adipogenesis
Adipocyte lipid accumulation during adipogenesis
Lean
Abd
SAT
Obese
Abd
SAT
Lean
VAT
Obese
VAT
D
* *
**
*
*
*
*
*
+
+
+
* *
0
5
10
15
20
25
30
0 2 4 6 8 10 12 14
F
re
e 
g
ly
ce
ro
l 
(m
g
/m
L
)
Day after initiation of adipogenesis
Adipocyte lipolysis during adipogenesis 
Lean
Abd
SAT
Obese
Abd
SAT
Lean
VAT
Obese
VAT
E
*
*
*
*
*
*
*
+
+
+
*
*
134 
Figure  4.2.1 legend: Primary human adipocytes had depot and BMI specific 
differences in lipid accumulation and lipolysis during adipogenesis. Preadipocytes 
from paired abdominal subcutaneous (Abd SAT) and visceral (VAT) depots from 
lean and obese subjects were cultured and had adipogenesis induced for 14 days. 
Hematoxylin and eosin (HE) and oil red-O (ORO) staining were compared in Abd 
SAT obese adipocytes on day 14 after induction of adipogenesis (A), nucleus - 
blue arrows,  lipid droplets - white arrows, cytoplasm - black arrows. Images of 
ORO stained adipocytes from lean and obese Abd SAT (B) and VAT (C) were 
compared and lipid accumulation (D) and lipolysis (E) was measured every 48 
hours. Data is expressed as mean ± SE. Significantly different values at each time 
point are indicated as follows: * P<0.05 compared to lean Abd SAT, + P<0.05 
compared to lean VAT. 
 
4.2.2 Cultured primary human preadipocytes had depot and BMI specific 
differences in glucose uptake during adipogenesis: VAT is insulin resistant 
To further characterise Abd SAT and VAT lean and obese adipogenesis, 
functional glucose uptake and insulin sensitivity was assessed 14 days after 
induction of adipogenesis (figure 4.2.2). SAT adipocytes from lean and obese 
subjects significantly increased glucose uptake after insulin stimulation (P<0.05 - 
P<0.001), however the adipocytes from lean had a greater increase in insulin 
stimulated glucose uptake compared to obese. VAT adipocytes from lean and 
obese subjects increased glucose uptake after insulin stimulation but did not reach 
significance. Their basal glucose uptake was significantly higher (P<0.05) than 
from SAT. The basal glucose uptake was significantly higher in obese subjects 
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compared to lean in both Abd SAT and VAT depots (P<0.05 and P<0.01 
respectively).  
 
Figure  4.2.2 Glucose uptake and insulin sensitivity in primary human   
  adipocytes varied depending on adipose tissue depot and BMI 
 
Figure  4.2.2 legend: Glucose uptake and insulin sensitivity in primary human 
adipocytes varied depending on adipose tissue depot and BMI. Paired Abd SAT 
and VAT preadipocytes from lean and obese subjects were cultured and 
differentiated for 14 days. On day 14, adipocytes were subjected to basal and 
insulin stimulated glucose uptake assays. Data is expressed as mean ± SE. 
Significantly different values are indicated as follows: * P<0.05, ** P<0.01, *** 
P<0.001. 
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4.2.3 The IRE1 - XBP1s UPR pathway was elevated during adipogenesis in 
obese subjects compared to lean 
ER stress in WAT is elevated in obese compared to lean subjects and ER stress 
was reduced in obese subjects after bariatric surgery (chapter 3). To compare ER 
stress during adipogenesis in lean and obese SAT and VAT derived 
preadipocytes, IRE1 and XBP1s mRNA expression was measured every 48 
hours during adipogenesis (figure 4.2.3 A – B). IRE1 and XBP1s mRNA 
expression in the lean SAT and VAT derived adipocytes decreased after the 
induction of adipogenesis. In contrast, IRE1 and XBP1s mRNA expression in 
the obese SAT and VAT derived adipocytes increased after the onset of 
adipogenesis in two phases. XBP1s mRNA expression was higher than day 0 for 
the entire duration of adipogenesis in obese SAT and VAT derived adipocytes. 
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Figure  4.2.3 The IRE1 - XBP1s pathway was elevated during adipogenesis in  
  adipocytes derived from obese subjects compared to lean 
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Figure  4.2.3 legend: The IRE1 - XBP1s pathway was elevated during 
adipogenesis in adipocytes derived from obese subjects compared to lean. 
Preadipocytes from paired Abd SAT and VAT depots in lean and obese subjects 
were differentiated for 14 days. IRE1 (A) and XBP1s (B) mRNA expression was 
measured every 48 hours. Data is expressed as mean ± SE. Significantly different 
values are indicated as follows: * P<0.05, ** P<0.01, *** P<0.001. 
4.2.4 Chronic disruption of the UPR after induction of adipogenesis inhibited 
adipogenic capacity 
The expression of UPR markers IRE1 and XBP1s varied between lean and 
obese derived preadipocytes during adipogenesis. To assess whether ER stress 
influences adipogenesis, ER stress was induced during early adipogenesis with 
TM. Lipid accumulation was considered a marker of adipogenic capacity and 
measured by ORO staining 14 days after the initiation of adipogenesis (figure 
4.2.4 A – B). Lipid accumulation in adipocytes from both SAT and VAT depots 
was significantly reduced (P<0.001) following TM treatment compared to control. 
The IRE1 - XBP1s UPR pathway was differentially expressed during 
adipogenesis in lean and obese derived preadipocytes. To assess whether the UPR 
pathway is necessary during adipogenesis IRE1 endonuclease activity was 
inhibited during early adipogenesis with 48C at two concentrations; 16 M and 
32 M. Lipid accumulation was considered a marker of adipogenic capacity and 
measured by ORO staining 14 days after the initiation of adipogenesis (figure 
4.2.4 C – D). Lipid accumulation was significantly reduced (P<0.001) in 
adipocytes derived from both SAT and VAT following 48C addition. The higher 
concentration of inhibitor resulted in lower lipid accumulation. 
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Figure  4.2.4 Chronic disruption of the UPR after induction of adipogenesis  
  inhibited adipogenic capacity 
A  
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Figure  4.2.4 legend: Chronic disruption of the UPR after induction of 
adipogenesis inhibited adipogenic capacity. Paired Abd SAT and VAT 
preadipocytes from lean subjects were cultured and differentiated for 14 days. 
Adipocytes were subjected to DMSO (control) or 1.0 g/mL TM (A - B), or 16 
M or 32 M 4μ8C (C - D) from induction of adipogenesis for 96 hours (day 0 to 
4) and then treatments were withdrawn. On day 14 after induction of 
adipogenesis, adipocytes were subjected to ORO staining and images captured. 
Data is expressed as mean ± SE. Significantly different values are indicated as 
follows: * P<0.05, ** P<0.01, *** P<0.001. 
 
4.2.5 To investigate the IRE1 - XBP1s pathway further a reproducible 
model system, human preadipocyte cell line ChubS7, was used 
In order to further assess the role of IRE1 - XBP1s during adipogenesis a 
suitable, reliable and consistent human preadipocyte model system was required. 
To assess ChubS7 adipogenic capacity and ER stress expression, adipogenesis 
was induced in ChubS7 preadipocytes for 14 days. Successful adipogenesis was 
confirmed by increased lipid accumulation, lipolysis, insulin stimulated glucose 
uptake and increased gene expression of adipogenesis regulators (figure 4.2.5 A – 
D). IRE1 and XBP1s mRNA expression was assessed every 48 hours (figure 
4.2.5 E). IRE1 expression initially decreased, then gradually increased to the 
same level as day 0. XBP1s expression followed the same pattern of expression as 
IRE1 although remained below the day 0 level. 
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Figure 4.2.5 To investigate the IRE1α - XBP1s pathway further, a reproducible  
  model system, human preadipocyte cell line ChubS7, was used  
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Figure  4.2.5 legend: To investigate the IRE1α - XBP1s pathway further, a 
reproducible model system, human preadipocyte cell line ChubS7, was used. 
Adipogenesis was induced in ChubS7 preadipocytes and the cells cultured for 14 
days. Lipid accumulation (A) and lipolysis (B) were measured every 48 hours. 
Glucose uptake without and with insulin stimulation was measured on day 14 (C). 
mRNA expression of adipogenic markers CEBP and PPAR (D) and UPR 
pathway IRE1 and XBP1s were measured every 48 hours (E). Data is expressed 
as mean ± SE. Significantly different values are indicated as follows: * P<0.05, ** 
P<0.01, *** P<0.001. 
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4.3 Discussion 
This study was designed to investigate adipogenesis in preadipocytes derived 
from different primary human WAT depots. The role of IRE1 - XBP1s UPR 
pathway in adipogenesis in preadipocytes from abdominal SAT and VAT depots 
from lean and obese subjects was studied. Accumulation of WAT in different 
depots has been reported to associate with different risk of developing T2DM 
(White and Tchoukalova, 2014). ER stress has been suggested to play an 
important role in the underlying mechanisms of insulin resistance and T2DM in 
obese subjects (Hummasti and Hotamisligil, 2010). And the ER stress pathway 
IRE1-XBP1s has been reported to be essential in murine adipogenesis (Sha, et 
al., 2009). The results of this study show that the extent of human adipogenesis 
depends on subject adiposity and specific WAT depot. Furthermore, ER stress 
significantly disrupts human adipogenesis and the IRE1-XBP1s pathway is 
essential in human adipogenesis.  
 
Human abdominal adipogenesis is influenced by subject adiposity (Isakson, et al., 
2009; Ma, et al., 2015; Maumus, et al., 2008). The results from this study support 
this theory. Preadipocytes from obese SAT and VAT depots accumulated more 
lipids during adipogenesis than matched depots from lean subjects. This finding 
contradicts van Harmelen et al. who reported no regional difference between 
human abdominal SAT and VAT differentiation, however they used adipocyte 
morphology and determination of glycerol-3-phosphate dehydrogenase (GPDH) 
to assess differentiation and therefore may not have resolved differences in lipid 
accumulation and lipolysis (van Harmelen, et al., 2004). Preadipocytes derived 
from obese SAT underwent more lipolysis during adipogenesis than lean SAT; 
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however conversely, lean VAT underwent more lipolysis than obese VAT. 
Furthermore in lean derived preadipocytes, those from VAT had higher levels 
lipolysis compared to SAT whereas in obese derived adipocytes SAT had higher 
levels of lipolysis than VAT. These findings are consistent with the hypothesis of 
Karpe et al. that NEFA concentration is largely unrelated to body fat mass (Karpe, 
et al., 2011). The observed differences in lipid accumulation and lipolysis may be 
due to different physiological functions of abdominal SAT and VAT, in 
accordance with existing dogma (Kissebah, et al., 1982). SAT may primarily 
serve as a long-term energy store whereas VAT may be more plastic and therefore 
release more NEFA. In lean subjects the higher VAT lipolysis may serve to 
supply the nearby liver with NEFA to be oxidized to transfer energy in a 
controlled way.  
 
This study indicated differences during adipogenesis in preadipocytes from 
different origin and importantly also showed differences in adipocyte function 
after adipogenesis. Adipocyte function was assessed by insulin stimulated glucose 
uptake. Lean Abd SAT adipocytes had the lowest basal glucose uptake and the 
biggest fold increase following insulin stimulation, over twice the basal rate. This 
reflects regulated metabolism and suggests the lean subjects Abd SAT was 
metabolically healthy and highly sensitive to insulin. Lean VAT adipocytes had a 
greater basal glucose uptake rate than Abd SAT, however there was no change 
after insulin stimulation. This further supports the hypothesis that WAT depot 
function is distinct (Kovacova, et al., 2012; McLaughlin, et al., 2011). Obese Abd 
SAT adipocytes had a higher basal glucose uptake and a lower fold increase upon 
insulin addition compared to lean but still had a significant increase. This suggests 
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obese Abd SAT adipocytes metabolism is compromised and less sensitive to 
insulin action. Obese VAT adipocytes had the greatest basal glucose uptake and it 
did not increase following insulin stimulation. This suggests that the obese VAT 
adipocytes are dysregulated and insulin resistant. Collectively these findings 
support human investigations that suggest Abd SAT is protective for insulin 
resistance whereas VAT mass has the opposite effect (McLaughlin, et al., 2011). 
 
The IRE1 - XBP1s UPR pathway is indispensible in murine adipogenesis (Sha, 
et al., 2009), therefore IRE1 and XBP1s mRNA expressions were measured 
during human adipogenesis. Abd SAT derived preadipocytes from both lean and 
obese subjects decreased IRE1 and XBP1s expression during adipogenesis. 
Conversely VAT derived preadipocytes from both lean and obese subjects 
increased IRE1 expression in a biphasic way peaking on days 4 and 12, and 
increased XBP1s expression throughout adipogenesis. Therefore there were clear 
depot specific differences in gene expression irrespective of adiposity. This study 
indicated adiposity and WAT region influence adipocyte metabolic function 
through altered lipid accumulation, lipolysis and glucose uptake and it also 
showed adiposity and WAT region influence gene expression during 
adipogenesis. These findings support Tchkonia et al. that WAT depot-specific 
characteristics are retained in strains derived from human preadipocytes 
(Tchkonia, et al., 2006). Since functional differences between mesenchymal stem 
cell populations are reflected by their transcriptome (Jansen, et al., 2010), the 
observed differences in gene expression likely reflect different adipocyte 
functions and further support the hypothesis that regional WAT depots have 
different functions (White and Tchoukalova, 2014).  
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This study showed that chronic inhibition or activation of the UPR during 
adipogenesis inhibits adipogenic capacity. The IRE1 - XBP1s pathway was 
differentially expressed in SAT and VAT adipogenesis and activation of the UPR 
has been linked to metabolic dysfunction (Hummasti and Hotamisligil, 2010). 
Therefore the UPR was hypothesised to play a key role in adipogenesis. Induction 
of ER stress with TM or blocking IRE1 endonuclease activity with 48C and 
depleting cellular XBP1s during the initial 4 days of adipogenesis prevented cell 
morphological changes and lipid accumulation, collectively blocking 
adipogenesis. Therefore functional ER integrity and XBP1s are required for 
successful adipogenesis in humans. The finding that XBP1s is essential for human 
adipogenesis supports murine studies (Sha, et al., 2009) and therefore provides a 
translation from mouse to man. The importance of ER integrity in adipogenesis 
supports the postulation that the ER is tightly connected to metabolic regulation 
(Unanue and Urano, 2014). Bariatric surgery induced WAT loss led to a reduction 
in ER stress and an improved metabolic profile (chapter 3). Therefore the reduced 
ER stress following WAT loss may have improved WAT metabolic function 
partly through improved adipogenesis regulation.  
 
SAT was investigated further because SAT represents the vast majority of AT 
(about 85 % of all body fat (Frayn and Karpe, 2014)) and the inability of SAT to 
expand has been causally related to obesity complications such as T2DM (Virtue 
and Vidal-Puig, 2010). In order to investigate SAT adipocyte signalling pathways 
in more detail a suitable human adipocyte cell line, ChubS7, was used for 
reproducibility. ChubS7 cells have previously been characterised in detail and 
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shown to express typical white adipocyte markers upon adipogenesis (Bujalska, et 
al., 2008; Darimont, et al., 2003; Gathercole, et al., 2007). In this study during 
adipogenesis ChubS7 preadipocytes accumulated lipids, had increased lipolysis, 
and increased adipogenic regulator gene expression, and adipocytes had 
significantly increased glucose uptake. Therefore they successfully differentiated 
in agreement with literature. IRE1 and XBP1s mRNA expression levels in 
ChubS7 cells significantly reduced upon activation of adipogenesis and then 
oscillated during the subsequent 14 days and therefore may play an important role 
in regulating adipogenesis. However ChubS7 cells were derived from an obese 
female subject with a BMI of 54 kg/m2 and ChubS7 cells coexpress human 
telomerase reverse transcriptase (hTERT) and papillomavirus E7 oncoprotein 
(HPV-E7) (Darimont, et al., 2003), therefore caution must be taken when 
extrapolating results from ChubS7 cells to adipocytes. Nonetheless, ChubS7 cells 
serve as a useful tool to optimise adipocyte treatment conditions due to their 
consistency. Thus in order to investigate the IRE1 - XBP1s pathway in further 
detail, ChubS7 cells were used for optimisation and pilot studies before key 
experiments were repeated in primary human adipocytes.  
 
 
 
 
 
 
151 
4.4 Conclusions 
In summary, this study showed that adipogenesis in primary human preadipocytes 
is influenced by both adiposity and WAT depot of preadipocyte source and that 
the IRE1 - XBP1s UPR pathway plays an integral role in human adipogenesis. 
Adipogenesis is an important process within WAT to allow normal turnover of 
adipocytes (Spalding, et al., 2008) and facilitate appropriate WAT expansion to 
respond to the energy needs of the body (Wang, et al., 2013). This investigation 
indicated that during adipogenesis obese derived preadipocytes accumulated more 
lipid than lean irrespective of WAT depot, however lipolysis and insulin 
sensitivity were both influenced by adiposity and WAT depot. Collectively these 
findings support human investigations that suggest Abd SAT is protective for 
insulin resistance whereas VAT mass has the opposite effect (McLaughlin, et al., 
2011). The expressions of IRE1 and XBP1s during adipogenesis differed 
between depots and may in part explain the observed functional differences in 
adipocytes. ER stress induction prevented adipogenesis irrespective of 
preadipocyte origin and may in part explain why WAT ER stress is associated 
with metabolic dysfunction (Hotamisligil, 2010). The novel finding that XBP1s is 
a prerequisite for human adipogenesis strengthens the link between UPR and 
adipogenesis, although further investigation is required to elucidate the role of 
XBP1s in human adipogenesis. These findings provide insight into adipocyte 
functional differences and their integration with the UPR and therefore this 
information will benefit development of translational clinical interventions to 
improve metabolic health. 
 
 
152 
 
 
 
Chapter 5: The role of the IRE1α - XBP1s 
UPR pathway in human adipogenesis and 
metabolism  
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5.1 Introduction 
WAT is able to expand and contract during adult life to accommodate the energy 
requirements of the body despite most development during prenatal and early 
postnatal life (Poulos, et al., 2010). Evidence suggests obesity complications in 
humans such as T2DM result from the inability of SAT to appropriately expand 
and store lipids, and consequently ectopic fat deposition and lipotoxicity 
contribute to insulin resistance (Hill, et al., 2009; Virtue and Vidal-Puig, 2010). 
Impaired WAT expandability is mainly due to defects in adipogenesis (Isakson, et 
al., 2009). Therefore adipogenesis is an important process to maintain metabolic 
function. Further understanding of adipogenesis may present targets to improve 
metabolic regulation. Preadipocytes derived from SAT and VAT were both 
effected by ER stress and blocking XBP1s expression during adipogenesis to the 
same extent (figure 4.2.4). SAT will be investigated further because SAT 
represents the vast majority of WAT (about 85 % of all body fat (Frayn and 
Karpe, 2014)) and the inability of SAT to expand has been causally related to 
obesity complications such as T2DM (Virtue and Vidal-Puig, 2010).  
 
Within adipocytes the ER plays a key role in metabolic regulation. ER stress can 
lead to activation of the UPR (figure 1.6.1) and influence metabolism and 
function of adipocytes (figures 1.7.1 and 1.7.2). Inducing ER stress with TM 
during induction of differentiation prevented adipogenesis (chapter 4). Therefore 
ER function is a prerequisite for successful adipogenesis. The IRE1-XBP1s UPR 
pathway is essential for adipogenesis in mouse cells (Sha, et al., 2009) and this 
study has confirmed this in human cells for the first time (chapter 4). However the 
role of XBP1s in human adipogenesis is not known. Understanding the role of 
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XBP1s in adipogenesis will provide insight into the regulation of adipogenesis 
and may reveal targets to boost adipogenesis. Forced expansion of WAT via 
increased hyperplasia induced by transgenic overexpression of adiponectin in 
ob/ob mice normalized glucose and insulin levels and prevented insulin resistance 
(Kim, et al., 2007). Therefore upregulating adipogenesis may have protective 
effects for metabolic health. Since XBP1s is essential for adipogenesis, then 
targeting XBP1s or its downstream targets may provide a mechanism to boost 
adipogenesis and subsequently help WAT expansion and prevent ectopic fat 
deposition and lipotoxicity, and therefore help metabolic regulation.   
 
Understanding how XBP1s fits into the complex system of adipogenesis 
regulation may provide pharmacological targets and therefore have clinical 
benefit. Characterisation of adipogenesis regulatory processes have benefited 
from the discovery of key pathways and transcription factors that contribute to the 
adipogenic process, as reviewed by Lefterova and Lazar (Lefterova and Lazar, 
2009). The transcription factors PPAR and CEBPs are the crucial determinants 
of adipocyte fate although other factors including extracellular acting Wnts and 
intracellular cell-cycle proteins also play roles in adipogenesis. There are several 
inhibitors of adipogenesis including CHOP, which is upregulated in ER stress 
(Hou, et al., 2013), and certain TCF/LEF proteins, activated by Wnt signalling 
(Farmer, 2006). Recently miRNA-540 has been suggested to impair adipogenesis 
via suppression of PPAR (Chen, et al., 2015). Therefore a network of 
transcription factors and cell-cycle regulators, in concert with transcriptional 
coactivators and corepressors, respond to extracellular stimuli to activate or 
repress adipogenesis. Cho et al. have shown in mouse 3T3-L1 cells that XBP1s 
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enhances adipogenesis through the downregulation of Wnt10b (Cho, et al., 2013). 
And in mouse 3T3-L1 cells that XBP1s is a key regulator of adipogenic 
modulator PPAR (Cho, et al., 2014). However the role of XBP1s in human cells 
during adipogenesis has not been studied. 
 
Therefore the aim of this study was to investigate the role of XBP1s in human 
adipogenesis. Human adipocytes were used to optimise inhibition conditions with 
IRE1 endonuclease inhibitor 48C and XBP1 siRNA. Human preadipocytes 
were subjected to various XBP1s inhibition studies via inhibitor or siRNA during 
adipogenesis. Adipogenesis and adipocyte function were assessed by lipid 
accumulation, lipolysis and glucose uptake. Expression of key adipogenic and ER 
stress proteins and mRNAs were measured during adipogenesis and following 
XBP1s inhibition.   
 
5.2 Results 
5.2.1 IRE1 endonuclease activity was specifically inhibited with the small 
molecule inhibitor 48C in adipocytes without effecting cell viability 
To investigate the IRE1 - XBP1s pathway in adipogenesis a method of blocking 
the signalling pathway was sought. The small molecule inhibitor 48C has been 
shown to block IRE1 endonuclease activity in mouse embryonic fibroblasts 
(MEF cells) (Cross, et al., 2012), but not human adipocytes. In order to assess the 
effects of 48C in human adipocytes on IRE1 inhibition, adipocytes were 
treated with DMSO (control) or subjected to ER stress by treatment with 0.75 
g/mL TM for 24 hours in the presence of 48C concentrations 0 – 64 M and 
156 
ER stress gene expressions measured (figure 5.2.1 A – E). In the absence of 
48C, TM increased XBP1s expression 13-fold higher than control. 48C 
decreased the expression of XBP1s both without and with ER stress induction in a 
dose dependent way. 16 M 48C reduced ER stress induced XBP1s expression 
by 99 % compared to control. XBP1u decreased in the presence of 48C without 
TM but increased in the presence of TM in a dose dependent way. In the absence 
of TM, IRE1 expression did not change with 48C up to 16 M, above this 
concentration IRE1 expression increased more with more inhibitor and so 
induced ER stress. In the presence of TM, IRE1 increased consistently to 4 – 5 
fold higher than without TM up to 16 M 48C, above this concentration IRE1 
expression increased to 8 fold higher than control. ATF6 expression did not 
change with TM or 48C up to 16 M, above this concentration it increased with 
and without TM. CHOP expression did not change without TM up to 16 M 
48C, above this concentration it increased. CHOP consistently increased 30 – 50 
fold in the presence of TM and up to 32 M 48C. At 64 M 48C and the 
presence of TM, CHOP expression increased 20 fold higher than control.  
 
In order to assess the effect of 48C on cell viability, cytotoxicity assays were 
conducted on ChubS7 and primary adipocytes with 48C concentrations 0 – 32 
M and without or with TM (figure 5.2.1 F – G). Cell viability compared to 
control with 4 M 48C for 24 hours was 99 % and for 48 hours was 90 % for 
both primary and ChubS7 adipocytes. Cell viability in the absence of 48C and 
with TM for 24 hours was 80 % and 60 % for primary and ChubS7 cells 
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respectively. As the concentration of 48C was increased cell viability decreased 
with dose and exposure.  
 
The optimum concentration of 48C to use in human adipogenesis experiments 
was decided as 4 M because XBP1s mRNA expression was reduced by over 90 
% whilst cell viability was over 90 % compared to control. All subsequent 
experiments used a concentration of 4 M 48C. 
 
Figure  5.2.1 IRE1α endonuclease activity was specifically inhibited with the  
  small molecule inhibitor 48C in adipocytes without effecting cell  
  viability 
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Figure  5.2.1 legend: IRE1α endonuclease activity was specifically inhibited with 
the small molecule inhibitor 48C in adipocytes without effecting cell viability. 
Adipogenesis was induced in ChubS7 cells and on day 14 cells were incubated for 
24 hours with 0.75 g/mL TM or DMSO without TM (control) with 4μ8C 
concentrations 0 – 64 M. mRNA expression of XBP1s (A), XBP1u (B), IRE1 
(C), ATF6 (D) and CHOP (E) were measured. The expressions of mRNA without 
and with TM are compared to 0 M 48C without and with TM respectively. 
Cytotoxicity assays were conducted on ChubS7 and primary lean SAT cells with 
treatments starting on day 0 (preadipocytes) and day 14 after induction of 
adipogenesis (adipocytes). No significant differences in cell viability between day 
0 and day 14 were detected. Cell viability is presented as mean of day 0 and day 
14. ER stress was induced for 24 or 48 hours with 0.75 g/mL TM or control 
without TM in the presence of 4μ8C, concentrations 0 – 32 M. Cell viability was 
assessed by MTT assay without TM (F) and with TM (G) and significantly lower 
cell viability compared to without 48C are indicated. Data is expressed as mean 
± SE. Significantly different values are indicated as follows: * P<0.05, ** P<0.01, 
*** P<0.001. 
 
 
5.2.2 During adipogenesis 48C reduced adipogenic capacity depending on 
time and duration of treatment 
ER stress induction and inhibition of IRE1 endonuclease activity during early 
adipogenesis reduced adipogenic capacity (chapter 4). To determine the critical 
period during early adipogenesis for the IRE1 - XBP1s pathway, adipogenesis 
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was induced in primary SAT lean preadipocytes for 14 days in conjunction with 
DMSO (control) or 4 µM 48C for different time periods during early 
adipogenesis. Adipogenesis was measured by lipid accumulation, lipolysis and 
insulin stimulated glucose uptake (figure 5.2.2 A – D). Treatment with 48C 
during the initial 48 hours of adipogenesis had no significant effect on lipid 
accumulation, lipolysis or glucose uptake. However treatment with 48C between 
48 hours and 96 hours after induction of adipogenesis significantly reduced lipid 
accumulation, lipolysis and glucose uptake. All three parameters were further 
reduced when 48C was administered for the initial 96 hours and furthermore 
during the initial 144 hours. Therefore, day 0 – 4 (96 hour) inhibition was used for 
all further studies. 
 
Figure  5.2.2 During adipogenesis 48C reduced adipogenic capacity   
  depending on time and duration of treatment 
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Figure  5.2.2 legend: During adipogenesis 48C reduced adipogenic capacity 
depending on time and duration of treatment. Adipogenesis was induced in 
primary SAT lean preadipocytes for 14 days without (control) and with 4 M 
48C for the initial 48 hours (day 0 – 2), between 48 and 96 hours (day 2 – 4), the 
initial 96 hours (day 0 – 4) and the initial 144 hours (day 0 – 6). Lipid 
accumulation was assessed on day 8 and day 14 after induction of adipogenesis 
(A – B), lipolysis was measured every 48 hours (C), and glucose uptake without 
or with insulin stimulation was measured on day 14 (D). Data is expressed as 
mean ± SE. Significantly different values are indicated as follows: * P<0.05, ** 
P<0.01, *** P<0.001. 
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5.2.3 During adipogenesis 48C inhibited XBP1s, adipogenic regulator and 
adiponectin mRNA expression depending on treatment duration 
Inhibiting IRE1 activity during early adipogenesis reduced lipid accumulation, 
lipolysis and glucose uptake compared to control (figure 5.2.2). To assess what 
effect the inhibition had on gene expression during adipogenesis, primary 
adipocytes were treated with 48C for different times during early adipogenesis 
and key ER stress and adipogenic gene expressions were measured every 48 hours 
for 14 days (figure 5.2.3 A – G). At every time point following 48C treatment 
XBP1s mRNA was significantly reduced (P<0.05), however XBP1u mRNA did 
not change compared to control. After inhibitor treatments had been withdrawn 
XBP1s mRNA recovered to within no significant difference from control, 
however XBP1u mRNA increased significantly higher (P<0.05) than control 
following 96 hour inhibitor treatment. Without inhibitor treatment IRE1 and 
CHOP expression decreased after induction of adipogenesis and fluctuated at 
levels below that of day 0. Both IRE1 and CHOP expression remained the same 
as control following 48C treatments at every time point during adipogenesis.  
 
In control cells CEBP expression peaked at day 8 of adipogenesis at 600 fold 
higher than day 0 and then gradually decreased to 400 fold higher than day 0 on 
day 14. CEBP expression was significantly reduced (P<0.05) on day 4 and day 6 
following IRE1 inhibition compared to control. CEBP expression following 
IRE1 inhibition then recovered to the control expression level between days 8 
and 12 but on day 14 it was significantly lower (P<0.05) than control for all 
treatment groups. PPAR expression, in control adipocytes, increased up to day 8 
166 
and then remained at the same level up to day 14. PPAR was significantly lower 
compared to control on day 6 for adipocytes with IRE1 inhibited day 0 – 2, 0 – 4 
and 0 – 6. At all other time points there was no significant difference from control 
to any of the treatment groups. Adiponectin mRNA was undetected on day 0 in 
control and all the treatment groups. The control adipocytes increased adiponectin 
mRNA expression on day 6 to over 3,000 fold higher than day 2. It remained 
around this level until day 12 and then it decreased on day 14 to 2,000 fold higher 
than day 2. Adiponectin expression was significantly (P<0.05) lower than control 
on day 4 and day 6 following IRE1 inhibition. Adiponectin expression remained 
significantly lower (P<0.05) than control 2 days after IRE1 inhibition had been 
withdrawn for day 0 – 4 and day 0 – 6 treatments. Adiponectin expression then 
recovered to control levels before decreasing to significantly below (P<0.05) 
control on day 12 and 14 in cell treated with 4 µM 4µ8C on days 2 – 4, 0 – 4 and 
0 – 6.  
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Figure  5.2.3 During adipogenesis 4μ8C inhibited XBP1s and adipogenic  
  regulator mRNA expression depending on treatment duration  
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Figure  5.2.3 legend: During adipogenesis 4μ8C inhibited XBP1s and adipogenic 
regulator mRNA expression depending on treatment duration. Adipogenesis was 
induced in primary SAT lean preadipocytes for 14 days with DMSO (control) or 4 
M 48C for the initial 48 hours (day 0 – 2), between 48 and 96 hours (day 2 – 
4), the initial 96 hours (day 0 – 4) and the initial 144 hours (day 0 – 6). mRNA 
expression was measured every 48 hours for XBP1s (A), XBP1u (B), IRE1 (C), 
CHOP (D), CEBP (E), PPAR (F), Adiponectin (G). Data is expressed as mean 
± SE. Significantly different values are indicated as follows: * P<0.05. 
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5.2.4 During adipogenesis 48C consistently reduced adipogenic capacity and 
function in adipocytes 
Inhibiting IRE1 with 48C for 96 hours (day 0 – 4) after induction of 
adipogenesis resulted in the most profound reduction in adipogenic capacity 
compared to other treatment durations (figures 5.2.2 – 5.2.3). Therefore this 
duration of inhibition was used in subsequent studies. To confirm the preliminary 
outcomes of 48C treatment during day 0 – 4 of adipogenesis in preadipocytes 
from one lean metabolically healthy subject, the treatments were repeated in SAT 
preadipocytes from three metabolically healthy lean subjects, each in triplicate. 
The preadipocytes were subjected to adipogenesis in DMSO (control) and 4 M 
48C treated conditions during day 0 – 4 of adipogenesis and then lipid 
accumulation, lipolysis and glucose uptake were measured (figure 5.2.4 A – C). 
Day 14 lipid accumulation, lipolysis and insulin stimulated glucose uptake were 
all significantly reduced (P<0.001) following 48C treatment compared to 
control.  
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Figure  5.2.4 During adipogenesis 4μ8C consistently reduced adipogenic  
  capacity and function in adipocytes  
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Figure  5.2.4 legend: During adipogenesis 4μ8C consistently reduced adipogenic 
capacity and function in adipocytes. Adipogenesis was induced in primary SAT 
lean preadipocytes (n=3, each in triplicate) for 14 days with DMSO (control) or 4 
M 48C for the initial 96 hours (day 0 – 4). Lipid accumulation was assessed on 
day 14 after induction of adipogenesis (A), lipolysis was measured during 
adipogenesis (B), and basal and insulin stimulated glucose uptake was measured 
on day 14 (C). Data is expressed as mean ± SE. Significantly different values are 
indicated as follows: * P<0.05, ** P<0.01, *** P<0.001. 
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5.2.5 During adipogenesis 48C inhibited XBP1s and adipogenic regulator 
mRNA expression 
Adipogenic capacity was significantly reduced in primary human adipocytes 
following 48C treatment (figure 5.2.4). To assess the effects of 48C on ER 
stress and adipogenic gene expression during adipogenesis, 4 M 48C was 
administered for the initial 96 hours of adipogenesis and ER stress and adipogenic 
regulator gene expressions were measured for 14 days (figure 5.2.6 A – G). The 
initial six days of adipogenesis were considered vital for adipogenic capacity 
outcome because in control cells, adipocyte marker adiponectin gene expression 
peaked on day 6 (figure 5.2.3 G). Therefore gene expression was measured every 
48 hours between day 0 and day 6 and every 96 hours between day 10 and day 14. 
XBP1s expression in control adipocytes reduced to 0.2 fold compared to day 0 on 
day 2 before gradually increasing to 1.5 fold higher than day 0 on day 14. 
Following 48C, XBP1s mRNA expression was significantly lower (P<0.01 – 
P<0.001) than control on day 2 and day 4. The inhibitor was removed on day 4, 
and on day 6 the expression of XBP1s remained significantly below (P<0.05) 
control. The expression of XBP1s matched that of control on day 10 and day 14. 
XBP1u expression in control and IRE1 inhibited adipocytes decreased to 0.4 
fold compared to day 0 on day 2 and then gradually increased to 1.1 fold 
compared to day 0 on day 14. IRE1 and CHOP expression in both control and 
IRE1 inhibited adipocytes decreased on day 2 and then fluctuated below the day 
0 level for the duration of adipogenesis. There were no significant differences in 
XBP1u, IRE1, or CHOP mRNA expression between control and IRE1 
inhibited adipocytes for the duration of adipogenesis. 
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CEBP expression in control adipocytes increased and peaked on day 6 – 10 after 
induction of adipogenesis, however the fold increase compared to day 0 varied 
between subjects and only the median control is shown. In all the subjects, IRE1 
inhibition reduced CEBP expression by approximately 50 % (P<0.001) from day 
4 to 14 of adipogenesis compared to control. PPAR expression gradually 
increased for the duration of adipogenesis in control cells, peaking on day 14 at 5 
fold higher than day 0. In 4 µM 4µ8C treated adipocytes, PPAR expression 
increased after initiation of adipogenesis but was significantly lower (P<0.05) 
than control from day 4 to day 14. Adiponectin was not detected on day 0 in any 
of the adipocytes. In control adipocytes, adiponectin increased considerably after 
day 2, and similarly to CEBP, the extent of fold increase compared to day 0 
varied between subjects. Following 4 µM 4µ8C treatment, adiponectin expression 
was reduced compared to control for the duration of adipogenesis. 
 
 
 
 
 
 
 
 
 
 
 
176 
Figure  5.2.5 During adipogenesis 4μ8C inhibited XBP1s and adipogenic  
  regulator mRNA expression 
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Figure  5.2.5 legend: During adipogenesis 4μ8C inhibited XBP1s and adipogenic 
regulator mRNA expression. Adipogenesis was induced in primary SAT lean 
preadipocytes (n=9) for 14 days with DMSO (control) or with 4 M 48C for the 
initial 96 hours (day 0 – 4). mRNA was measured during adipogenesis for XBP1s 
(A), XBP1u (B), IRE1 (C), and CHOP (D). Data is expressed as mean ± SE. 
Significantly different values are indicated as follows: * P<0.05, ** P<0.01, *** 
P<0.001. 
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5.2.6 48C reduced insulin stimulated glucose uptake and inhibited Akt 
phosphorylation  
XBP1s mRNA correlated with plasma glucose in subjects after bariatric surgery 
(figure 3.2.3) and glucose uptake was affected after 48C treatment during early 
adipogenesis (5.2.4 C), suggesting a possible link between the IRE1 - XBP1s 
pathway and glucose uptake. To investigate the role of IRE1 - XBP1s during 
glucose uptake, 4µM 48C was added during the final 24 or 96 hours of 
adipogenesis up to day 14 and on day 14 insulin stimulated glucose uptake, p-Akt 
and glut4 proteins, and XBP1s, XBP1u and GLUT4 mRNA expression were 
measured (figure 5.2.6 A – D). Day 14 insulin stimulated glucose uptake was 
significantly reduced (P<0.001) following IRE1 inhibition for 24 and 96 hours. 
p-Akt protein normalised with total Akt was highly expressed in control 
adipocytes and significantly reduced (P<0.001) following 48C treatment 
compared to control. There was no difference in glut4 protein expression between 
control and IRE1 inhibited adipocytes. XBP1s mRNA was significantly reduced 
(P<0.01) and XBP1u mRNA was significantly increased (P<0.05) following 
48C treatment compared to control. There was no difference in GLUT4 mRNA 
following 24 hours with 48C but there was a significant reduction (P<0.05) 
following 96 hours with 48C compared to control. 
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Figure 5.2.6 4μ8C reduced insulin  stimulated glucose uptake and inhibited Akt 
phosphorylation 
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Figure 5.2.6 legend: 4μ8C reduced insulin  stimulated glucose uptake and 
inhibited Akt phosphorylation. Adipogenesis was induced for 14 days in ChubS7 
cells and treated for the final 24 hours with DMSO (control 24 hours) or 4 M 
48C, or treated for the final 96 hours with DMSO (control 96 hours) or 4 M 
48C. On day 14 after induction of adipogenesis, insulin stimulated glucose 
uptake (A), p-Akt (B) and glut4 (C) protein expression, and XBP1s, XBP1u, and 
GLUT4 (D) mRNA expression were measured. Data is expressed as mean ± SE. 
Significantly different values are indicated as follows: * P<0.05, ** P<0.01, *** 
P<0.001. 
 
5.2.7 XBP1 siRNA transfection during early adipogenesis reduced adipocyte 
function 
To validate the findings using 48C to downregulate XBP1s (figure 5.2.4), XBP1 
siRNA treatment was performed. XBP1 siRNA treatment was optimised and 
administered during day 0 – 4 of adipogenesis. To ensure successful XBP1 
knockdown with XBP1 siRNA, XBP1s and XBP1u mRNA were measured on day 
4. Glucose uptake was measured on day 14 following induction of adipogenesis 
and siRNA transfection (figure 5.2.7 A – C). During optimisation both XBP1s and 
XBP1u mRNA were significantly reduced (P<0.05) following XBP1 siRNA 
compared to non-targeting siRNA treatment in a dose dependent way. The higher 
concentration of transfection reagent (1 % DharmaFECT Duo) reduced the XBP1 
mRNAs more than the lower concentration (0.5 % DharmaFECT Duo). 25 nmol 
XBP1 siRNA with DharmaFECT Duo 0.5 % was selected to inhibit XBP1 during 
adipogenesis because it significantly reduced XBP1s and XBP1u mRNA whilst 
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having the fewest cytotoxic effects, since it was the lowest concentration of 
siRNA and transfection reagent. On day 4 following XBP1 siRNA transfection 
XBP1s and XBP1u mRNA were significantly reduced (P<0.01) compared to non-
targeting siRNA transfection. On day 14 following induction of adipogenesis, 
insulin stimulated glucose uptake was significantly reduced (P<0.01) following 
XBP1 siRNA compared to non-targeting siRNA transfection.   
 
Figure  5.2.7 XBP1 siRNA transfection during early adipogenesis reduced  
  adipocyte function 
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Figure 5.2.7 legend: XBP1 siRNA transfection during early adipogenesis reduced 
adipocyte function. Optimal XBP1 siRNA conditions were established in ChubS7 
adipocytes (A) (25 nm, 50 nm, 100 nm; 25 nmol, 50 nmol, 100 nmol, NT; non-
targeting siRNA, XBP1; XBP1 siRNA). Adipogenesis was induced in ChubS7 
adipocytes and transfection was carried out with 50 nmol non-targeting (NT) or 
25 nmol XBP1 siRNA treatment at induction (day 0) and at 48 hours after 
induction (day 2). XBP1s and XBP1u mRNA expression was measured at 96 
hours following adipogenesis induction (day 4) (B). Adipogenic capacity was 
assed by functional glucose uptake under basal and insulin stimulated conditions 
on day 14 after induction of adipogenesis (C). Data is expressed as mean ± SE. 
Significantly different values are indicated as follows: * P<0.05, ** P<0.01, *** 
P<0.001. 
 
 
 
 
 
 
 
 
 
187 
5.3 Discussion 
This study was designed to investigate the role of XBP1s in human adipogenesis. 
Inhibition of XBP1s was optimised in human adipocytes with small molecule 
inhibitor 48C and then the effects of inhibiting XBP1s during adipogenesis were 
assessed before investigating the molecular mechanisms and validating the 
findings with XBP1 siRNA. Adipogenesis is an important process to maintain 
WAT metabolic function. The study in chapter 4 found that the IRE1 - XBP1s 
pathway is indispensible for successful human adipogenesis, however the role of 
XBP1s in human adipogenesis is not known. Recently Cho et al. have shown in 
mouse 3T3-L1 cells that XBP1s is a key regulator of adipogenic modulator 
PPAR (Cho, et al., 2014). The results of this study show that XBP1s plays a key 
role in early human adipogenesis independently of other UPR pathways and may 
mediate its effects through PPAR and CEBP. Furthermore, XBP1s is essential 
for insulin stimulated Akt phosphorylation mediated glucose uptake. Therefore 
XBP1s is necessary for adipogenesis and transmitting insulin action and thus 
plays a key role in glucose uptake, metabolic health, insulin resistance and T2DM.  
 
The small molecule inhibitor 48C has been used to inhibit IRE1 endonuclease 
activity without effecting cell viability (Cross, et al., 2012; Qiu, et al., 2013; 
Zhang, et al., 2014a). However previous reports have investigated 48C in MEF 
cells (Cross, et al., 2012), macrophages from the synovial fluid of rheumatoid 
arthritis patients (Qiu, et al., 2013) and mouse pancreatic beta-cells (Zhang, et al., 
2014a) but not human adipocytes. Therefore appropriate pharmacological studies 
were conducted to ascertain a suitable dose to use in human adipocytes that 
inhibited XBP1s expression without inducing cytotoxic effects. This study found 
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that 48C specifically inhibits IRE1 endonuclease activity in adipocytes; it 
reduced the expression of XBP1s in the presence of TM without affecting the 
expression of IRE1, ATF6 or CHOP in agreement with Cross et al. (Cross, et 
al., 2012). In the absence of TM, 48C reduced the expression of XBP1u, 
however in the presence of TM, 48C increased the expression of XBP1u perhaps 
as a compensatory mechanism of the adipocytes to increase the substrate of 
IRE1 endonuclease activity in an attempt to restore expression of XBP1s. This 
study found that human adipocytes treated with 4 M 48C maintained 100 % 
cell viability when treated for 24 hours and over 90 % cell viability when treated 
for 48 hours. As the concentration of inhibitor increased, adipocyte cell viability 
decreased in contrast to studies in MEF cells (Cross, et al., 2012), however the 
MEF cells were only exposed to 48C for 6 hours and therefore any cytotoxic 
effects may not have had time to take effect. The optimum concentration of 48C 
for human adipocytes was decided as 4 M because this concentration reduced 
TM induced XBP1s expression by 90 % and maintained 90 % cell viability after 
48 hours of treatment. Therefore 4 M 48C was used for all subsequent studies. 
 
This investigation found that the time and duration of XBP1s inhibition during 
adipogenesis affected adipogenic capacity in primary human adipocytes. 
Inhibiting XBP1s did not alter other UPR factors during adipogenesis and 
therefore its effects are likely to be mediated independently of UPR activation and 
via alternative mechanisms. This study shows that during adipogenesis in control 
cells, XBP1s significantly decreased initially until day 2 and then gradually 
increased to above the day 0 expression. This overall pattern of XBP1s expression 
during adipogenesis is the same as Cho et al. reported in 3T3-L1 cells (Cho, et al., 
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2013). However, Cho et al. suggested that an increase in XBP1s expression 
during the initial onset of adipogenesis plays a role in successful adipogenesis 
(Cho, et al., 2013). This study disagrees with their hypothesis because inhibiting 
XBP1s during the initial 48 hours of adipogenesis had no effect on adipogenesis 
or adipocyte function as assessed by CEBP, PPAR and adiponectin mRNA 
expression, lipid accumulation, lipolysis, or adipocyte glucose uptake. This study 
found that inhibiting XBP1s during day 2 – 4 of adipogenesis significantly 
reduced CEBP and adiponectin expression on day 4 and 6, reduced PPAR on 
day 6 and significantly reduced lipid accumulation compared to control. 
Administering 48C for the initial 4 days of adipogenesis resulted in significantly 
lower CEBP expression on days 4 and 6, reduced PPAR on day 6 and reduced 
adipogenic capacity, measured by lipid accumulation, lipolysis and glucose 
uptake. There was no additional impact on adipogenesis when XBP1s was 
inhibited for the initial 6 days of adipogenesis. Therefore collectively these results 
suggest that XBP1s exerts its effects during the early but not immediate early 
stages of adipogenesis. In context of existing literature, this suggests XBP1s acts 
downstream of the early activated CEBP (Guo, et al., 2015) and may interact 
directly with CEBP or PPAR. 
 
A link between UPR signalling and metabolism has been suggested (Hotamisligil, 
2010; Lee and Ozcan, 2014). This study showed that XBP1s plays a key role 
during early adipogenesis in primary human adipogenesis and affects primary 
human adipocyte metabolism. Having found that inhibiting IRE1 endonuclease 
activity and subsequent depletion of XBP1s during early adipogenesis reduced 
primary human adipogenic capacity, it was validated further with primary human 
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preadipocytes from three lean metabolically healthy subjects, each with 
experiments repeated in triplicate. This study showed that inhibiting IRE1 with 4 
M 48C during the initial 4 days of adipogenesis consistently and significantly 
reduced lipid uptake, lipolysis and insulin stimulated glucose uptake in primary 
human adipocytes. Therefore concurring with the hypothesis of a link between ER 
stress and insulin resistance (Flamment, et al., 2012). 
 
This investigation showed that XBP1s exerts its effects on adipogenesis 
independently of other UPR signalling factors and it may regulate CEBP and 
PPAR expression. These findings are the first of their kind in human adipocytes 
and support the mouse cell line work of Cho et al. that suggest XBP1s may 
regulate PPAR in adipogenesis (Cho, et al., 2014). Blocking XBP1s expression 
had no significant effect compared to control on CHOP expression, which has 
been shown to inhibit adipogenesis (Hou, et al., 2013). All three lean 
metabolically healthy subjects had varying degrees of CEBP activation during 
adipogenesis, however inhibition of XBP1s resulted in consistent downregulation 
of CEBP compared to control. Despite the variation in CEBP expression 
during adipogenesis between the preadipocytes, PPAR expression was 
consistent. Nonetheless, when XBP1s was inhibited PPAR was downregulated 
compared to control. Thus, XBP1s likely acts upstream of CEBP and PPAR in 
the sequential transcriptional processes involved in adipogenesis.  
 
XBP1s has been shown to promote adiponectin multimerisation and improve 
glucose regulation in mice (Sha, et al., 2014). Furthermore, WAT XBP1s and 
plasma glucose were both reduced after bariatric surgery in humans (chapter 3). 
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This study provides novel evidence that XBP1s is necessary for insulin stimulated 
glucose uptake in a controlled human adipocyte cell culture system. Insulin 
stimulated glucose uptake on day 14 of adipogenesis was blocked in human 
adipocytes when treated with 48C for the final 24 and 96 hours of adipogenesis. 
To investigate the molecular mechanisms linking XBP1s and glucose uptake, key 
proteins and mRNA expressions were measured. GLUT4 mRNA expression was 
not affected by 24 hour XBP1s inhibition but was significantly reduced following 
96 hours of inhibition compared to control, although this was not reflected at the 
protein level. In control adipocytes, 30 minutes following insulin addition, p-Akt 
was highly expressed whereas it was almost completely blocked in 48C treated 
adipocytes irrespective of inhibitor treatment duration. This suggests that XBP1s 
is necessary for transmitting the acute action of insulin and therefore plays a key 
role in metabolism. Therefore this study provides a novel mechanism that links 
the UPR to metabolism and supports the hypothesis of UPR integration with 
metabolism (Lee and Ozcan, 2014). The findings using 48C to inhibit XBP1s 
were supported by XBP1 siRNA transfection. XBP1s siRNA transfection during 
early adipogenesis in human preadipocyte cell line ChubS7 significantly reduced 
day 14 insulin stimulated glucose uptake compared to non-targeting siRNA 
transfection. A summary of findings from this study and proposed roles of UPR 
signalling in adipocyte metabolism are shown in figure 5.3.1.  
 
 
 
 
192 
Figure 5.3.1 Proposed roles of unfolded protein response molecular signalling  
  in adipocyte metabolism 
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Figure 5.3.1 legend: Proposed roles of unfolded protein response molecular 
signalling in adipocyte metabolism. The results from this study indicate that the 
unfolded protein response (UPR) plays an integrated role in adipocyte 
metabolism. UPR may be directly activated by glycaemic status and it influences 
short-term glucose uptake via Akt phosphorylation and long-term adipogenesis 
via balancing inhibiting and activating adipogenic factors. (ER; endoplasmic 
reticulum, Bip; binding immunoglobulin protein – also known as GRP78; glucose 
regulated protein 78 kDa, PERK; protein kinase RNA-like endoplasmic reticulum 
kinase, p; phosphorylated, eIF2; eukaryotic translation initiation factor 2 A, 
ATF4; activating transcription factor 4, CHOP; C/EBP homologous protein, 
IRE1; inositol requiring enzyme 1 alpha, XBP1u; X-box binding protein 1 
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unspliced, XBP1s; X-box binding protein 1 spliced, GRPs; glucose regulated 
proteins, AKT; Akt, also known as protein kinase B (PKB), PPAR; peroxisome 
proliferator-activated receptor gamma, CEBP; CCAAT/enhancer-binding 
protein alpha, GLUT4; Glucose transporter type 4).  
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5.4 Conclusions 
In summary, this study has shown that XBP1s plays a vital role upstream of 
CEBP and PPAR in human adipogenesis and that it is necessary for mediating 
the action of insulin. These findings are the first of their kind in human adipocytes 
and support the mouse cell line work of Cho et al. that suggest XBP1s may 
regulate PPAR in adipogenesis (Cho, et al., 2014). XBP1s has been shown to 
promote adiponectin multimerisation and improve glucose regulation in mice 
(Sha, et al., 2014). Furthermore, WAT XBP1s and plasma glucose improved after 
bariatric surgery in humans (chapter 3). This study provides novel evidence that 
XBP1s is necessary for insulin stimulated glucose uptake in a controlled human 
adipocyte cell culture system. Taken together, these results support the link 
between UPR signalling and metabolism (Hotamisligil, 2010; Lee and Ozcan, 
2014). Although further research is required, these findings have provided useful 
insight into the role of XBP1s in adipogenesis and metabolism and will benefit the 
development of clinical interventions to alleviate metabolic diseases. 
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Chapter 6: Wnt10b in human 
adipogenesis 
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6.1 Introduction 
Adipogenesis is an important process to maintain WAT metabolic function. WAT 
can dynamically change in size during adult life to accommodate the energy 
requirements of the body (Poulos, et al., 2010). Obesity complications in humans 
such as T2DM can result from the inability of SAT to appropriately expand and 
store lipids (Virtue and Vidal-Puig, 2010). Impaired WAT expandability is mainly 
due to defects in adipogenesis (Isakson, et al., 2009). Further understanding of 
adipogenesis may present targets to improve metabolic regulation. The IRE1-
XBP1s UPR pathway is essential for adipogenesis in mouse cells (Sha, et al., 
2009) and in human cells (chapters 4 and 5). XBP1s plays an important role 
during early human adipogenesis and may regulate CEBP and PPAR (chapter 
5). It has been hypothesised that reciprocal repression might exist during 
adipogenesis between Wnt signalling and CEBP or PPAR because activation of 
these factors can lead to a substantial reduction in Wnt downstream signalling -
catenin levels (Moldes, et al., 2003). More recently it has been suggested that Wnt 
normally inhibits CEBP as a negative feedback loop to reduce adipogenesis 
(Christodoulides, et al., 2009). Cho et al. have shown in mouse 3T3-L1 cells that 
XBP1s enhances adipogenesis through the downregulation of Wnt10b (Cho, et 
al., 2013). Therefore there may be a link between XBP1s and Wnt10b in human 
adipogenesis, however it has not been studied.  
 
Wnt proteins comprise a family of highly conserved secreted proteins that exert 
autocrine and paracrine actions via binding to cell-surface receptors (Herr, et al., 
2012). Wnt ligands bind to the frizzled (FZD) and low-density-lipoprotein-related 
protein 5/6 (LRP5/6) coreceptor complex to activate the canonical Wnt signalling 
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pathway. The activated receptor complex disrupts or functionally inactivates a -
catenin destruction complex. The destruction complex consists of the scaffold 
protein Axin, adenomatous polyposis coli (APC), glycogen synthase kinase-3 
(GSK-3) and casein kinase-1 (CKI). When Wnt is not bound to its surface 
receptors, the destruction complex is active and regulates the phosphorylation, 
ubiquitination and subsequent degradation of -catenin. When Wnt is bound to its 
surface receptors, the destruction complex is inhibited, -catenin accumulates in 
the cytoplasm and translocates to the nucleus where is engages the TCF/LEF 
transcription factors to activate the Wnt transcriptional program (figure 1.5.3) (Li, 
et al., 2012). Several TCF/LEF targets are linked to cell differentiation. For 
example TCF7 has been shown to regulate a self-renewal/differentiation switch 
that operates in the absence of Wnt signalling (Wu, et al., 2012). Negative 
feedback regulation of the Wnt pathway is mediated through conductin, encoded 
by the AXIN2 gene and also known as axin2 (Bernkopf, et al., 2015). Wnt10b has 
been extensively studied in an adipogenesis context (Rosen and MacDougald, 
2006). Wnt10b has been shown to impair WAT and BAT formation in vivo when 
overexpressed specifically in mouse adipocytes (Longo, et al., 2004). 
Furthermore, increasing Wnt10b levels in WAT leads to decreased susceptibility 
to obesity in both diet-induced (Longo, et al., 2004) and genetic mouse models 
(Wright, et al., 2007). Wnt10b also seems to play a key inhibitory role in human 
adipogenesis. Naturally occurring mutations in the WNT10B gene such as C256Y 
are associated with early-onset obesity (Christodoulides, et al., 2006). 
Furthermore, Wnt10b has been shown to impair human preadipocyte 
differentiation (Isakson, et al., 2009) and abnormal expression of genes involved 
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in Wnt signalling have been recorded in the adipose tissue of PCOS patients 
(Chazenbalk, et al., 2012).  
 
Characterisation of adipogenesis regulatory processes have benefited from the 
discovery of key pathways and transcription factors that contribute to the 
adipogenic process, as reviewed by Lefterova and Lazar (Lefterova and Lazar, 
2009). The transcription factors PPAR and CEBPs are the crucial determinants 
of adipocyte fate. There are several inhibitors of adipogenesis including CHOP, 
upregulated in ER stress (Hou, et al., 2013), and certain TCF/LEF proteins, 
activated by Wnt signalling (Farmer, 2006). Therefore a network of transcription 
factors and cell-cycle regulators, in concert with transcriptional coactivators and 
corepressors, respond to extracellular stimuli to activate or repress adipogenesis. 
Understanding how Wnt10b and XBP1s fit together in the complex system of 
adipogenesis regulation may provide pharmacological targets and therefore have 
clinical benefit. 
 
Therefore the aim of this study was to investigate the role of Wnt10b in human 
adipogenesis and whether it is linked to XBP1s. In order to investigate the role of 
Wnt10b in human adipogenesis, anthropometry and a SAT biopsy were collected 
from a female subject with a naturally occurring WNT10B C256Y mutation 
rendering a non-functional Wnt10b protein, characterised by Christodoulides et 
al. (Christodoulides, et al., 2006). Preadipocytes were extracted from the 
WNT10B C256Y SAT biopsy, cultured and adipogenesis induced and compared 
with preadipocytes derived from SAT of lean metabolically healthy subjects. 
Adipogenesis and adipocyte function were assessed by lipid accumulation, 
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lipolysis and glucose uptake. Expression of key adipogenic, ER stress and Wnt 
signalling proteins and mRNAs were measured during adipogenesis. 
 
6.2 Results 
6.2.1 Body composition and metabolic profile of a WNT10B C256Y subject 
The systemic effects of non-functional Wnt10b on body composition and 
metabolic profile were studied. Anthropometric measurements were collected for 
a subject with a WNT10B C256Y mutation (table 6.2.1). The female subject was 
19 years old and had a BMI of 62 kg/m2. Her body weight (143.2 kg) and fat mass 
(59.8 % body weight) were greater than any of the obese T2DM subjects 
described in chapter 3 (table 3.2.1). However, unlike the subjects who underwent 
bariatric surgery, the WNT10B C256Y subject was not diabetic and had normal 
glucose control. Her HbA1c (40 mmol/mol) and fasting plasma glucose (4.2 
mmol/L) were in the reference range for subjects with controlled blood glucose 
concentrations. She had a more favorable lipid profile than the obese T2DM 
subjects prior to their bariatric surgery. Her total cholesterol (4.5 mmol/L), LDL 
(2.5 mmol/L) and TAG (1.2 mmol/L) were lower, and her HDL (1.3 mmol/L) was 
higher than the obese T2DM subjects prior to bariatric surgery. 
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Table 6.2.1 Body composition and metabolic profile of a WNT10B C256Y  
  subject 
Gender Female 
Age (Years) 19 
Body Weight (kg) 143.2 
BMI (kg/m2) 62 
Fat Mass (kg) 57.6 
Fat Free Mass (kg) 85.6 
Fat Mass (% Body Weight) 59.8 
Fat Free Mass (% Body Weight) 40.2 
HbA1c (mmol/mol) 40 
Plasma Glucose (mmol/L)  4.2 
Total Cholesterol (mmol/L) 4.5 
LDL Cholesterol (mmol/L) 2.5 
HDL Cholesterol (mmol/L) 1.3 
Triglyceride (TAG) (mmol/L) 1.2 
HDL/LDL (ratio) 0.52 
 
Table 6.2.1 legend: Body composition and metabolic profile of a WNT10B 
C256Y subject. Anthropometric measurements were taken for a WNT10B C256Y 
subject. 
 
6.2.2 Functional Wnt10b was not required for adipogenesis 
To assess the role of Wnt during adipogenesis, adipogenesis was induced in Abd 
SAT WNT10B C256Y and lean and obese preadipocytes for 14 days. Lipid 
accumulation and lipolysis were measured during adipogenesis and basal and 
insulin stimulated glucose uptake were measured on day 14 (figure 6.2.2 A – D). 
During adipogenesis the WNT10B C256Y adipocytes accumulated more lipid 
than lean or obese SAT adipocytes. They underwent the same level of lipolysis as 
lean while the obese control Abd SAT adipocytes underwent significantly higher 
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lipolysis than lean. On day 14 after induction of adipogenesis, the adipocytes had 
significantly higher (P<0.01) insulin stimulated glucose uptake compared to basal.  
 
Figure  6.2.2  Functional Wnt10b was not required for adipogenesis 
A             Lipid accumulation during WNT10B C256Y adipogenesis 
 
Day       20x   20x                        40x   40x 
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Figure  6.2.2 legend: Functional Wnt10b was not required for adipogenesis. 
Adipogenesis was induced in Abd SAT WNT10B C256Y and lean and obese 
control preadipocytes for 14 days. Lipid accumulation (A - B), and lipolysis were 
measured every 48 hours (C), and basal and insulin stimulated glucose uptake 
were measured on day 14 (D). Data is expressed as mean ± SE. Significantly 
different values are indicated as follows: * P<0.05, ** P<0.01, *** P<0.001. 
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6.2.3 XBP1s mRNA expression was reduced during adipogenesis in SAT 
WNT10B C256Y adipocytes compared to lean 
To assess UPR in non-functional Wnt adipogenesis, adipogenesis was induced in 
SAT lean (control) and SAT WNT10B C256Y adipocytes for 14 days and key 
UPR gene expressions were measured (figure 6.2.3 A – D). XBP1s mRNA 
decreased on day 2 after induction of adipogenesis in control and WNT10B 
C256Y adipocytes. After day 2 XBP1s expression increased in the control cells to 
1.5 fold higher than day 0 on day 14. XBP1s mRNA also increased after day 2 in 
the WNT10B C256Y adipocytes, however it was significantly lower (P<0.05 – 
P<0.01) than control cells for the remaining days of adipogenesis and on day 14 it 
was less than half compared to day 0. XBP1u expression was similar to XBP1s 
and at every time point after day 0 the WNT10B C256Y subject had lower 
XBP1u expression compared to control, although this only reached significance 
(P<0.05) on day 6. IRE1 and CHOP expression decreased after day 0 and 
remained below the day 0 level for the duration of adipogenesis in both control 
and WNT10B C256Y adipocytes. At almost every time point for IRE1 and 
CHOP, WNT10B C256Y adipocytes had lower expression levels compared to 
control, although they only reached significance (P<0.05) for IRE1 on day 6.  
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Figure 6.2.3 XBP1s mRNA expression was reduced during adipogenesis in 
WNT10B C256Y adipocytes compared to lean 
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Figure  6.2.3 legend: XBP1s mRNA expression was reduced during adipogenesis 
in WNT10B C256Y adipocytes compared to lean. Adipogenesis was induced in 
lean (control) and WNT10B C256Y adipocytes for 14 days. mRNA expression 
was measured during adipogenesis for XBP1s (A), XBP1u (B), IRE1 (C) and 
CHOP (D). Data is expressed as mean ± SE. Significantly different values are 
indicated as follows: * P<0.05, ** P<0.01. 
 
6.2.4 Adipogenesis regulator CEBPα gene expression was altered during 
adipogenesis in SAT WNT10B C256Y adipocytes compared to lean 
To assess adipogenesis regulation and adipocyte gene expression in non-
functional Wnt adipogenesis, adipogenesis was induced in SAT lean (control) and 
SAT WNT10B C256Y adipocytes for 14 days and adipogenesis regulator and 
adipocyte gene expressions were measured (figure 6.2.4 A – C). In WNT10B 
C256Y adipocytes, CEBP expression increased gradually throughout 
adipogenesis unlike control adipocytes where CEBP expression peaked on day 6 
– 10 of adipogenesis (figure 5.2.7 A – C). PPAR expression increased during 
adipogenesis in both control and WNT10B C256Y adipogenesis. However the 
WNT10B C256Y adipocytes had lower PPAR expression at every time point 
during adipogenesis, although this only reached significance (P<0.05) on day 6. 
Adiponectin was not detected on day 0 in the WNT10B C256Y or control 
adipocytes. After day 2 the adiponectin expression profile in WNT10B C256Y 
adipocytes was significantly lower than the median control adipocytes. 
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Figure 6.2.4 Adipogenesis regulator CEBP gene expression continued to 
increase during adipogenesis in WNT10B C256Y adipocytes 
unlike lean 
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Figure  6.2.4 legend: Adipogenesis regulator CEBPα gene expression continued to 
increase during adipogenesis in WNT10B C256Y adipocytes unlike lean. 
Adipogenesis was induced in lean (control) and WNT10B C256Y adipocytes for 
14 days. mRNA expression was measured during adipogenesis for CEBP (A), 
PPAR (B), adiponectin (C). Data is expressed as mean ± SE. Significantly 
different values are indicated as follows: * P<0.05, ** P<0.01, *** P<0.001. 
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6.2.5 Wnt signalling was altered during adipogenesis in SAT WNT10B 
C256Y adipocytes compared to lean 
To assess Wnt signalling in adipogenesis, adipogenesis was induced in lean 
(control) and WNT10B C256Y adipocytes for 14 days. During adipogenesis 
expression of phosphorylated -catenin and unphosphorylated -catenin and 
mRNA expression of WNT10B, TCF7, and AXIN2 were measured (figure 6.2.5 
A – D). In control adipocytes p--catenin expression relative to -catenin 
increased by 10 % during adipogenesis and peaked on day 10. However in 
WNT10B C256Y adipocytes p--catenin expression relative to -catenin 
increased by 50 % and peaked on day 4. The p--catenin expression relative to -
catenin was significantly higher (P<0.05) in WNT10B C256Y adipocytes on day 
4 and day 6 compared to control. In control cells WNT10B and TCF7 mRNA 
expression decreased on day 2 after induction of adipogenesis and continued to 
decrease through adipogenesis. In WNT10B C256Y adipocytes WNT10B mRNA 
expression remained the same as day 0 on day 2, significantly higher (P<0.05) 
than control, before decreasing to within no significant difference from control 
adipocytes. In WNT10B C256Y adipocytes, TCF7 mRNA expression was 
significantly lower (P<0.05) than control on days 2 – 6. In control adipocytes 
AXIN2 mRNA expression increased after induction of adipogenesis and remained 
3 fold higher than day 0 for the duration of adipogenesis. In contrast, the 
expression of AXIN2 in the WNT10B C256Y adipocytes remained at the same 
level as day 0 until increasing on day 14. At every time point during adipogenesis 
the WNT10B C256Y adipocytes had significantly lower (P<0.05 – P<0.01) 
AXIN2 expression compared to the control adipocytes. 
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Figure 6.2.5 Wnt signalling protein and gene expression significantly differed 
during adipogenesis in WNT10B C256Y adipocytes compared to 
lean 
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Figure  6.2.5: Wnt signalling protein and gene expression significantly differed 
during adipogenesis in WNT10B C256Y adipocytes compared to lean. 
Adipogenesis was induced in lean (control) and WNT10B C256Y adipocytes for 
14 days. During adipogenesis protein expression of phosphorylated -catenin and 
unphosphorylated -catenin (A), and mRNA expression of WNT10B (B), TCF7 
(C), and AXIN2 (D) were measured. Data is expressed as mean ± SE. 
Significantly different values are indicated as follows: * P<0.05, ** P<0.01. 
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6.3 Discussion 
This study was designed to investigate the role of Wnt10b in human adipogenesis 
and whether it is linked to XBP1s. Preadipocytes were extracted from abdominal 
SAT of a naturally occurring genetically defective WNT10B subject and from 
lean metabolically healthy subjects (control). These were then cultured and 
adipogenesis induced. Adipogenic capacity, adipocyte function and key 
adipogenic, Wnt signalling and ER stress gene and protein expressions were 
compared. Adipogenesis is an important process to maintain WAT metabolic 
function. Studies have implicated Wnt10b as a key inhibitor in human 
adipogenesis (Christodoulides, et al., 2006), (Isakson, et al., 2009), (Chazenbalk, 
et al., 2012) and recently Cho et al. have shown in mouse 3T3-L1 cells that 
XBP1s enhances adipogenesis through the downregulation of Wnt10b (Cho, et 
al., 2013). This study showed that functional Wnt10b was not required for 
adipogenesis, XBP1s expression was significantly lower and Wnt cellular 
signalling was altered in non-functional Wnt10b adipogenesis compared to 
control.  
 
Christodoulides et al. reported that non-functional Wnt10b is associated with 
early-onset obesity (Christodoulides, et al., 2006). This study supports their 
findings. Interestingly, despite the subject’s substantial obesity, they had and a 
healthy metabolic profile (table 6.2.1) and therefore were considered 
metabolically healthy but obese (MHO) (Seo and Rhee, 2014). The female subject 
was 19 years old and had a BMI of 62 kg/m2. She had normal glycaemic control, 
measured both by HbA1c (40 mmol/mol) and fasting plasma glucose (4.2 
mmol/L). She had a more favourable lipid profile than the subjects investigated in 
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chapter 3 (table 3.2.1). Her total cholesterol (4.5 mmol/L), LDL (2.5 mmol/L) and 
TAG (1.2 mmol/L) were lower, and her HDL (1.3 mmol/L) was higher than the 
obese T2DM subjects prior to bariatric surgery. Collectively these results suggest 
that the expanded WAT in the WNT10B C256Y subject is regulated and 
metabolically healthy. The expanded WAT may protect the subject from 
metabolic dysfunction in a similar way to ob/ob mice, when forced WAT 
expansion normalized glucose and insulin levels and prevented insulin resistance 
despite massive obesity (Kim, et al., 2007). The defective Wnt10b protein was 
thought to play a role in the vast WAT expansion because of its reported 
inhibitory role in human adipogenesis (Isakson, et al., 2009). Therefore a SAT 
biopsy was collected from the subject, preadipocytes were extracted and 
adipogenesis was studied in more detail. 
 
During adipogenesis WNT10B C256Y preadipocytes accumulated lipid, 
increased lipolysis and adipocytes had significantly higher insulin stimulated 
glucose uptake compared to basal. Therefore the cells successfully underwent 
adipogenesis, functional Wnt10b was not required for adipogenesis and non-
functional Wnt10b adipocytes were sensitive to insulin. During adipogenesis the 
SAT derived defective Wnt10b preadipocytes accumulated more lipids and 
underwent less lipolysis than preadipocytes derived from obese SAT and more 
closely resembled preadipocytes derived from lean SAT studied in chapter 4 
(figure 4.2.1 D - E). Taken together, these results suggest that the Wnt10b 
defective adipocytes can accumulate and retain lipids better than functional 
Wnt10b obese adipocytes. This may in part explain why the WNT10B C256Y 
subject had a healthy lipid profile. The favorable lipid regulation in the adipocytes 
216 
of the defective Wnt10b MHO subject exemplifies the findings of Karpe et al. 
who convincingly discredited the hypothesis that adiposity correlates with plasma 
NEFA (Karpe, et al., 2011). Furthermore, these results suggest that plasma NEFA 
may correlate with adipocyte and WAT metabolic function, irrespective of 
adiposity. The defective Wnt10b adipocytes significantly increased insulin 
stimulated glucose uptake compared to basal, and therefore were sensitive to 
insulin. This suggests the defective Wnt10b adipocytes are able to respond to the 
anabolic hormone insulin and may explain why the subject had a healthy 
carbohydrate profile. Taken together, these findings indicate that the WNT10B 
C256Y subject has metabolically regulated and functional adipocytes and may 
explain their MHO phenotype.  
 
This investigation showed that WNT10B C256Y adipocytes had significantly 
lower XBP1s expression during adipogenesis compared to control. This 
downregulation of XBP1s may have been due to less XBP1u substrate and also 
less IRE1 since both their expressions were lower in Wnt10b defective cells 
compared to control, although this only reached significance on day 6. This 
suggests that the Wnt10b defective cells may have had less ER stress during 
adipogenesis and subsequently less IRE1 and XBP1s expression. However, there 
was no difference in CHOP expression between the Wnt10b defective and control 
adipocytes, thus the level of ER stress and subsequent UPR activation may not 
have been different. Nonetheless, the diversity of ER stress induced UPR 
signalling likely generates suitable outcomes that are specific to the stress 
imposed and the homeostatic needs of the cell (Kim, et al., 2008). Therefore it is 
possible that the IRE1 - XBP1s and PERK - eIF2 - ATF4 - CHOP UPR 
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pathways are differentially activated during adipogenesis and the reported 
inhibitory role of CHOP on adipogenesis (Hou, et al., 2013) may act 
independently of the IRE1 - XBP1s UPR pathway. Cho et al. have shown in 
mouse 3T3-L1 cells that XBP1s enhances adipogenesis through the 
downregulation of Wnt10b, and that XBP1s and Wnt10b have a reciprocal mRNA 
expression profile during adipogenesis (Cho, et al., 2013). This study disagrees 
with their findings because both WNT10B and XBP1s mRNA expression 
decreased initially after induction of adipogenesis, suggesting an alternative 
upstream factor inhibits their expression. In order to investigate this further, Wnt 
signalling was studied. 
 
Wnt signalling during adipogenesis in WNT10B C256Y cells was significantly 
altered compared to control cells and supports the findings that Wnt10b plays an 
inhibitory role in human adipogenesis (Christodoulides, et al., 2006), (Isakson, et 
al., 2009), (Chazenbalk, et al., 2012). WNT10B mRNA expression was measured 
to assess its upstream activation during adipogenesis. The expression of WNT10B 
mRNA in control cells decreased by day 2 of adipogenesis and stayed low for the 
duration of adipogenesis, however the Wnt10b defective cells remained the same 
as day 0 until day 2 before decreasing. This suggests that Wnt10b is suppressed 
upon activation of adipogenesis and the Wnt10b defective cells may have 
experienced a lack of inhibition during immediate early differentiation. Li et al. 
proposed that Wnt proteins mediate their action via unphosphorylated -catenin 
when p--catenin has saturated the destruction complex (Li, et al., 2012). This 
study found no differences in unphosphorylated -catenin expression during 
adipogenesis between defective Wnt10b and control cells, however 
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phosphorylated -catenin (p--catenin) levels were significantly higher in Wnt10b 
defective cells on day 4 and 6 compared to control cells. In order to assess the 
activity of Wnt signalling, the expression of downstream target genes TCF7 and 
AXIN2 were measured. TCF7 expression decreased after induction of 
adipogenesis in both defective Wnt10b and control cells and supports the finding 
that TCF7 regulates a self-renewal/differentiation switch that operates in the 
absence of Wnt signalling (Wu, et al., 2012). Negative feedback regulation of the 
Wnt pathway is mediated through Axin2, encoded by the AXIN2 gene (Bernkopf, 
et al., 2015). Control cells increased the expression of AXIN2 from day 2 for the 
duration of adipogenesis, whereas the expression in defective Wnt10b cells 
remained the same as day 0 until day 14 and was significantly lower than control 
cells for the duration of adipogenesis. Therefore, collectively, these results show 
that Wnt signalling is significantly altered in defective Wnt10b adipocytes 
compared to control and may be due to dysregulated negative feedback 
mechanisms.  
 
The findings in control cells in this study support the hypotheses that reciprocal 
repression might exist during adipogenesis between Wnt signalling and CEBP or 
PPAR (Moldes, et al., 2003) and that Wnt normally inhibits CEBP as a 
negative feedback loop to reduce adipogenesis (Christodoulides, et al., 2009). 
Wnt10b defective cells expressed slightly lower levels of PPAR during 
adipogenesis compared to control cells, although this only reached significance on 
day 6 and the pattern of expression was largely the same. The expression pattern 
of adipocyte marker adiponectin in Wnt10b defective cells largely matched that of 
control cells, peaking before day 14 of adipogenesis, showing that they 
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successfully underwent adipogenesis. Furthermore, this suggests that the WAT 
expansion in the WNT10B C256Y subject developed independently of 
upregulated adiponectin, unlike the forced expansion of WAT in ob/ob mouse 
investigation (Kim, et al., 2007). This study found that the expression of CEBP 
in Wnt10b defective cells continued to increase throughout adipogenesis whereas 
in control cells it peaked on day 6 – 10 (figure 5.2.7). This suggests that CEBP is 
inhibited late in regulated adipogenesis control cells and that WNT10B C256Y 
cells lack the ability to inhibit CEBP. Thus, given CEBP acts as a key 
adipogenic factor (Lefterova and Lazar, 2009), continued upregulation of CEBP 
in the Wnt10b defective subject may have induced considerable adipogenesis and 
may partly explain their substantial WAT mass. Therefore collectively these data 
suggest that upon activation of adipogenesis in adipocytes from metabolically 
healthy lean subjects, Wnt signalling changes from active Wnt on to inactive Wnt 
off, summarised in figure 6.3.1.  
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Figure 6.3.1  Proposed changes in Wnt signalling during adipogenesis 
APC
Wnt offWnt on
Wnt
Wnt target genesWnt target genes
LRPLRP FrizzledFrizzled
TCFTCF Grouchoβ-catenin
β-catenin
p
p
p
β-catenin
p Ub
Ub
Ub
Degradation
p
p
Dvl Axin
CK1
β-TrCP
GSK3
APC
β-catenin
p
p
p p
Dvl Axin
CK1
β-TrCP
GSK3
Cell differentiationCell differentiation
NucleusNucleus
CytoplasmCytoplasm
Adipogenesis
CEBPα, PPARγ, adiponectin
WNT10B, TCF7
AXIN2
CEBPα, PPARγ, adiponectin
WNT10B, TCF7
AXIN2
 
Figure 6.3.1 legend: Proposed changes in Wnt signalling during adipogenesis. 
The results from this study indicate that upon activation of adipogenesis Wnt 
signalling changes from Wnt on to Wnt off. (Wnt; Wingless-type mouse 
mammary tumour virus integration site family protein, LRP; low-density-
lipoprotein-related protein, Dvl; dishevelled, APC; adenomatous polyposis coli, 
GSK-3; glycogen synthase kinase-3, CKI; casein kinase-1, -TrCP; beta-
transducin repeat containing E3 ubiquitin protein ligase, p; phosphorylated, Ub; 
ubiquitin, TCF; T-cell factor, WNT10B; Wingless-type mouse mammary tumour 
virus integration site family protein 10b, TCF; T-cell factor 7, CEBP; 
CCAAT/enhancer binding protein alpha, PPAR; peroxisome proliferator-
activated receptor gamma, AXIN2; axis inhibitory protein 2.) 
 
221 
6.4 Conclusions 
In summary, the results of this study suggest that Wnt10b plays an inhibitory role 
in human adipogenesis and acts independently of XBP1s. A subject with a 
naturally occurring WNT10B C256Y mutation rendering a non-functional 
Wnt10b protein was severely obese and had a metabolically healthy phonotype. 
This study found a reciprocal expression profile between WNT10B and CEBP 
or PPAR in preadipocytes derived from healthy lean subjects during 
adipogenesis and supports the hypotheses that reciprocal repression might exist 
during adipogenesis between Wnt signalling and CEBP or PPAR (Moldes, et 
al., 2003) and that Wnt normally inhibits CEBP as a negative feedback loop to 
reduce adipogenesis (Christodoulides, et al., 2009). This study disagrees with the 
murine findings of Cho et al. that XBP1s downregulates Wnt10b (Cho, et al., 
2013) because both WNT10B and XBP1s mRNA expression decreased initially 
after induction of adipogenesis. Taken together, the results in this study suggest 
that non-functional Wnt10b leads to dysregulated Wnt signalling, upregulation of 
CEBP and subsequent enhanced adipogenesis and expanded metabolically 
healthy WAT. These findings provide a molecular mechanistic hypothesis to 
partially explain the MHO phenotype. However, further research is required to 
fully elucidate the roles of Wnt10b and XBP1s in human adipogenesis. 
Nonetheless, these studies have identified Wnt10b as an exciting potential 
pharmacological target to improve metabolic health and reduce the burden of 
insulin resistance and T2DM. 
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7.1 Overall discussion 
This thesis researched the role of ER stress and consequent UPR activation in 
human WAT regulation in metabolic health and T2DM. Current evidence about 
WAT regulation and UPR activation was reviewed to identify areas where further 
research had the potential to benefit T2DM clinical outcomes. Translational 
experimental methodologies from humans to the laboratory were adopted in order 
to generate valid and representative information about human WAT regulation. 
SAT from T2DM subjects before and after bariatric surgery, paired SAT and 
VAT from lean and obese non-diabetic subjects and SAT from a naturally 
occurring non-functional Wnt10b subject were utilised alongside a human 
adipocyte cell line to investigate the molecular mechanisms governing WAT 
regulation. Standardised cell culture and analytical laboratory techniques were 
employed to systematically research the role of UPR activation in human WAT 
regulation in metabolic health and T2DM. Several novel outcomes from this body 
of research provide mechanistic insight into the regulation of human WAT and 
have identified potential therapeutic targets to improve metabolic health.  
 
Current evidence about the role of WAT in metabolic regulation and T2DM was 
studied. The main outcomes of the literature review found the following: the 
chronic metabolic disease T2DM presents a huge burden on individuals and 
global society through medical, social and financial implications. Obesity, 
characterised by WAT expansion, is the most significant risk factor for 
developing T2DM. WAT is a multifunctional organ that plays a key role in 
metabolic health and regulating energy homeostasis. An inability of WAT to 
expand to accommodate excess nutrients is predominantly due to impaired 
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adipogenesis and results in ectopic fat deposition, lipotoxicity and insulin 
resistance. Adipogenesis is influenced by several extracellular and intercellular 
factors. Obesity associated physiological characteristics such as hyperglycaemia, 
endotoxemia, elevated circulating FFAs, and local hypoxia induce adipocyte ER 
stress. This occurs via several mechanisms including increased demand on the ER 
for protein synthesis and processing, lipid droplet formation and lipid partitioning, 
and elevated ROS production. ER stress is a key factor in the initiation of insulin 
resistance through inhibiting insulin action and inducing WAT inflammation and 
may interfere with adipogenesis. Interventions that alleviate ER stress may be 
suitable first-line treatments to restore ER function and metabolic regulation in 
metabolic diseases such as T2DM.  
 
The most durably effective treatment for T2DM has emerged as bariatric surgery, 
however the mechanisms governing the improvement in glucose homeostasis 
have not been fully elucidated (Nguyen and Korner, 2014). Some bariatric 
procedures improve glycaemic control in people with T2DM beyond that 
expected for weight loss alone (Dixon, et al., 2012). Since WAT plays a vital role 
in metabolic health, it was hypothesised that the improvements in glycaemic 
regulation after bariatric surgery may be due to alleviated ER stress in WAT and 
improved regulation and function. The study in chapter 3 demonstrated that both 
restrictive and malabsorptive bariatric interventions are effective weight loss 
interventions for obese T2DM patients resulting in significantly improved glucose 
and insulin levels six months after surgery. While malabsorptive bariatric surgery 
involves more complicated procedures and requires long-term vitamin and other 
supplementation, the restrictive bariatric procedures are less complicated and 
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induce almost equal benefits. In this study WAT health was better following the 
two restrictive procedures (LAGB and LGCP) compared to BPD as shown by 
higher reduction of ER stress markers as well as improved regulation of CHOP. 
The data from Bradley et al. (Bradley, et al., 2012) obtained from non-diabetic 
obese patients did not specifically support malabsorptive (RYGB) over restrictive 
surgery type (LAGB) and suggested that further studies were required which 
could apply to obese patients with T2DM. This study offers novel data in that 
direction indicating that while the clinical outcomes regarding parameters such as 
% EBL and HbA1c were better following BPD, the adipose tissue health was 
significantly improved following the restrictive procedures. The clinical 
implications of these findings in the longer term require further investigations. 
Overall, all the surgery types investigated significantly improved the metabolic 
health of obese diabetics included in this study irrespective of surgery type. 
 
WAT health and subsequent metabolic regulation was improved in obese T2DM 
subjects who lost weight almost exclusively through WAT mass reduction 
following bariatric surgery. Therefore mechanisms governing WAT regulation 
were considered vital for metabolic health. Evidence suggests obesity 
complications in humans such as T2DM result from the inability of SAT to 
appropriately expand and store lipids, and consequently ectopic fat deposition and 
lipotoxicity contribute to insulin resistance (Hill, et al., 2009; Virtue and Vidal-
Puig, 2010). Impaired WAT expandability is mainly due to defects in 
adipogenesis (Isakson, et al., 2009). Adipogenesis is an important process within 
WAT to allow normal turnover of adipocytes (Spalding, et al., 2008) and facilitate 
appropriate WAT expansion to respond to the energy needs of the body (Wang, et 
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al., 2013), therefore adipogenesis in primary human preadipocytes was studied. 
The studies in chapter 4 showed that adipogenesis in primary human 
preadipocytes is influenced by both adiposity and WAT depot of preadipocyte 
source and that the IRE1 - XBP1s UPR pathway plays an integral role in human 
adipogenesis. This investigation indicated that during adipogenesis obese derived 
preadipocytes accumulated more lipid than lean irrespective of WAT depot, 
however lipolysis and insulin sensitivity were both influenced by adiposity and 
WAT depot. Collectively these findings support human investigations that suggest 
abdominal SAT is protective for insulin resistance whereas VAT mass has the 
opposite effect (McLaughlin, et al., 2011). The expressions of IRE1 and XBP1s 
during adipogenesis differed between depots and may in part explain the observed 
functional differences in adipocytes. ER stress prevented adipogenesis 
irrespective of preadipocyte origin and may in part explain why WAT ER stress is 
associated with metabolic dysfunction (Hotamisligil, 2010). The novel finding 
that XBP1s is a prerequisite for human adipogenesis strengthens the link between 
UPR and adipogenesis, although further investigation is required to elucidate the 
role of XBP1s in human adipogenesis. These findings provide insight into 
adipocyte functional differences and their integration with the UPR and therefore 
this information will benefit development of translational clinical interventions to 
improve metabolic health. 
 
Adipogenesis in preadipocytes derived from SAT was investigated further 
because SAT represents the vast majority of WAT (about 85 % of all body fat 
(Frayn and Karpe, 2014)) and the inability of SAT to expand has been causally 
related to obesity complications such as T2DM (Virtue and Vidal-Puig, 2010). 
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Chapter 4 indicated that XBP1s is essential for adipogenesis, therefore the role of 
XBP1s in adipogenesis was investigated further. The studies in chapter 5 showed 
that XBP1s plays a vital role upstream of CEBP and PPAR in human 
adipogenesis and that it is necessary for mediating the action of insulin. These 
findings are the first of their kind in human adipocytes and support the mouse cell 
line work of Cho et al. that suggest XBP1s may regulate PPAR in adipogenesis 
(Cho, et al., 2014). XBP1s has been shown to promote adiponectin 
multimerisation and improve glucose regulation in mice (Sha, et al., 2014). 
Furthermore, WAT XBP1s and plasma glucose reduced after bariatric surgery in 
humans (chapter 3). This study provides novel evidence that XBP1s is necessary 
for insulin stimulated glucose uptake in controlled human adipocyte cell culture 
system. Taken together, these results support the link between UPR signalling and 
metabolism (Hotamisligil, 2010; Lee and Ozcan, 2014). Although further research 
is required, these findings have provided useful insight into the role of XBP1s in 
adipogenesis and metabolism and will benefit the development of clinical 
interventions to alleviate metabolic diseases. 
 
A link between XBP1s and Wnt10b in human adipogenesis was considered 
because Cho et al. have reported in mouse 3T3-L1 cells that XBP1s enhances 
adipogenesis through the downregulation of Wnt10b (Cho, et al., 2013). 
Therefore the role of Wnt10b in primary human adipogenesis was investigated in 
chapter 6. The results from this study suggest that Wnt10b plays an inhibitory role 
in human adipogenesis and acts independently of XBP1s. A subject with a 
naturally occurring WNT10B C256Y mutation rendering a non-functional 
Wnt10b protein was severely obese and had a metabolically healthy phonotype. 
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This study found a reciprocal expression profile between WNT10B and CEBP 
or PPAR in preadipocytes derived from healthy lean subjects during 
adipogenesis. The study supports the hypotheses that reciprocal repression might 
exist during adipogenesis between Wnt signalling and CEBP or PPAR 
(Moldes, et al., 2003) and that Wnt normally inhibits CEBP as a negative 
feedback loop to reduce adipogenesis (Christodoulides, et al., 2009). This study 
disagrees with the murine findings of Cho et al. that XBP1s downregulates 
Wnt10b (Cho, et al., 2013) because both WNT10B and XBP1s mRNA expression 
decreased initially after induction of adipogenesis. Taken together, the results in 
this study suggest that non-functional Wnt10b leads to dysregulated Wnt 
signalling, upregulation of CEBP and subsequent enhanced adipogenesis and 
expanded metabolically healthy WAT. These findings provide a molecular 
mechanistic hypothesis to partially explain the MHO phenotype. Given the 
expanded WAT in non-functional WNT10B C256Y subject, Wnt10b may 
influence appetite. Furthermore, given the subjects favourable metabolic profile 
considering their BMI of 62 kg/m2, having non-functional Wnt10b may protect 
against T2DM. Although the subject was only 19 years old and therefore unlikely 
to have developed T2DM at such a young age, irrespective of severe obesity. 
Follow up studies of the WNT10B C256Y subject would be beneficial to 
ascertain whether T2DM develops. Further research is also required to fully 
elucidate the roles of Wnt10b and XBP1s in human adipogenesis. Nonetheless, 
these studies have identified Wnt10b as an exciting potential pharmacological 
target to improve metabolic health and reduce the burden of insulin resistance and 
T2DM.  
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7.2 Future work 
This body of work has generated novel data about the role of ER stress in human 
adipose tissue metabolism. The results from this thesis suggest that WAT function 
is crucial for metabolic regulation and adipocyte ER stress signalling may play an 
integrative role between metabolic function and systemic homeostasis. If these 
results are corroborated in future investigations then specific pharmaceutical 
agents to ameliorate ER stress and improve metabolic function may provide 
substantial tangible clinical benefits. Therefore the findings in this thesis warrant 
further investigations.  
 
The subjects who underwent bariatric surgery improved their metabolic profile 
and their WAT ER stress levels and regulation six months after surgery (chapter 
3). Although the subjects appeared to have an improved metabolic profile six 
months after surgery, their metabolic status is likely to fluctuate with time. During 
the initial six months after surgery the subjects experienced a negative energy flux 
where more calories were used compared to being consumed. Consequently the 
subjects lost weight almost exclusively from a reduction in WAT mass. Their rate 
of weight loss is unsustainable, they cannot continue to lose weight indefinitely. 
Therefore there must be a certain point when their body weight stabilises. This 
will be partly influenced by their surgery type since their altered physiology will 
govern the rate at which calories from ingested food can be absorbed and stored or 
utilised. In addition, there are likely to be considerable WAT reorganisation 
events such as altered innervation, vasculature and cell composition. Since WAT 
plays a key integrative role in regulating metabolism (figure 1.4.3) it is likely that 
the altered WAT architecture will influence the subject’s long-term metabolism. 
230 
For example, the reciprocal hormonal brain – WAT axis controlling appetite may 
be altered, leading to changes in calorie consumption. Or the immune cell 
repertoire may change thus altering the local cytokine production and 
consequently influencing the inflammatory status of the WAT. Furthermore, the 
regulation of adipogenesis may be altered following the changes in WAT 
physiology. Therefore to investigate the long-term metabolic changes following 
LAGB, LGCP and BPD bariatric surgery procedures further studies will be 
required. Annual anthropometric measurements and Abd SAT biopsies from the 
subjects will allow long-term follow up and assessment of metabolic profile, ER 
stress levels and WAT regulation. Preadipocytes can be extracted from the 
biopsies and adipogenesis experiments conducted to investigate the change in 
adipogenesis regulation over time. Furthermore, the long-term follow up may 
indicate which procedure is most favourable for WAT health and therefore 
influence clinical decision making when considering a patient for bariatric 
surgery. 
 
The IRE1α – XBP1s pathway was found to play an essential role in adipogenesis 
and insulin stimulated glucose uptake (chapters 4 and 5). Perhaps the reason why 
the UPR pathway is essential for adipogenesis is because it is essential to mediate 
the effects of insulin signalling. This study found that insulin stimulated glucose 
uptake and Akt phosphorylation were almost completely blocked in the presence 
of IRE1α endonuclease inhibitor 4µ8C compared to control (figure 5.2.6). It is 
possible that 4µ8C has off-target effects and simultaneously blocks IRE1α 
endonuclease and insulin signalling upstream of Akt. However XBP1 knockdown 
with XBP1 siRNA also prevented insulin stimulated glucose uptake compared to 
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non-targeting siRNA (figure 5.2.7). Therefore suggesting that XBP1s does indeed 
play a key role in insulin stimulated glucose uptake. Further studies to pinpoint 
the role of XBP1s in insulin stimulated glucose uptake are required. For example, 
assessing IRS1 phosphorylation upstream of Akt following insulin stimulation in 
control adipocytes and in the presence of 4µ8C. Elucidating a role for IRE1α 
and/or XBP1s in insulin stimulated glucose uptake will have profound effects on 
clinical management. For instance, if a T2DM patient has elevated ER stress and 
IRE1α and XBP1s, treatment with insulin might be ineffective.   
 
A subject with a WNT10B C256Y mutation rendering a non-functional Wnt10b 
protein was severely obese with a healthy metabolic profile (chapter 6). The 
subject’s adipocytes continued to increase the expression of adipogenesis master 
regulator CEBPα upon activation of adipogenesis whereas the marker peaked on 
day 6 – 10 in preadipoctes from control lean subjects (figure 6.2.4). Furthermore, 
the WNT10B C256Y subject had significantly different Wnt signalling gene and 
protein expression during adipogenesis compared to lean control (figure 6.2.5). 
AXIN2 gene expression increased in lean adipocytes during adipogenesis, 
however it did not increase in the WNT C256Y subject. Therefore Axin2, 
encoded by the AXIN2 gene may act as a negative feedback regulator to ‘turn off’ 
CEBPα during adipogenesis. Further studies are required to elucidate the role of 
Wnt signalling and Axin2 in adipogenesis. Elucidating the signalling networks 
involved in adipogenesis may allow the process to be manipulated to favour the 
metabolic health of the patients with T2DM. For example, a regulated expanded 
WAT with sufficient functioning adipocytes can act like an active pool to uptake 
harmful lipids and glucose from the circulation, thereby protecting the subject 
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from the adverse effects of hyperlipidemia and hyperglycemia. The WNT10B 
C256Y subject had a metabolically healthy phenotype despite her massive 
obesity. This may be because her expanded WAT is metabolically healthy or it 
could be that she has dysregulated WAT but it has not had sufficient time to 
influence her metabolic profile because she is only 19 years old. Therefore follow 
up studies are required to assess the subjects metabolic profile over time. Will she 
be protected from insulin resistance with her expanded WAT, or will she develop 
insulin resistance because of her expanded WAT? Follow up studies of this rare 
naturally occurring mutation have the potential to provide useful information 
about the regulation of adipogenesis and overall WAT health. 
 
Further studies investigating people with MONW and MHO phenotypes, PCOS 
and matched controls may identify additional regulatory factors in adipose tissue 
health and metabolism. WAT biopsies alongside anthropometric data from the 
aforementioned groups can be utilised to assess differences in genome using 
GWAS, ER stress levels assessing protein and gene expression and adipogenesis 
regulation by extracting stem cells and inducing adipogenesis in vitro. These 
naturally occurring differences in WAT and metabolic regulation may assist the 
identification of integrated pathways of metabolism. Understanding the metabolic 
pathways involved will allow development of therapeutics to modulate said 
pathways in order to improve metabolic health and thus reduce the encumbrance 
of T2DM. 
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7.3 Overall conclusions 
In conclusion, this thesis has researched the role of ER stress and consequent UPR 
activation in human WAT regulation in metabolic health and T2DM. The main 
outcomes of these studies have shown: Both restrictive and malabsorptive 
bariatric interventions are effective weight loss interventions for obese T2DM 
patients and result in significantly improved glucose and insulin levels six months 
after surgery. WAT health is better following restrictive procedures (LAGB and 
LGCP) compared to BPD as shown by higher reduction of ER stress markers as 
well as improved regulation of CHOP. Adipogenesis in primary human 
preadipocytes is influenced by both adiposity and WAT depot of preadipocyte 
source and the IRE1 - XBP1s UPR pathway plays an integral role in human 
adipogenesis. XBP1s plays a vital role upstream of CEBP and PPAR in human 
adipogenesis and it is necessary for mediating the action of insulin. Wnt10b plays 
an inhibitory role in human adipogenesis and acts independently of XBP1s. 
Collectively these findings suggest that WAT function is key for metabolic health 
and can be impaired by ER stress; however regulated adipogenesis may serve to 
improve WAT function and therefore improve metabolic health. In order to 
confirm these findings further studies are required with larger numbers of human 
subjects and specific in vivo investigations. If confirmed, clinical trials with 
therapeutic targets to improve adipogenesis and therefore WAT function and 
metabolic health could hold significant clinical potential.  
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